Orlando | May 15-20

[Link]
ATS 2026 INTERNATIONAL CONFERENCE
MAY 15-20, Orlando, FL

This ATS International Conference Advance Program is published by the ATS as a service to attendees.
This publication contains the programs and speakers for the postgraduate courses, scientific and
educational sessions presented at the conference.

While every effort is made to ensure accuracy, ATS makes no warranties, expressed or implied, related to
the information. Information contained herein is subject to change without notice.

The information contained in this program is up to date as of January 20,2026.

Click on the session title to view more information about ATS events, assemblies and sections.

i General Registration Fee

1 Friday Postgradua te Courses
9 Saturday Postgraduate Courses
19 Sunday Conference Sessions
40 Monday Conference Sessions
62 Tuesday Conference Sessions
78 Wednesday C onference Sessions

[Link]

The Advance Program is published by the ATS as a service to attendees. While every effort is made to ensure accuracy,
ATS makes no warranties, expressed or implied, related to the information. Information contained herein is subject to change without notice
i

General Registration Fee

While the ATS International Conference does not host official “social” events, it does offer several
networking opportunities where attendees can discuss the science presented at the conference
or their own work. Registration fees cover the cost of all items at the International Conference
listed under the General Registration Fee below. The ATS, through other revenue sources like
member dues and advertising, covers the cost of any ancillary food/beverage costs at the Inter-
national Conference. These costs are not included as part of the registration fee.
General Registration Fee
• Attendance at the following:
• Keynote Sessions
• Clinical Topics in Pulmonary Medicine Sessions
• Critical Care Track Sessions
• Basic Science Core Sessions
• Year in Review Sessions
• Clinical Trial Symposium
• AJRCCM, NEJM, JAMA Journal Sessions
• Scientific Symposia
• Medical Education Seminars
• Advocacy Seminars
• Mini Symposia
• Poster Discussion Sessions
• RAPiD: Rapid Abstract Poster Discussion Sessions
• Thematic Poster Sessions
• Amberson Lecture
• Recognition for Scientific Accomplishments Awards Session
• Adult and Pediatric Core Curriculum Sessions
• Assembly and Section Membership Meetings
• Mid-Day Symposia
• Industry Programs in the Exhibit Hall
 ii

• Access to the
• Opening Ceremony
• Plenary Session
• Exhibit Hall
• AI Lab
• Conference Mobile App
• Access to ATSConference365 online program
itinerary
• Access to ATS NOW
• Access to the Virtual Final Program
• Livestream to select sessions
• Admittance to Networking Super Center
• Admittance to Collaboration Lounges

Additional Registration and Fees

For select events, meals are included. Participation in these sessions requires a separate ticket
and additional fee, which is not included in the general conference registration fee.
• Diversity Forum
• Meet the Expert Seminars
• Pediatrics Assembly Celebration of Excellence Dinner
• Postgraduate Courses (Full-Day and Half-Day Courses)
• Research Program Benefit
• Respiratory Innovation Summit
• Women’s Forum
FRIDAY • MAY 15 Click on the session title to view the speakers 1

ATS: COMMITTED TO EXCELLENCE IN CONTINUING

MEDICAL EDUCATION AND SCIENTIFIC EXCHANGE
The American Thoracic Society is committed to providing education and scientific
exchange of the highest quality at our International Conference and other programs.
As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), the ATS
must ensure objectivity, scientific rigor, balance, and freedom from commercial bias in Conference presentations.
ATS relies on the assistance of Conference Session organizers, chairs and presenters, Assembly Program
Committees, and the ATS International Conference Committee to accomplish this. In keeping with ACCME
standards and ATS policies on management of conflict of interest, all moderators and speakers must
complete conflict of interest review and resolution prior to the Conference.
ATS thanks Conference presenters for their cooperation in completing disclosure forms by announced deadlines, and
thanks Conference session organizers and all those involved in this important process.

POSTGRADUATE COURSES
Target Audience
This course is relevant to all pediatric pulmonologists, fellows,
and advanced providers. Our specific target audience is
individuals preparing to take the 2026 certifying board exam in
pediatric pulmonology.
Objectives
At the conclusion of this session, the participant will be able to:
• apply knowledge and resources from this comprehensive
review of pediatric pulmonology to board exam preparation as
well as clinical practice.
• incorporate the forthcoming American Board of Pediatrics
pediatric pulmonary content outline, as well as clinical
Friday, May 15 guidelines (where applicable), into board exam preparation
and clinical care.
• at the conclusion of this program, the learner will be better
CLINICAL prepared for the American Board of Pediatrics initial
POSTGRADUATE COURSE certification exam, as well as for clinical practice.
This postgraduate course will serve as a comprehensive review
PG1A TAKE IT ALL IN!: COMPREHENSIVE of contemporary topics in pediatric pulmonology. It will serve an
REVIEW OF PEDIATRIC PULMONOLOGY unmet need by providing board review for test takers preparing
AND PREPARATION FOR THE BOARDS for the 2026 American Board of Pediatrics initial certification
R This is part 1 of a two-part course which includes PG1B on Saturday, examination. It will also be relevant and applicable to all pediatric
May 16. Those registering for PG1A will registered for PG1A and pulmonologists, nurse practitioners, and others who may benefit
PG1B. Pre-registration and additional fees required. Attendance is from this extensive learning opportunity from experts in the field.
limited.
Member $930 In-Training Member $550 8:00 Welcome
LMIC Member $650 LMIC In-Training Member $385
Non-Member $1140 In-Training Non-Member $810 8:10 Lung Development
Assemblies on Pediatrics, Steering Committee on 8:45 Respiratory Disorders of the Neonate and Infant
Advancement and Learning (SCALe) 9:20 Respiratory Infections 1
8:00 A.M. - 4:00 P.M. 9:55 Break

ATS 2026 Advance Conference Program • Orlando, FL

2 Click on the session title to view the speakers FRIDAY • MAY 15

10:05 Cystic Fibrosis This interactive session is designed for clinicians and educators
10:40 Sleep and Control of Breathing seeking to reinforce basic point of care ultrasound skills for acutely ill
patients. Participants will review diagnostic protocols, refine image
11:15 Respiratory Failure acquisition and interpretation techniques with live models, and review
11:50 Lunch tips and tricks of ultrasonography with expert faculty. The session will
also focus on practical strategies for using and teaching ultrasound
12:20 Physiology Small Groups 1
effectively, addressing common pitfalls, ergonomic techniques, and
1:15 Interstitial Lung Disease learner engagement across experience levels. This course bridges
1:50 Pulmonary Function Testing clinical application and education, equipping participants to both
perform and teach high-quality ultrasound at the bedside.
2:25 Break
8:00 Introduction
2:35 Imaging
8:15 Part 1: Ultrasound for Respiratory Failure and
3:10 Lung Diseases Associated with Systemic Disorders Vascular
3:45 Wrap-Up 9:05 Movement
9:10 Practical Skills Session
CLINICAL 10:10 Break
POSTGRADUATE COURSE 10:40 Part 2: Ultrasound for Hemodynamic Instability

PG2 ULTRASOUND UNLOCKED: 11:30 Movement

ADVANCING ULTRASOUND PRACTICE 11:35 Practical Skills Session
AND INSTRUCTION 12:35 Lunch
R Pre-registration and additional fees required. Attendance is limited.
Member $630
LMIC Member $441
Non-Member $735
In-Training Member $405
LMIC In-Training Member $284
In-Training Non-Member $530
Assemblies on Critical Care, Behavioral Science and Health
1:05
1:45
Lunch & Demonstration
Part 3: Tips and Tricks for Ultrasonography and
Education
2:35 Movement
Services Research, Clinical Problems, Critical Care,
Nursing, Pediatrics, Pulmonary Circulation; Section on 2:40 Practical Skills Session
Medical Education 3:40 Movement
8:00 A.M. - 4:00 P.M. 3:45 Conclusion
Target Audience
This session is designed for a multidisciplinary audience of
healthcare professionals who use or teach point-of-care CLINICAL
ultrasound (POCUS) in the care of acutely ill patients. POSTGRADUATE COURSE
Objectives
At the conclusion of this session, the participant will be able to: PG3 BRONCH DAY 2026: A
COMPREHENSIVE, HANDS-ON GUIDE
• perform and interpret lung, cardiac, and vascular ultrasound to
TO BASIC BRONCHOSCOPY, EBUS,
diagnose respiratory failure, assess hemodynamic instability, and
guide vascular access in critically ill patients. AND GUIDED BRONCHOSCOPY
•

•
integrate standardized ultrasound protocols and dynamic
parameters into clinical decision-making to improve diagnostic
accuracy and procedural safety.
enhance ultrasound teaching effectiveness by identifying technical
R Pre-registration and additional fees required. Attendance is limited.
Member $630
LMIC Member $441
Non-Member $735
In-Training Member $405
LMIC In-Training Member $284
In-Training Non-Member $530
Assemblies on Clinical Problems, Thoracic Oncology
pitfalls, applying ergonomic techniques, and utilizing evidence-based 8:00 A.M. - 4:00 P.M.
strategies for bedside instruction and learner assessment.

ATS 2026 Advance Conference Program • Orlando, FL

FRIDAY • MAY 15 Click on the session title to view the speakers 3

Target Audience 12:30 Practical Skills Session: Bronchoscopic

Adult and pediatric pulmonologists and intensivists, thoracic Management of Hemoptysis
surgeons, physicians in training, allied health professionals,
12:55 Practical Skills Session: Management of the
anesthesiologists interested in improving their skills in diagnostic
and therapeutic flexible bronchoscopy and EBUS Difficult Airway Including Trachcostomy Tubes

Objectives 1:20 Practical Skills Session: Techniques for Foreign

At the conclusion of this session, the participant will be able to: Body Removal Using Flexible Bronchoscopy

• Diagnose and manage adults with benign and malignant 1:45 Practical Skills Session: Navigational
respiratory diseases that require bronchoscopic intervention. Bronchoscopy With Radial Endobronchial
Ultrasound
• Understand the indications for basic and adavanced
bronchoscopy, linear and radial endobronchial ultrasound as 2:10 Break
well as endobronchial valves and the skills necessary to 2:20 Practical Skills Session: Robotic Bronchoscopy
perform these procedures. 2:45 Practical Skills Session: Endobronchial Ultrasound
• Improve knowledge of navigational and robotic bronchoscopy Anatomy
and strengthen these procedural skills. 3:10 Practical Skills Session: Endobronchial
This course is designed to provide a comprehensive introduction Ultrasound-Guided Transbronchial Needle
to diagnostic and therapeutic flexible bronchoscopy. Participants Aspiration
will acquire the knowledge and skills to improve their proficiency 3:35 Practical Skills Session: Endobronchial Valves
in basic bronchoscopic techniques and be exposed to advanced
skills such as linear EBUS, radial EBUS, navigational and robotic
bronchoscopy. A series of lectures will be followed by intensive, BASIC • CLINICAL
hands-on stations. Through the use of physical and virtual reality
simulators, participants will strengthen their procedural skills. POSTGRADUATE COURSE
This course is of particular interest to providers seeking to refine
PG4 SARCOIDOSIS: WHAT WE NEED TO
their bronchoscopy skills and who wish to review the most
up-to-date data behind the various bronchoscopic techniques KNOW TODAY
used today.
8:00
8:05
Introduction
Optimizing Basic Bronchoscopy Skills
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assemblies on Clinical Problems, Allergy, Immunology and
8:30 Maximize Bronchoscopic Outcomes in High Risk
Inflammation, Behavioral Science and Health Services
Patients
Research
8:55 Role of Flexible Bronchoscopy in Management of
8:00 A.M. - 4:00 P.M.
Hemoptysis
Target Audience
9:20 Foreign Body Aspiration
Providers of lung health; those serving patients with pulmonary
9:45 Break and extrapulmonary sarcoidosis.
10:00 The Fundamentals of Linear EBUS Objectives
10:25 Navigational Bronchoscopy: From Fluoroscopy to At the conclusion of this session, the participant will be able to:
Robotics • at the conclusion of this session, the learner will be better able to
10:50 Bronchoscopic Lung Volume Reduction define, implement, and counsel patients on updated strategies,
guidelines, and new approaches in the diagnosis, treatment, and
11:15 Lunch follow-up of patients with pulmonary sarcoidosis.
12:05 Practical Skills Session: Bronchoscopy With • the learner will better understand the management of and the
Biopsy and Needle Aspiration of Endobronchial need for early referral of patients with severe forms of
Lesion

ATS 2026 Advance Conference Program • Orlando, FL

4 Click on the session title to view the speakers FRIDAY • MAY 15

pulmonary sarcoidosis, including fibrotic pulmonary sarcoidosis 2:15 Neurosarcoidosis and Sarcoidosis Associated
and sarcoidosis-associated pulmonary hypertension. Small Fiber Neuropathy (SSFN)
• the learner will be better able to screen for, diagnose, and 2:45 Break
manage important extrapulmonary manifestations of 2:55 Fatigue, Cognitive Difficulty, Brain Fog, and
sarcoidosis-such as cardiac sarcoidosis, neurosarcoidosis, Depression in Sarcoidosis
fatigue, and sarcoidosis-associated small fiber neuropathy.
3:15 Mind the Gap - The Psycosocial & Economic
The last decade has seen an explosion in the number of published Burden of Sarcoidosis
studies including clinical trials and novel treatment approaches in
sarcoidosis and it is important that practicing pulmonologist stay 3:35 A Pragmatic Approach to Shared Decision Making
abreast of these changes. This session aims to provide updates in & Multi-Disciplinary Care in Pulmonary Sarcoidosis
the diagnosis, evaluation, and management of patients with 3:55 Wrap up of the day
pulmonary and extrapulmonary sarcoidosis. We will provide a
synopsis of current practice with emphasis on recent updates. The
goal is to equip the learners with the most up to date information CLINICAL
necessary to provide an evidence based comprehensive care to
patients with pulmonary and extrapulmonary sarcoidosis. POSTGRADUATE COURSE
8:00 Introduction PG5 ADVOCACY TOOLS FOR PULMONARY,
8:05 I Have Sarcoidosis and This Is My Story - Keeping CRITICAL CARE AND SLEEP MEDICINE

8:20

8:40
the Patient Front & Center
The Epidemiology of Sarcoidosis - Focus on Recent
Patterns and Trends of Disease
The Etiology of Sarcoidosis - Genetics &
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assemblies on Pediatrics, Nursing; Health Policy
Environmental/Occupational ExposuresThe Committee Pediatric Advocacy Committee
Etiology of Sarcoidosis - Genetics 8:00 A.M. - 4:00 P.M.
&Environmental/Occupational Exposures
Target Audience
9:15 Understanding The Pathobiology & Immunology of Early career professionals who are looking to be more involved
Sarcoid Granuloma Formation in advocacy however this would be applicable to mid and late
9:35 Break career individuals too. It is not clinically focused and open to
researchers and health care providers
10:00 The Diagnosis of Sarcoidosis
Objectives
10:10 The Treatment of Pulmonary Sarcoidosis At the conclusion of this session, the participant will be able to:
10:35 Updates on Emerging Therapies & New Treatment • apply lessons learned in advocacy training to real-world advocacy
Approaches in Sarcoidosis
• at the conclusion of the session participants will be able to identify
11:00 Monitoring The Patient with Pulmonary Sarcoidosis key issues affecting their communities.
- The Role of PFTs, Symptom & QoL Assessments,
and Imaging • participants should be able to articulate their message clearly to
various audiences including policymakers, the public and other
11:25 Breakout Session with Case Discussions & Review stakeholders
11:55 Summary of Morning Session Advocacy in pulmonary, critical care and sleep medicine has
12:00 Lunch become increasingly more important for both clinicians and
1:00 Fibrotic Pulmonary Sarcoidosis scientists. Lessons on effective advocacy in healthcare are
critical for the growth and development of ATS members. The
1:25 Sarcoidosis Associated Pulmonary Hypertension morning session includes exemplars in advocacy, experts will
(SAPH) share foundational elements of effective advocacy at all levels
followed by engagement with group dialogue. Different from

ATS 2026 Advance Conference Program • Orlando, FL

FRIDAY • MAY 15 Click on the session title to view the speakers 5

previous symposia, this provides active engagement, so • to gain further understanding of the principles and practice of
attendees will leave with a toolkit and foundation for future pulmonary function diagnostic tests
advocacy activities and leadership. Providing a primer on the • to develop greater confidence interpreting pulmonary function
broad range of advocacy in ATS to better understand the test results in clinical practice
emerging advocacy environment.
• to identify strategies to approach the interpretation of
8:00 Introduction pulmonary function test results in complex patients
8:10 Integrating Advocacy Roles into Career This course focuses on clinical lung function testing, integrating
Opportunities and Responsibilities recent technical standards and interpretive strategies with
8:55 Levels of Advocacy interactive, small-group learning. Participants will engage in
9:40 Break didactic lectures, case-based instruction, and live demonstrations
of pulmonary function testing (PFT). A multidisciplinary
10:00 Current ATS advocacy Landscape team-including clinicians, respiratory therapists, and lab
10:45 Voice of a legislator directors-will guide discussions. Emphasis will be placed on
race-neutral equations in PFT, reflecting evolving literature. The
11:30 Lunch
course concludes with expert panel discussions of complex
12:30 Advocacy Journey cases, offering diverse perspectives and practical insights into
1:30 Advocacy in the Media - Breakout Session PFT performance, interpretation, and reporting.
1:50 OP Eds - Finding your Lede - Breakout 8:00 Introduction
2:10 Meeting with your Legislator - Break Out 8:05 Spirometry Measurement and Interpretation
2:30 Break 8:30 Spirometry Reference Equations
2:50 Local Advocacy -Breakout 8:55 Assessment and Interpretation of Static Lung
Volumes
3:10 State and Federal Testimonies
9:20 Diffusing Capacity Assessment and Interpretation
3:30 Debrief - End of Session
9:45 Break
10:00 Use of the Forced Oscillation Technique in Clinical
CLINICAL Practice
POSTGRADUATE COURSE 10:30 Real-time Demonstration of PFT Assessment and
Troubleshooting
PG6 BEST PRACTICES IN PULMONARY
FUNCTION TESTING 11:10 PFT Small Group Case Discussion #1
11:50 Lunch
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assemblies on Respiratory Structure and Function, Clinical
12:30

1:00
Pediatric Considerations in Pulmonary Function
Testing
Bronchial Challenge Testing: Insights into Current
Problems Guidelines

8:00 A.M. - 4:00 P.M. 1:40 Break

Target Audience 1:55 Complex Patterns in Pulmonary Function

The target audience includes Current and future directors of PFT 2:25 Small Group PFT Case Discussions #2
labs, attending physicians, respiratory therapists, trainees,
3:05 Break
fellows, and other interested health care providers including
advance practice providers. 3:15 Full of Hot Air: Expert Panel Case Debate
Objectives 3:50 Concluding Remarks
At the conclusion of this session, the participant will be able to:

ATS 2026 Advance Conference Program • Orlando, FL

6 Click on the session title to view the speakers FRIDAY • MAY 15

BASIC • CLINICAL • TRANSLATIONAL 8:50 Update on Chronic Bronchitis

9:05 Is Pharmacotherapy for Emphysema Possible?
POSTGRADUATE COURSE
9:20 Questions and Answers
PG7 COPD 2026: STATE OF THE ART 9:45 Break
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assemblies on Clinical Problems, Allergy, Immunology and
10:15
10:30
10:45
Diagnosis of COPD: A Multidimensional Approach
Evaluating Exercise Intolerance in COPD
Biomarkers in COPD
Inflammation, Pulmonary Rehabilitation, Respiratory 11:00 Disease Trajectories in COPD
Structure and Function 11:15 GOLD 2026. What’s New?
8:00 A.M. - 4:00 P.M. 11:30 Questions and Answers
Target Audience 11:45 Lunch
Clinicians, basic scientists, nurses, other allied health staff,
researchers, investigators in basic and clinical science pertinent 12:45 Treatable Traits in COPD
to COPD, and sponsors of research 1:00 Type 2 Biologicals in COPD
Objectives 1:15 Targeting Alarmins in COPD
At the conclusion of this session, the participant will be able to:
1:30 Preventing and Managing COPD Exacerbation
• identify challenges associated with the contemporary
1:45 Questions and Answers
assessment and management of COPD based on
evidence-based clinical practice guidelines recommendations 2:00 Break
and improve knowledge on COPD pathophysiology, clinical 2:30 Update on Bronchoscopic Interventions
presentation, and assessment
2:45 Non-Invasive Ventilation in COPD
• understand the clinical, physiological and radiological
3:00 Update on Pulmonary Rehabilitation
phenotypes of COPD and learn new findings and gain
competence in providing pharmacological and 3:15 Oxygen Therapy: Progress and hurdles
non-pharmacological management of COPD 3:30 Managing the Multimorbidity of COPD
• become familiar with recent and ongoing clinical trials for 3:45 Questions and Answers
COPD management and recognize unmet needs for future
research in the field 3:55 Closing Remarks

This course will provide a state-of-the-art update on the

understanding of the pathophysiology, clinical course, CLINICAL • TRANSLATIONAL
assessment and management of COPD. It will shed light on
recent and ongoing clinical trials and outline evidence-based POSTGRADUATE COURSE
pharmacological and non-pharmacological management
PG8 BRONCHIECTASIS AND NTM
strategies. Attendees will be updated on understanding COPD
phenotypes, endotypes and biomarkers as well as recent PULMONARY DISEASE: ETIOLOGIES,
advances in disease management. The course will also outline COMPLEX CASE MANAGEMENT, AND
unmet and future research needs. UPDATED GUIDELINES
8:00
8:05
8:20
Welcome and Introductions
Immunologic Underpinnings of COPD
Shedding Light on Genetics of COPD
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assembly on Pulmonary Infections and Tuberculosis
8:35 Decoding COPD Using Big Data: Mapping Disease
Phenotypes Through Time 8:00 A.M. - 4:00 P.M.

ATS 2026 Advance Conference Program • Orlando, FL

FRIDAY • MAY 15 Click on the session title to view the speakers 7

Target Audience 10:55 Panel Discussion

Respiratory therapists, pulmonologists/respirologists, post
11:05 Breakout Discussion: Advanced Bronchiectasis Cases
graduate trainees, advanced practitioner, those seeing patients
with NTM and bronchiectasis without frequent access to expert 11:45 Lunch
guidance, those starting or directing specialized programs 12:45 Practicalities of Airway Clearance
Objectives 1:10 Beyond the Guidelines: Advanced Management of
At the conclusion of this session, the participant will be able to: MAC and M. Abscessus
• describe recent advances in translational research and clinical 1:30 Advanced Management of Other Clinically
studies that inform evolving approaches to the diagnosis and Significant NTM
management of bronchiectasis and NTM pulmonary disease.
1:50 Breakout Discussion: Implementing Guidelines in
• apply evidence-based treatment strategies for bronchiectasis, the Real-World
including approaches to airway clearance, exacerbation
prevention, and use of new therapeutic options. 2:35 Break

• incorporate advanced treatment options and emerging 3:05 Rapid Fire: NTM Therapeutic Pipeline: Trials, Novel
therapies for NTM pulmonary disease into clinical practice to Diagnostics, and Recruitment Challenges
improve patient outcomes. 3:30 Rapid Fire: Bronchiectasis Clinical Trials and
The diagnosis and management of bronchiectasis and Emerging Therapies: Opportunities and Barriers
nontuberculous mycobacteria (NTM) pulmonary infections are 3:55 Closing Remarks
challenging due to the complexity of these chronic lung diseases
and limited evidence-based management strategies. There have
fortunately been multiple significant advances, and this session BEHAVIORAL • CLINICAL • TRANSLATIONAL
will provide learners on the evolving landscape. Topics include
current epidemiology, environmental risk factors,
POSTGRADUATE COURSE
pathophysiology, and diagnostic considerations. The session will PG9 STATE OF THE ART: LUNG CANCER IN
review new bronchiectasis management guidelines expected in 2026
late 2025 and explore novel approaches being pursued in active
clinical trials. Through a combination of didactic presentations
and expert panel discussions, participants will gain practical
insights to enhance patient care and clinical decision-making.
8:00 Introduction: Day of Bronchiectasis and NTM
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
Assembly on Thoracic Oncology
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405

8:05 Global Perspectives on NTM Epidemiology, 8:00 A.M. - 4:00 P.M.

Acquisition, and Clinical Significance Target Audience
8:25 Bronchiectasis Insights From Global Epidemiology All providers caring for patients with known or suspected lung
and Registry-Driven Advances cancer (pulmonologist, thoracic surgeons, radiation oncologist,
medical oncologist, APPs) and those interested in translational
8:45 Panel Discussion: Epidemiology
research in this field.
8:55 Unraveling the Diverse Etiologies of Bronchiectasis
Objectives
9:15 Genetic Etiologies of Bronchiectasis: What, When, At the conclusion of this session, the participant will be able to:
and How to Test
• review and understand recent advances and changes in the
9:35 Panel Discussion: Etiologies personalized treatment of lung cancer.
9:45 Break • understand the role of biomarkers across the spectrum of lung
10:15 Update in Bronchiectasis Guidelines: New cancer from early detection to treatment response.
Recommendations and Clinical Implications • understand the practical implications of lung cancer staging
10:35 New Horizons in Bronchiectasis: Targeting guidelines on invasive staging procedures and impact on
Endotypes with Novel Therapies patient treatment and outcomes.

ATS 2026 Advance Conference Program • Orlando, FL

8 Click on the session title to view the speakers FRIDAY • MAY 15

This course will provide a comprehensive review of topics in the

evaluation and management of patients with known and
suspected lung cancer. We will discuss recent developments in
the areas of tobacco control, updated guidelines for lung cancer
staging, advances in lung cancer screening, invasive diagnostic
approaches for patients with lung nodules and mediastinal
staging, biomarkers across the spectrum of lung cancer, and
updates in multimodal treatment approaches for lung cancer.
Attention will be given to global variations and potential
disparities across the lung cancer continuum. Interactive tumor
boards will be held to highlight these topics and encourage
participant engagement.
8:00 Introduction
8:05 Lung Cancer Across the Globe: Shifts in
Epidemiology That Should Impact Research
Priorities
8:30 Lung Cancer Screening US and Global Updates
8:55 Evolution of Surgery for Early-Stage Lung Cancer
Treatments
9:20 Updates in Interventional Pulmonary for the
Diagnosis, Staging, Treatment of Lung Cancer
9:45 Break
10:05 Updates in Multimodality Treatment for Early-Stage
Lung Cancer: an Oncologist’s Perspective
10:30 Updates in Radiation Oncology and Other Ablative
Methods for Lung Cancer
10:55 Thoracic Tumor Board #1
11:30 Lunch
12:35 Prioritizing Tobacco Treatment Across the Lung
Cancer Continuum.
1:00 Lung Cancer Staging: Changes and Impact on
Management and Outcomes
1:25 The Importance of Biomarker Testing: Practical
Updates
1:50 Addressing Disparities Across the Lung Cancer
Continuum
2:15 Break
2:35 Updates in Mesothelioma
3:00 Thoracic Tumor Board #2
3:35 The Top 5 in Thoracic Oncology: This Year’s Most
Important Articles

ATS 2026 Advance Conference Program • Orlando, FL

SATURDAY • MAY 16 Click on the session title to view the speakers 9

This postgraduate course will serve as a comprehensive review

of contemporary topics in pediatric pulmonology. It will serve an
unmet need by providing board review for test takers preparing
for the 2026 American Board of Pediatrics initial certification
examination. It will also be relevant and applicable to all pediatric
pulmonologists, nurse practitioners, and others who may benefit
from this extensive learning opportunity from experts in the field.
8:00 Welcome to Course
8:10 Congenital and Acquired Malformations of the
Lungs
8:45 Respiratory Infections 2
9:20 Non-CF Bronchiectasis
Saturday, May 16 9:55 Break
10:05 Asthma
CLINICAL 10:40 Restrictive Lung Disease
POSTGRADUATE COURSE 11:00 Pulmonary Vascular Disease and Lymphatic
Disorders
PG1B TAKE IT ALL IN!: COMPREHENSIVE
11:50 Small Groups 2
REVIEW OF PEDIATRIC PULMONOLOGY
AND PREPARATION FOR THE BOARDS 12:45 Lunch
1:15 Lung Diseases Associated with Systemic Disorders 2
R This is part 2 of a two-part course which includes PG1A on Friday,
May 15. Pre-registration and additional fees required. Attendance is
limited. See PG1A for course fees.
Assemblies on Pediatrics, Steering Committee on
Advancement and Learning (SCALe)
1:50
2:25
2:25
Environmental Injuries and Exposures
Break
Respiratory System Under Stress
8:00 A.M. - 4:00 P.M. 3:10 Core Knowledge in Scholarly Activities
Target Audience 3:45 Wrap-Up
This course is relevant to all pediatric pulmonologists, fellows
and advanced providers. Our specific target audience are
individuals preparing to take the 2026 certifying board exam in CLINICAL
pediatric pulmonology.
POSTGRADUATE COURSE
Objectives
At the conclusion of this session, the participant will be able to: PG10 MECHANISTIC AND MULTIMODAL OSA
• apply knowledge and resources from this comprehensive TREATMENT: NERVE STIMULATION,
review of pediatric pulmonology to board exam preparation as SURGERY, ORAL APPLIANCES, AND
well as clinical practice. EMERGING PHARMACOTHERAPY
• incorporate the forthcoming American Board of Pediatrics
pediatric pulmonary content outline, as well as clinical
guidelines (where applicable) into board exam preparation and
clinical care,
R Pre-registration and additional fees required. Attendance is limited.
Member $630
LMIC Member $441
Non-Member $735
In-Training Member $405
LMIC In-Training Member $284
In-Training Non-Member $530
Assemblies on Sleep and Respiratory Neurobiology, Clinical
• at the conclusion of this program, the learner will be better Problems, Nursing, Pediatrics
prepared for the American Board of Pediatrics initial
certification exam, as well as for clinical practice. 8:00 A.M. - 4:00 P.M.

ATS 2026 Advance Conference Program • Orlando, FL

10 Click on the session title to view the speakers SATURDAY • MAY 16

Objectives 12:55 Personalized Pathways in OSA: Combining

At the conclusion of this session, the participant will be able to: Modalities for Optimal Outcomes
• describe new findings about HNS, OA, MMA surgery, and 1:25 Break
emerging pharmacologic agents as evidence-based 1:40 Practical Skills Session: Nuts and Bolts of Single
alternatives to positive airway pressure (PAP) in the treatment Lead HNS Device
of obstructive sleep apnea (OSA).
2:30 Practical Skills Session: Bilateral Hypoglossal
• apply patient-specific criteria to identify and refer candidates Nerve Stimulator Therapy
for appropriate non-PAP therapies, incorporating current
clinical evidence, anatomical considerations, and comorbidity 3:10 Practical Skills Session: Optimizing Patient
profiles into individualized treatment plans. Selection and Outcomes of OSA with Dental Sleep
Medicine
• improve the quality of life and health status of patients with
OSA by integrating multimodal, mechanism-based treatment 3:55 Summarize the Course and Open Questions and
strategies into practice when PAP therapy is not used. Answers
Hypoglossal Nerve Stimulation (HNS), Oral Appliance (OA),
Maxillary Mandibular Advancement (MMA) surgery, and CLINICAL
pharmacotherapy are evidence-based positive airway pressure
(PAP) treatment alternatives for obstructive sleep apnea (OSA). POSTGRADUATE COURSE
Dual GLP-1 and GIP receptor agonist and mechanistically
targeted combination treatment (aroxybutynin and atomoxetine)
PG11 PEDIATRIC ADVANCED DIAGNOSTIC
are expected to become viable alternatives to PAP for selected AND INTERVENTIONAL
patients. This session will review recent clinical evidence and BRONCHOSCOPY
technical advancements in non-PAP OSA therapies. Interactive R Pre-registration and additional fees required. Attendance is limited.
case studies and hands-on workshops will provide participants Member $630 In-Training Member $405
with practical training in HNS titration, OA device selection, and LMIC Member $441 LMIC In-Training Member $284
Non-Member $735 In-Training Non-Member $530
adherence tracking technologies.
Assembly on Pediatrics
8:00 Introduction to Course Outline and Objectives
8:00 A.M. - 4:00 P.M.
8:10 Hypoglossal Nerve Stimulation (HNS) for OSA:
Mechanisms, Evidence, and Indications Target Audience
Clinicians, Pediatric Pulmonologists, and Clinical Fellows Who
8:40 Before the Stimulation: Interdisciplinary Sleep Perform Bronchoscopy
Medicine and ENT Evaluation for HNS Success
Objectives
9:10 Break At the conclusion of this session, the participant will be able to:
9:25 Precision and Progress: Surgical and Device • describe new advanced diagnostic and interventional
Innovations in HNS, Ansa Cervicalis Stimulation bronchoscopy techniques in children.
9:55 Dialing it in: Monitoring and Titration Strategies for • more appropriately refer and provide care to children who could
HNS Success benefit from advanced diagnostic and therapeutic bronchoscopy
10:25 Lunch procedures.
11:10 Bite-Sized Innovation: Advances in Oral Appliance • define likely complications and management strategies for
Therapy for OSA advanced bronchoscopic procedures in children.
11:40 Weight Loss as Airway Therapy: Tirzepatide and the This course will introduce attendees to a broad spectrum of
Metabolic Approach to OSA advanced diagnostic and interventional pediatric flexible
bronchoscopy techniques including cryotherapy, electrocautery,
12:10 Break
transbronchial biopsy, endobronchial ultrasound, navigational
12:25 Mechanistic Drug Therapy for OSA with biopsies, and endobronchial valves. Indications, risks, and benefits
Aroxybutynin and Atomoxetine will be discussed as well was strategies for starting a program and

ATS 2026 Advance Conference Program • Orlando, FL

SATURDAY • MAY 16 Click on the session title to view the speakers 11

partnering with adult pulmonologists. This will be followed with Objectives

hands-on practice under the guidance of leaders in the field of At the conclusion of this session, the participant will be able to:
advanced pediatric bronchoscopy. The course will offer insights • understand when to refer patients with cardiogenic shock for
relevant to both trainees and experienced bronchoscopists. mechanical circulatory support
8:00 Introduction • explain the physiology of the most common MCS devices (IABP
8:05 Endoscopic Cryotherapy and Impella) and VA-ECMO, and develop a system of picking the
8:27 Pediatric Advanced Diagnostic Bronchoscopy first device modality

8:49 Persistant Air Leak and Endobronchial Valves in • review the basic physiology, functioning, and management of the
Pediatrics most common MCS modalities (IABP and Impella) and VA ECMO

9:11 Break There is a steady trend of increased use of mechanical circulatory

support (MCS) and veno arterial extracorporeal membrane
9:41 Management of Complications of Interventional oxygenation (VA-ECMO) for hemodynamic support in cardiogenic
Pulmonary Procedures shock. Given the growing complexity of critically ill patients, an
10:03 Starting An Advanced Diagnostic Program understanding of when to refer patients for MCS or ECMO, and how
these support modalities work, is becoming essential for critical care
10:25 Lunch
providers. Despite this, resources and education for general
11:25 Introduction to Hands-On Portion intensivists are lacking. The goal of this session is to provide a broad
11:30 Endobronchial Valve Placement and Chest Tube overview of MCS ECMO for ICU providers, and to review the basic
Drainage System Hands On Station physiology, assessment, and troubleshooting of the three most
common MCS modalities: VA-ECMO, Impellas, and intra-aortic
12:10 Practical Skills Session: Endoscopic Extraction balloon pumps.
1:30 Break 12:00 Welcome & Introduction
2:00 Practical Skills Session: Endobronchial Ultrasound 12:05 Early identification of Cardiogenic Shock and
Guided Transbronchial Needle Aspiration Review of SCAI Stages
2:40 Practical Skills Session: CT Navigation, Radial 12:20 Pressure Volume Loops and the Physiology of
EBUS, and Transbronchial Needle Biopsy Cardiogenic Shock
3:20 Practical Skills Session: Management of 12:40 Medical Management in Cardiogenic Shock
Complications
1:00 IABP Hands-On Session (Didactic)
1:20 IABP Hands-On Session (Facilitator A)
CLINICAL
2:00 Impella Hands-On Station (Didactic)
POSTGRADUATE COURSE 2:20 Impella Hands-On (Facilitator A)
PG12 SUPPORTING THE FAILING HEART: 3:00 ECMO Hands-On Station (Didactic)
MCS AND VA-ECMO FOR THE 3:20 ECMO Hands-On Station. (Facilitator A)
PRACTICING INTENSIVIST
R Pre-registration and additional fees required. Attendance is limited.
Member $300
LMIC Member $230
Non-Member $360
Assembly on Critical Care
In-Training Member $155
LMIC In-Training Member $120
In-Training Non-Member $280

12:00 P.M. - 4:00 P.M.

Target Audience
Professionals working in Critical Care: Physicians, Trainees,
Allied Health

ATS 2026 Advance Conference Program • Orlando, FL

12 Click on the session title to view the speakers SATURDAY • MAY 16

CLINICAL 9:25 What’s Ro52 Got to do with it?: Identifying Risk of

Progression in Patients with CTD-ILD
POSTGRADUATE COURSE 9:50 Break
PG13 INTERSTITIAL LUNG DISEASE: A 10:20 Care of Critically Ill Patients with ILD: ECMO,
PRACTICAL APPROACH TO Ventilation and Lung Transplantation
DIAGNOSIS AND MANAGEMENT 10:45 Pulling it All Together: Speed MDD
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assemblies on Clinical Problems, Allergy, Immunology and
11:55
12:55
Lunch
Therapies for Pulmonary Fibrosis and What to Do if
Patients Progress
1:20 Therapies for CTD-ILD and What to Do if Patients
Inflammation, Behavioral Science and Health Services Progress
Research, Critical Care, Nursing, Pulmonary Circulation,
Pulmonary Rehabilitation 1:45 Feels & Functions: Managing Cough, Dyspnea and
Fatigue in ILD
8:00 A.M. - 4:00 P.M.
2:10 Break
Target Audience
This session should be broadly relevant to those who provide 2:40 Let’s Make it Complicated: Tough Cases
clinical care for patients with ILD including pulmonary fellows, 3:50 Wrap Up: Putting Together the Puzzle of ILD
general pulmonologists, ILD specialists, and advanced care
nurses.
Objectives CLINICAL
At the conclusion of this session, the participant will be able to: POSTGRADUATE COURSE
• be able to apply a consistent, effective strategy to ILD/IPF
diagnosis PG14 CARDIOPULMONARY EXERCISE
TESTING: ADVANCES AND
• understand the range of therapeutics available for ILD and
APPLICATIONS
how and when to prescribe them
• be able to integrate a holistic and interdisciplinary approach to
ILD patient care
This session will provide a practical approach to the diagnosis
R Pre-registration and additional fees required. Attendance is limited.
Member $465
LMIC Member $326
Non-Member $570
In-Training Member $275
LMIC In-Training Member $193
In-Training Non-Member $405
Assemblies on Pulmonary Rehabilitation, Clinical Problems,
and management of patients with ILD with a particular focus on
risk for disease progression. It will bring the most recent Respiratory Structure and Function
recommendations and guidelines into a usable strategy that will 8:00 A.M. - 4:00 P.M.
facilitate the care of patients with ILD. This will be accomplished
Target Audience
through didactics, simulated MDD and panel discussion of
CPET lab directors, attending physicians, clinical physiologists,
difficult cases—providing a range of learning methods to reach exercise physiologists, clinical fellows, research fellows.
the largest number of learners.
Objectives
8:00 Welcome and Introduction At the conclusion of this session, the participant will be able to:
8:10 Let's Keep This Simple: A Practical Approach to the • to better understand the physiologic principles of CPET that
Diagnosis of ILD determine the pulmonary, cardiovascular and neuromuscular
8:35 No Longer in the Dark: Using Radiologic Patterns in responses during exercise in health, and how these are
the Diagnosis of ILD modified in chronic cardiopulmonary disease.
9:00 Not All Progress is Good: Predictors of Progression • to better understand the utility of CPET to: 1) assess
in Patients with IPF and HP mechanisms of dyspnea and exercise intolerance; 2) stratify
disease severity or prognosis.

ATS 2026 Advance Conference Program • Orlando, FL

SATURDAY • MAY 16 Click on the session title to view the speakers 13

This course focuses on the cardiopulmonary exercise test Assemblies on Allergy, Immunology and Inflammation,
(CPET). This includes education on the physiologic basis for Environmental, Occupational and Population Health,
CPET, current guidelines, quality control and advances in CPET Pediatrics, Respiratory Structure and Function
methods to assess the pulmonary system and central 12:00 P.M. - 4:00 P.M.
hemodynamics during exercise. Interpretative strategies and
common CPET responses in disease states will be presented in Target Audience
didactic sessions and followed by practice-based learning in an Providers of lung health; those serving a specific patient group or
interactive small group setting. Learners will be supported during multiple groups; those with clinical, research, or administrative
responsibilities; those needing instruction in areas of medicine
practice-based learning by expert Faculty. The inclusion of a live
outside of their specialty
CPET demonstration will complement the didactic sessions, and
highlight the multidisciplinary components necessary for Objectives
performing high-quality CPET. At the conclusion of this session, the participant will be able to:
8:00 Physiologic Basis for CPET • understand mechanisms of airway inflammation with a focus
on type 2 inflammation. Review methods for scientific
8:45 Understanding Pulmonary System Limitations to
investigation in immune-mediated airway diseases such as
Exercise
asthma and COPD.
9:15 Open Panel Q&A on the Fundamental Principles of
• understand the physiology and environmental factors that
CPET
drive asthma and COPD pathophysiology.
9:30 Break
• discuss the current and future state of advanced therapies for
9:45 Exercise and the Heart: Invasive CPET asthma and COPD. Special sessions dedication to discussion
10:30 Use of CPET in Exercise Rehabilitation Programs of disparities in therapy and considerations for pediatric
asthma.
11:00 Initial Case Discussion
This session will provide a state of the art summary of the current
11:20 Conducting the Test: Practical Issues
understanding of the mechanisms, physiology and management
11:50 Lunch of immune mediated airway diseases such as asthma and
12:20 CPET Demonstration COPD, with a focus on type 2 inflammation. The course will also
present a comprehensive review of the factors that influence
1:05 Quality Control and Troubleshooting disease progression and the current management paradigm.
1:35 Data Analysis from Graphic Display 12:00 The Immunology of Type 2 Inflammation in Asthma:
2:05 References Values What a Pulmonologist Needs to Know
2:35 Spectrum of CPET Responses Among Disease 12:30 Pediatric Asthma - Special Considerations and
States Treatment
3:05 Making the Case - Round Table Discussions 1:00 Non-Type 2 Asthma - Mechanisms
3:10 Round Table Discussions 1:30 Small Airways Dysfunction in Asthma and COPD
2:00 Break
CLINICAL • TRANSLATIONAL 2:20 Type 2 Inflammation in COPD
2:50 Molecular Phenotyping in Asthma
POSTGRADUATE COURSE
3:20 New Therapeutic Targets for Asthma
PG15 ASTHMA AND BEYOND: MOLECULAR
MECHANISMS, PHYSIOLOGY, AND
TREATMENT
R Pre-registration and additional fees required. Attendance is limited.
Member $235
LMIC Member $165
Non-Member $290
In-Training Member $140
LMIC In-Training Member $98
In-Training Non-Member $210

ATS 2026 Advance Conference Program • Orlando, FL

14 Click on the session title to view the speakers SATURDAY • MAY 16

BEHAVIORAL • CLINICAL 12:05 Basics of QI: Project Selection, Review Of

Diagnostic Tools Methods and Project Measures
POSTGRADUATE COURSE 12:25 Breakout: Basics of QI: Project Selection, Review of
PG16 BUILDING BETTER CARE: A Diagnostic Tools, Methods and Project Measures
HANDS-ON GUIDE TO QUALITY 12:55 Break and Networking
IMPROVEMENT 1:15 How to Collect and Utilize Data in QI: Pearls and
R Pre-registration and additional fees required. Attendance is limited. Pitfalls
Member $235 In-Training Member $140 1:35 Breakout: How to collect and utilize data in QI:
LMIC Member $165 LMIC In-Training Member $98
Non-Member $290 In-Training Non-Member $210 pearls and pitfalls
Assemblies on Behavioral Science and Health Services 2:00 Project Implementation
Research, QIIC committee is sponsoring this post graduate 2:20 Breakout: Project Implementation
course
2:40 Forming Alliances: How to Leverage your
12:00 P.M. - 4:00 P.M. Stakeholders for Success
Target Audience 3:00 Breakout: Forming Alliances: How to Leverage Your
Early career faculty, clinicians and inter-professional members in Stakeholders for Success
new QI leadership positions or seeking QI leadership positions;
members interested in QI scholarly work, medical educators, 3:20 Break and Networking
trainees with a career focus in QI 3:40 Ask the Experts Panel Discussion
Objectives
At the conclusion of this session, the participant will be able to:
CLINICAL • TRANSLATIONAL
• participants will be able to demonstrate strategic project
selection in QI, apply key QI methods and tools (e.g. process POSTGRADUATE COURSE
map, pareto chart),navigate data collection and tracking for
optimal project execution PG17 FROM VENTILATOR SETUP TO
LIBERATION: PRACTICAL
• participants will acquire useful skills to teach QI principles,
FOUNDATIONS AND IMPLEMENTATION
mentor in QI projects at their institutions and how to leverage
work for publication and academic promotion.
AT THE BEDSIDE.

• participants will be able to apply sustainable implementation

strategies for their proposed QI projects including
troubleshooting common roadblocks
This course, being offered by the ATS Quality Improvement and
R Pre-registration and additional fees required. Attendance is limited.
Member $235
LMIC Member $165
Non-Member $290
Assembly on Critical Care
In-Training Member $140
LMIC In-Training Member $98
In-Training Non-Member $210

Implementation Committee (QIIC), will teach attendees 12:00 P.M. - 4:00 P.M.
foundational quality improvement (QI) principles and
Target Audience
methodologies to meaningfully integrate QI into clinical work and
Pulmonary and critical care physicians, PCCM fellows,
improve processes and outcomes at their institutions. The
anesthesiologists, emergency medicine providers, respiratory
sessions will broadly cover components of strategic project
therapists, and ICU advanced practice providers seeking to
selection and design, data collection and tracking, improve practical skills in mechanical ventilation.
implementation of QI innovations, how to set up QI work for
success in terms of patient outcomes as well as for publication Objectives
and academic promotion. The course will feature breakout At the conclusion of this session, the participant will be able to:
sessions during which attendees will have the opportunity to • at the conclusion of this session, the learner will be better able
consult with QI expert faculty on their own current/active projects to apply patient-centered approaches to ventilator setup and
to further enhance their experience. titration using physiologic parameters such as P0.1, driving
12:00 Introduction pressure, and esophageal pressure.

ATS 2026 Advance Conference Program • Orlando, FL

SATURDAY • MAY 16 Click on the session title to view the speakers 15

• at the conclusion of this session, the learner will be better able Assemblies on Clinical Problems, Behavioral Science and
to identify and address patient-ventilator dyssynchrony using Health Services Research, Clinical Problems, Sleep and
ventilator waveforms and adjust support settings to optimize Respiratory Neurobiology
synchrony and diaphragm protection. 12:00 P.M. - 4:00 P.M.
• at the conclusion of this session, the learner will be better able Target Audience
to integrate ventilator liberation strategies including All fellows, junior and senior faculty
spontaneous breathing trial criteria, sedation optimization, and
diaphragm-protective weaning approaches. Objectives
At the conclusion of this session, the participant will be able to:
Educational Objectives By the conclusion of this session,
participants will be able to: 1. Interpret ventilator waveforms to • analyze how LLMs influence curiosity, critical thinking, and
detect and manage common forms of patient-ventilator uncertainty in medical education and clinical care, while evaluating
dyssynchrony. 2. Apply principles of driving pressure and ethical concerns like bias, validity, and transparency.
mechanical power to ventilator titration. 3. Evaluate patient • apply prompt engineering and use AI tools for tasks such as case
respiratory drive using tools such as P0.1 and esophageal writing, data analysis, letters, and study aids; critique their
pressure to reduce the risk of P-SILI. 4. Compare PEEP titration educational value and limitations.
strategies including those based on esophageal pressure
• construct faculty development strageties and perspectives on AI
monitoring. 5. Implement protocols for safe and effective
use in learner assessment and coaching with reflection on
liberation from mechanical ventilation.
pedagogical, technical, and ethical implications and preserving
12:00 Welcome and Framing the Day: What Every ICU critical thinking and preventing cognitive deskilling.
Clinician Should Know in 2026
This dynamic session explores strategies for medical educators
12:10 Waveforms at the Bedside: What to Look For and navigating the evolving landscape of AI in education. Focusing on
When to Act preclerkship and clerkship learning, assessment practices, and
12:35 P0.1 and the Physiology of Effort: Using Drive to faculty development, it addresses the ethical, valid, and unbiased
Prevent P-SILI integration of AI tools. Participants will examine the opportunities and
challenges AI presents in enhancing learning while guarding against
1:00 Driving Pressure, Mechanical Power, and Other cognitive deskilling. Through case-based discussion and practical
Metrics to Target frameworks, the session offers guidance on fostering adaptive
1:25 PEEP Titration: Esophageal Manometry and Other expertise, ensuring assessment integrity, and promoting critical
Strategies engagement with technology. Educators will leave equipped to
thoughtfully harness AI’s potential while preserving core clinical
1:50 Break
reasoning and judgment in medical training.
2:10 Protecting the Diaphragm: When Less Support May
12:00 Part A: Didactics Intro
Be More
12:05 AI, Curiosity, and Critical Thinking: Evolving Core
2:35 Liberation From Mechanical Ventilation: Protocols
Competencies in the Age of Algorithms
and Pitfalls
12:25 Navigating Uncertainty: The Role of AI in Medical
3:00 Case-Based Audience Panel: What Would You Do
Education vs. Clinical Decision-Making
12:45 How Do Large Language Models Work? A Primer
BEHAVIORAL • CLINICAL for Medical Educators
POSTGRADUATE COURSE 1:05 Prompt Engineering for Educators and Clinicians:
From Good to Great Prompting
PG18 AI IN MEDICINE: EDUCATING THE
1:25 AI Tools in Action: A Survey of Practical
FUTURE, TRANSFORMING PRACTICE Applications in Medical Education
R Pre-registration and additional fees required. Attendance is limited.
Member $235
LMIC Member $165
Non-Member $290
In-Training Member $140
LMIC In-Training Member $98
In-Training Non-Member $210
1:45 Practical Skills Session 1: Prompt Engineering for
Case Generation

ATS 2026 Advance Conference Program • Orlando, FL

16 Click on the session title to view the speakers SATURDAY • MAY 16

2:05 Practical Skills Session: Simple Data Analysis practice sessions interpreting cases and waveforms (led by
Using AI experienced faculty), learners will enhance their understanding of
2:25 Practical Skills Session: Letters with AI - Efficiency how to correctly acquire data using pulmonary artery catheters,
and Ethics how to troubleshoot during the procedure and ensure high-quality
data capture, and how to interpret the resulting data to guide
2:45 Practical Skills Session: AI as a Study Tool - Design clinical decision-making in both inpatient and outpatient settings.
and Evaluate
12:00 Nuts and Bolts of Performing Right Heart
3:05 Practical Skills Session Can AI Be a Coach? Catheterization.
3:19 Practical Skills Session Debate - Should AI Be Used 12:20 Case Based Discussion 1
in Learner Assessment?
12:40 Breakout Session 1
3:25 Questions and Answers
1:20 Waveforms, Cardiac Output Calculations and
Vasoreactivity Testing,
CLINICAL 1:40 Exercise RHC: Who, What, When, Why and How
POSTGRADUATE COURSE 2:00 Breakout Session 2
2:26 Break
PG19 WAVE GOODBYE TO CONFUSION:
RIGHT HEART CATHETERIZATION AND 2:40 Case Based Discussion 2
WAVEFORM INTERPRETATION 3:00 Breakout Session 3
R Pre-registration and additional fees required. Attendance is limited.
Member $235
LMIC Member $165
Non-Member $290
In-Training Member $140
LMIC In-Training Member $98
In-Training Non-Member $210
Assemblies on Pulmonary Circulation, Critical Care
CLINICAL
POSTGRADUATE COURSE

12:00 P.M. - 4:00 P.M. PG20 CONTEMPORARY QUESTIONS IN

Target Audience PULMONARY INFECTIONS IN THE
Cardiopulmonary providers, intensivists, providers using or IMMUNOCOMPROMISED HOST
encountering pulmonary artery catheters, trainees and staff R Pre-registration and additional fees required. Attendance is limited.
(nurses, PA/NP) encountering or using pulmonary artery Member $235 In-Training Member $140
catheters LMIC Member $165 LMIC In-Training Member $98
Non-Member $290 In-Training Non-Member $210
Objectives
Assembly on Pulmonary Infections and Tuberculosis
At the conclusion of this session, the participant will be able to:
• learn expert procedural technique for catheter insertion, 12:00 P.M. - 4:00 P.M.
preparation, and troubleshooting, to acquire accurate, reliable, Target Audience
and reproducible cardiopulmonary hemodynamic data. Clinicians who manage immunocompromised patients with lung
infections
• assess pulmonary artery catheter waveforms and interpret
resulting hemodynamic data, quantify flow through the Objectives
cardiopulmonary system, calculate shunting. Learners will be At the conclusion of this session, the participant will be able to:
able to confidently interpret PAC data to guide management. • appreciate recent advances in the diagnostic and therapeutic
• use pulmonary artery catheter data for advanced calculations, approaches to invasive pulmonary aspergillosis in the
such as shunt calculations, use of exercise testing, and applying immunocompromised host.
PAC data to the critically ill patient • recognize the at-risk patient who may have a non-traditional
This course will review the technical considerations, execution, and immunosuppressed state such as receipt of a novel biologic agent.
interpretation of pulmonary artery catheterization (waveforms and • become familiar with contemporary thinking regarding prevention of
data). Using both case-based lectures and multiple small group viral and pneumocystis infection in the immunocompromised host.

ATS 2026 Advance Conference Program • Orlando, FL

SATURDAY • MAY 16 Click on the session title to view the speakers 17

In this course, a multidisciplinary group of speakers will expose 12:00 P.M. - 4:00 P.M.
clinicians to six current and vexing challenges in pulmonary infections Target Audience
in the immunocompromised host. The focus will center on, but will not Basic scientist and clinician scientist and clinicians with an
be limited to, fungal and viral pathogens. The course will also include interest in translational research
an overview of nontraditional immunocompromised states. Each talk
will begin with a representative case example followed by a Objectives
multiple-choice question, which the attendees will answer using an At the conclusion of this session, the participant will be able to:
audience response system (ARS). The chairs will moderate a panel • at the end of the session the learner will be able to name
discussion between the attendees and speakers after each pair of different, clinical relevant ex vivo models based on PCLS.
talks. • at the end of the session the learner will be able to discuss
12:00 Introduction advantages and disadvantages of PCLS as a preclinical
12:05 Nontraditional Immunocompromised States: What human model for chronic lung diseases such as IPF and be
Are They and is the Risk Real? able to pick a fitting ex vivo model to answer their scientific
question.
12:30 Emerging Biologics: What’s New and What’s the
Infection Risk? • at the end of the session, the learner will be able to describe
the application of state-of-the-art technologies to PCLS.
12:55 Panel Discussion
The PG course on the emerging human lung tissue-based
1:10 Break translational model precision cut lung slices (PCLS) highlights the
1:30 Who Needs Pneumocystis Prophylaxis in 2026? need for advanced model systems in lung disease research. It
explores recent advances in PCLS for studying infection and
1:55 Are We Ready for Precision Prevention of Viral
fibrosis, the use of ex vivo models to measure tissue function and
Infections in the Immunocompromised Host?
understand COPD, and the application of PCLS for studying
2:20 Panel Discussion aging-related hallmarks and identifying biomarkers for premature
2:35 Break lung aging. The adaptation of PCLS to incorporate cyclical
stretching and the use of mathematical modeling for predicting
2:55 Nonculture Diagnostics for IPA: What Do We Have antifibrotic therapeutic targets will also be discussed, alongside
and What Do We Need? future challenges and perspectives in human PCLS use for drug
3:20 What Do Recent Guidelines Say About Combination development and validation.
Therapy for IPA? 12:00 The PCLS Path for Pulmonary Science and
3:45 Panel Discussion and Wrap Up Medicine
12:25 Live Demonstration
BASIC • TRANSLATIONAL 12:50 How to Get PCLS if You Cannot Make Them
Yourself
POSTGRADUATE COURSE
1:05 Using PCLS to Study Infection and Fibrosis in the
PG21 TRANSLATIONAL WINDOWS INTO THE Human Lung
LUNG MICROENVIRONMENT: 1:30 Watching Alveologenesis in Real Time
ADVANCES WITH PRECISION-CUT
1:55 Break
LUNG SLICES
2:20 Human Lung Aging in a Dish
R Pre-registration and additional fees required. Attendance is limited.
Member $235
LMIC Member $165
Non-Member $290
In-Training Member $140
LMIC In-Training Member $98
In-Training Non-Member $210
Assemblies on Respiratory Cell and Molecular Biology,
2:45

3:10
Using PCLS to Close the Therapeutic Gap in
Pulmonary Fibrosis
Taking it to the Next Level- Mechanobiology on
Ex Vivo Models
Allergy, Immunology and Inflammation, Pediatrics,
Respiratory Structure and Function 3:35 Exploring PCLS - One Niche at a Time

ATS 2026 Advance Conference Program • Orlando, FL

18 Click on the session title to view the speakers SATURDAY • MAY 16

4:30 - 5:30 p.m.

OPENING CEREMONY
The ATS is thrilled to kick off the 2026 International Conference with an inspiring Opening Ceremony on Saturday, May 16, in
Orlando. The Opening Ceremony is free for all registered attendees, offering a unique opportunity to connect with peers and be
inspired by one of medicine's most dynamic voices.
The ATS thanks GSK for its support of the ATS 2026 Plenary Session.

NETWORKING SUPER CENTER

Stop by the Networking Super Center to visit the ATS Center, the International Participants Center, and the Learning Studio.
The Learning Studio and the International Participants Center offer unique programming, and the ATS Center hosts resources
to help you maximize your conference experience.
COLLABORATE, EDUCATE, CONNECT AND LEARN

5:30 - 6:30 p.m.

THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS

Join us for a welcome networking event for all Early Career Professionals immediately following the Opening Ceremony. This
one-hour networking event offers the opportunity to connect with peers, meet ATS leadership, and learn more about conference
offerings and ways to get involved with ATS. Enjoy drinks and appetizers while mingling in a relaxed setting. Members of the
Professional Development Committee and ATS leadership will be on hand to answer questions, share insights, or simply say
hello. Attendees can also learn how to become an ATS in-training member—for FREE!

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 19

MTE10 USE OF BIOLOGIC THERAPIES IN THE

TREATMENT OF INTERSTITIAL LUNG DISEASE
MTE11 SELECTION AND MANAGEMENT OF “HIGH RISK”
LUNG TRANSPLANT CANDIDATES
MTE12 SHARED DECISIONS = SHARED SUCCESS: A
GUIDE TO LCS SHARED-DECISION MAKING?
MTE13 MICROPLASTICS: RESEARCH CHALLENGES,
OPPORTUNITIES, AND APPROACHES

KEYNOTE SERIES

8:00 a.m. -8:45 a.m.

Sunday Morning, May 17
K1 The Science and History of
Vaccines
MEET THE EXPERT SEMINARS The ATS Keynote Series focuses on timely topics of high
relevance to the pulmonary, critical care, and sleep
R
MTE1
Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
10:45 a.m. - 11:45 a.m.
TRIALS IN THE TRENCHES ? PRACTICALITIES OF
medicine community.
Keynote lectures feature leaders who have made major
contributions in the important themes programmed at the
2026 conference and are unopposed by any other
INITIATION AND CONDUCT OF CLINICAL TRIALS IN
CRITICALLY ILL POPULATIONS programming.

MTE2 A PRACTICAL GUIDE TO USING GENERATIVE AI IN Keynote Speaker: Demetre Daskalakis, MD, MPH
RESEARCH
MTE3 REWIRING MOTOR CIRCUITS: PRECISION DOSING
OF INTERMITTENT HYPOXIA THERAPY
YEAR IN REVIEW
MTE4 SMALL BUT MIGHTY-EVS IN LUNG HEALTH AND
DISEASE A1 CLINICAL YEAR IN REVIEW
MTE5 BRONCHIECTASIS: A SILENT STORM BEHIND THE 9:15 A.M. - 10:45 A.M.
COUGH
Target Audience
MTE6 THE MULTIFACETED ROLE OF FLEXIBLE Pulmonary, critical care, and sleep providers
BRONCHOSCOPY IN ASTHMA: FROM DIAGNOSIS
Objectives
TO PHENOTYPING AND PRECISION CARE
At the conclusion of this session, the participant will be able to:
MTE7 EXPLORING PUBLIC DATASETS AND
• be able to apply new clinical research knowledge to clinical
INTEGRATING MULTI-OMICS FOR
practice
TRANSLATIONAL RESEARCH: AN
INVESTIGATOR’S GUIDE TO NAVIGATING THE • learn new findings about key conditions in pulmonary, critical
WORLD OF OMICS care and sleep
MTE8 ADVANCING PULMONARY REHAB: RESPIRATORY • have new strategies to manage the care of common conditions
MUSCLE TRAINING ACROSS CARE SETTINGS in pulmonary, critical care, and sleep
MTE9 COMPLICATED PLEURAL DISEASE: AN This program has been developed to include core topics in
EVIDENCED BASED APPROACH pulmonary, critical care, and sleep medicine. The goal of the
session is to discuss critical state-of-the-art topics and evolving

ATS 2026 Advance Conference Program • Orlando, FL

20 Click on the session title to view the speakers SUNDAY • MAY 17

concepts. The learner will be exposed to a carefully curated applying these tools in clinical trials, drawing insights from other
review of the current literature by emerging leaders in the field. disciplines (e.g.: oncology).
After the course, participants will better understand novel 9:15 Multimodal Profiling for Pulmonary Disease:
concepts in each specific domain that we hope will translate to Clinical Needs and Applications
improved patient care.
9:20 Image-Based Spatial Transcriptomics for Molecular
9:15 Asthma Characterization of Cellular Niches in Lung Fibrosis
9:37 Pulmonary Vascular Disease 9:34 Identification of Novel Protein Biomarkers of
10:00 Vaccines CT-Based Quantitative Interstitial Abnormalities
10:23 Sleep 9:48 Optical Coherence Tomography for Early,
Microscopic Detection, Diagnosis, and Monitoring
of Lung Disease
BASIC • CLINICAL • TRANSLATIONAL
10:02 Visualizing Pathobiology: PET Imaging of Cellular
BASIC SCIENCE CORE and Molecular Drivers of Lung Disease
10:16 Seeing is Believing: Using Advanced Imaging
A2 VISUALIZING THE TARGET:
Technologies in Clinical Trials
IMAGE-BASED MULTIMODAL
PROFILING OF MICRO AND 10:30 Placeholder
MACROENVIRONMENT IN LUNG
DISEASE CLINICAL
Assemblies on Clinical Problems, Respiratory Cell and
Molecular Biology
CLINICAL TOPICS IN PULMONARY MEDICINE

9:15 A.M. - 10:45 A.M. A3 FELLOWS CASE CONFERENCE

Target Audience Assemblies on Behavioral Science and Health Services
Basic, translational, and clinical researchers; providers of lung Research, Clinical Problems; SCALe: Professional
health care Development Committee
Objectives 9:15 A.M. - 10:45 A.M.
At the conclusion of this session, the participant will be able to:
Target Audience
• describe new strategies to apply image-based transcriptomic Trainees including fellows, residents and students; educators;
and proteomic findings in lung disease profiling clinicians; nurses; and researchers aiming to broaden their
• describe new findings for preclinical and clinical imaging of clinical acumen to facilitate clinical and translational research
and education.
pulmonary disease
Objectives
• integrate novel imaging tools into clinical trials
At the conclusion of this session, the participant will be able to:
A deeper molecular understanding of lung disease pathobiology
• Recognize clinical, radiographic, and pathologic findings of
is essential for developing targeted therapies and improving
rare diseases.
disease monitoring. Recent advances in spatial omics, and
microscopic and molecular imaging methods have opened new • Gain insight into clinical decision-making skills demonstrated
frontiers in biomarker discovery and spatial characterization of by master clinicians, radiologists, and pathologists which will
lung disease initiation and development. This session will first improve the quality of learners’ practice and potentially
outline clinical challenges and unmet needs, followed by improve the quality of care for the learner’s patients.
highlighting cutting-edge multimodal approaches that are • Develop strategies to evaluate patients with common
reshaping our understanding of pulmonary diseases, including symptoms that include uncommon/ rare diseases in the
spatial transcriptomics and proteomics, optical coherence differential diagnosis when appropriate.
tomography, and molecular PET imaging. Finally, it will focus on

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 21

Four unknown cases will be presented by adult PCCM fellows to NHLBI and ATS. The success of host-directed therapies (HDTs)
a panel of experts in a traditional Clinical Pathology Conference in COVID-19-such as dexamethasone and tocilizumab-has
(CPC) format. The panel of experts includes three master reinvigorated interest in HDTs for sepsis. This symposium will
clinicians , a chest radiologist , and a pathologist. The clinician feature international leaders discussing the current HDT
experts will discuss the key clinical elements of the history and a landscape, key lessons from past trials, and how ongoing studies
differential diagnosis. The expert radiologist and pathologist will aim to advance precision immunomodulation in sepsis.
interpret the imaging and pathology, respectively, which the 9:15 Back to Basics: The Dysregulated Host Response
expert clinicians will use to further discussion and make a in Sepsis
diagnosis. High yield summarizing teaching points will be
incorporated into each presentation. 9:30 Genetics: Differences in Immunologic Susceptibility
to a Dysregulated Host Response
9:15 Expert Clinician
9:45 Still in Flux: Immunomodulatory Therapies and
9:33 Expert Clinician Sepsis - A Case Yet to Be Closed
9:51 Expert Clinician 10:00 Molecular Diagnostics: Are We There Yet?
10:09 Expert Radiologist 10:15 Outsmarting the Host: Implementing HDT in Sepsis
10:27 Expert Pathologist Clinical Trials
10:30 Looking Forward: How to Catalyze Implementation
CLINICAL • TRANSLATIONAL of HDT in Sepsis

CRITICAL CARE TRACK

BASIC • TRANSLATIONAL
A4 HOST-DIRECTED THERAPEUTICS IN
SEPSIS: LESSONS LEARNED AND SCIENTIFIC SYMPOSIUM
FUTURE DIRECTIONS A6 THE OBESE LUNG
Assemblies on Critical Care, Pulmonary Infections and MICROENVIRONMENT: NEW INSIGHTS
Tuberculosis INTO ASTHMA PATHWAYS AND
9:15 A.M. - 10:45 A.M.
THERAPEUTIC TARGETS
Target Audience Assemblies on Respiratory Structure and Function, Allergy,
Clinicians and researchers who care for or conduct research on Immunology and Inflammation, Pediatrics, Respiratory
adult patients with sepsis, pneumonia, infection in a hospitalized Structure and Function
setting 9:15 A.M. - 10:45 A.M.
Objectives Target Audience
At the conclusion of this session, the participant will be able to: Investigators from diverse disciplines including molecular and
• understand the role of modulating the host response in sepsis cellular biology, systems biology, translational science, and
to improve patient outcomes clinical research

• understand the variation in immunological susceptibility for a Objectives

dysregulated host response in sepsis and how corticosteroids At the conclusion of this session, the participant will be able to:
may modify the host response and improve patient outcomes • describe new findings about the mechanistic links between
• become familiar with ongoing clinical trials that are applying metabolic dysregulation and airway inflammation, smooth muscle
molecular diagnostics and testing HDT for sepsis function, and immune responses in obesity-related asthma

Sepsis, defined as a dysregulated host response to infection, • integrate emerging omics approaches and systems biology
remains a major cause of morbidity and mortality. Yet treatment insights to better define the heterogeneity of obesity-related
largely focuses on antibiotics and source control, with limited asthma and identify novel therapeutic targets
strategies to modulate the host response. Identifying pathways to • apply new knowledge of neuro-immune-endocrine interactions to
recalibrate immune responses has emerged as a priority for improve patient stratification and inform the development of

ATS 2026 Advance Conference Program • Orlando, FL

22 Click on the session title to view the speakers SUNDAY • MAY 17

personalized treatment strategies for individuals with • describe new findings about how sex hormones, chromosomal
obesity-related asthma factors, and gendered exposures influence lung and heart
Obesity-related asthma is a phenotype with increasing prevalence, development and disease risk at key life stages
marked by poor symptom control, reduced treatment response, and • apply sex- and gender-informed approaches to research
complex, systemic pathophysiology. This symposium will explore design and clinical care for patients with pulmonary vascular
multifaceted mechanisms that link metabolic dysregulation within and right heart disease
cells or in the context of metabolic disease. to airway inflammation, • better counsel patients on sex-specific risk factors and
smooth muscle function, neural regulation, and immune responses. life-stage-dependent influences (e.g., pregnancy, menopause)
We aim to bring together investigators across disciplines- from on lung and heart health
molecular and cellular biology to systems biology, translational
science and clinical research. This session will highlight emerging This session will explore how biologic sex and gender influence
basic and translational research-from smooth muscle remodeling, pulmonary vascular and right ventricular health from fetal life
neuro-immune-endocrine interactions, and emerging omics through aging. Speakers will examine hormonal, chromosomal,
approaches that offer insight into disease heterogeneity and potential and lifestyle factors that drive remodeling of the pulmonary
therapeutic targets. circulation and RV, affecting disease susceptibility, progression,
and treatment response in pulmonary hypertension. Through life
9:15 Cross Talk between CD4+ T cells and Airway stages including fetal development, childhood through
Smooth Muscle in Pediatric Obesity-Related adolescence, pregnancy, loss of gonadal function, and aging, the
Asthma symposium will present integrated basic, translational, and
9:33 Integrating Genomics as Clinical Biomarkers in clinical perspectives. The session will conclude by addressing
Obesity-Associated Asthma sex-based disparities in treatment decisions and drug
9:51 Neuro-Immune-Endocrine Interactions in development, offering a roadmap toward individualized therapies
Obesity-Related Asthma in pulmonary vascular disease.

10:09 Diet, Obesity, and Asthma 9:15 Sex and Hormones in Cardiopulmonary
Development in Neonates
10:27 Gaps and Future Directions in Clinical Research on
Obesity-Related Asthma 9:30 From Childhood to Adolescence: Emerging Sex
Differences in Lung and Cardiovascular Health
9:45 Sex Chromosome Effects in Cardiopulmonary
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL Vascular Disease
SCIENTIFIC SYMPOSIUM 10:00 Cardiopulmonary Stress and Adaptation in
Pregnancy
A7 FROM EARLY DEVELOPMENT
10:15 Aging and Sex Hormone Loss in the Lungs and RV
THROUGH AGING: SEX AND GENDER
EFFECTS ON CARDIOPULMONARY 10:30 Toward Individualized Treatments: Sex Differences
DISEASE in PH Therapies

Assemblies on Pulmonary Circulation, Pediatrics,

Respiratory Cell and Molecular Biology BASIC • TRANSLATIONAL
9:15 A.M. - 10:45 A.M. SCIENTIFIC SYMPOSIUM
Target Audience
Clinicians and researchers involved in the diagnosis, A8 THE WOUNDED LUNG: CELLULAR
management, or investigation of pulmonary vascular and right STRESS, INFLAMMATION AND
heart disease, with a focus on effects of sex differences, CARCINOGENESIS
hormonal influences, and aging on cardiopulmonary disease.
Assemblies on Thoracic Oncology, Allergy, Immunology
Objectives and Inflammation, Respiratory Cell and Molecular Biology
At the conclusion of this session, the participant will be able to:
9:15 A.M. - 10:45 A.M.

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 23

Target Audience CLINICAL • TRANSLATIONAL

Researchers in basic, translational and clinical fields interested
in understanding the immunopathogenesis of lung injury and SCIENTIFIC SYMPOSIUM
lung cancer
Objectives
A9 PRIMARY CILIARY DYSKINESIA IN A
At the conclusion of this session, the participant will be able to: GENOMIC THERAPEUTIC ERA
• describe the cellular and immunologic mechanisms by which Assemblies on Pediatrics, Pulmonary Infections and
chronic lung injury, including in IPF and COPD, promotes Tuberculosis
epithelial plasticity and malignant transformation 9:15 A.M. - 10:45 A.M.
• explain how chronic inflammation remodels the lung immune Target Audience
microenvironment to facilitate immune evasion and tumor Paediatricians, clinicians, pulmonologists, geneticists, basic
progression scientists
• evaluate experimental model systems that recapitulate chronic Objectives
lung injury and its transition to cancer, and assess their utility At the conclusion of this session, the participant will be able to:
in studying disease mechanisms and testing novel
• identify patients with primary ciliary dyskinesia - including
interventions
those in resource limited regions
This symposium will explore how cellular stress and immune
• accurately diagnose primary ciliary dyskinesia
dysregulation contribute to the pathogenesis of lung injury and
carcinogenesis. Experts in basic and translational research will • recommend treatment options and future treatments available
highlight emerging mechanisms by which epithelial damage, Primary ciliary dyskinesia is a multimorbid inherited lung
chronic inflammation, and immune remodeling shape the injured condition. Symptoms include neonatal respiratory distress,
lung microenvironment and drive malignant transformation. oto-sino- pulmonary disease and recurrent infections leading to
Emphasis will be placed on the intersection of stress signaling, bronchiectasis in adults. It is significantly underdiagnosed.
host immunity, and epithelial plasticity as convergent pathways Advances in genomic medicine pave the way for neonatal
linking injury to cancer. diagnosis and genetic therapies. This session will cover state of
9:15 Epithelial Cell Response to Classic and Emerging the art in diagnosis and treatment with a focus on improving
Exposures in Lung Carcinogenesis health disparities in genetic diseases to improve equity, and
inclusion. The session will highlight the first joint ATS/ERS
9:33 The Inflammatory Continuum: COPD-Associated
diagnostic guideline (to be published end 2025), the completion
Lung Microenvironment as a Fertile Ground for
of the 4 year NIH clingen gene project defining disease - gene
Lung Cancer Progression
associations, patient priorities and access in low resource
9:51 Complement in the Lung: A Double-Edged Sword in settings and the latest in therapeutic trials.
Immune Defense and Tumor Promotion
9:15 ERS/ ATS clinical practice guidelines for the
10:09 Tracing Lung Cancer Back to its Progenitors diagnosis of primary ciliary dyskinesia
10:27 Lung Organoids: Windows to Regulation of 9:35 Genetics of primary ciliary dyskinesia:
Progenitors in Lung Homeostasis, Injury Repair, Gene-disease relationships
and Cancer
9:55 Setting up a PCD centre and strategies for
managment
10:15 Translational research and new therapies for
Primary ciliary dyskinesia

ATS 2026 Advance Conference Program • Orlando, FL

24 Click on the session title to view the speakers SUNDAY • MAY 17

BASIC • CLINICAL • TRANSLATIONAL BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM SCIENTIFIC SYMPOSIUM
A10 IS IT SARCOIDOSIS? - I DON’T KNOW A11 ADVANCING HEALTHCARE QUALITY
Assemblies on Allergy, Immunology and Inflammation, THROUGH WORKFORCE EQUITY
Clinical Problems, Environmental, Occupational and Assemblies on Nursing, Behavioral Science and Health
Population Health, Pulmonary Infections and Tuberculosis, Services Research, Critical Care, Pediatrics
Respiratory Cell and Molecular Biology
9:15 A.M. - 10:45 A.M.
9:15 A.M. - 10:45 A.M.
Target Audience
Target Audience Administrators, providers (nurses, MDs, APPs), researchers,
Pulmonologists, rheumatologists, immunologists, cell biologists, trainees. Applicable to all ATS members
and clinical researchers involved in sarcoidosis or other
Objectives
granulomatoues diseases
At the conclusion of this session, the participant will be able to:
Objectives
• explain the benefits of a diverse and inclusive healthcare
At the conclusion of this session, the participant will be able to:
workforce for improving healthcare quality and equity
• differentiate granulomatous lung diseases using integrated
• assess institutional structures that may inhibit equitable
clinical, radiographic, and pathological data.
practice or diverse workforce engagement
• expanding knowledge of the granuloma biology and their
• implement policies and programs that support diversity, equity,
impact on targeted therapeutic strategies.
and inclusion to enhance patient outcomes and workforce
• discuss challenges and pitfalls in the diagnosis of satisfaction
granulomatous lung diseases
The Agency for Healthcare Research and Quality (AHRQ)
The diagnosis of sarcoidosis can be challenging, often mimicking identifies six dimensions of healthcare quality: safety, efficacy,
other granulomatous diseases and requiring careful exclusion of timeliness, efficiency, patient-centeredness, and equity. Yet
alternative etiologies. This session will provide a unique equity remains underemphasized despite persistent disparities in
opportunity for clinicians to engage with leading experts on the outcomes. Recent U.S. policy shifts further challenge traditional
diagnostic dilemmas encountered in sarcoidosis. The session will strategies, creating urgency for innovative, actionable
focus on distinguishing sarcoidosis from other conditions approaches. This symposium presents evidence-based
presenting with granulomas, leveraging cutting-edge molecular strategies to embed equity into workforce development and
and spatial analysis techniques, and bridging the gap between institutional quality improvement. Sessions move from a
basic research and clinical practice. big-picture view of equity in healthcare quality to targeted
9:15 Unraveling the Microarchitecture of Sarcoidosis, approaches in evaluation, mentorship, and data analytics,
the Prototypical Granulomatous Disease concluding with concrete steps to build an inclusive,
high-performing workforce delivering consistently high-quality,
9:33 Granulomas of Infectious Origin: A Deep Dive into equitable care across settings.
Tuberculosis and Other Pathogens
9:15 Introduction
9:51 Granuloma in Rheumatological Diseases: Mimics
and Associations 9:20 Addressing Bias in Professional Evaluation to
Advance Healthcare Quality
10:09 All Granulomas Are Not Sarcoidosis: Chronic
Beryllium Disease and Other Exposures Causing 9:32 Breaking the Glass Ceiling: Strengthening the
Granulomas Nursing Workforce for Equity-Driven Quality
10:27 Bench to Bedside: Translating Granuloma Research 9:44 Uncovering Inequities Through Big Data to Improve
into the clinics Care Quality
9:56 Mentorship as a Workforce Strategy for Sustaining
Equity and Quality

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 25

10:08 Training the Next Generation: ACGME Strategies for session will feature a series of pro/con discussions addressing
an Inclusive, High-Quality Workforce these questions and others.
10:20 International Medical Graduates (IMGs) in the 9:15 Introduction
Workforce 9:25 AI Reduces Clinician Burnout Without Negatively
10:32 Summary & Action Framework From Equity Impacting Patients
Principles to Quality Outcomes: A Practical 9:37 AI Reduces Clinician Burnout Without Negatively
Roadmap Impacting Patients
10:39 Discussion & Q&A 9:49 AI Reduces Clinician Burnout Without Negatively
Impacting Patients - Discussion
BEHAVIORAL • CLINICAL 10:01 AI Enhances Research Innovation and Productivity
Without Perpetuating Bias or Impacting Privacy
SCIENTIFIC SYMPOSIUM
10:13 AI Enhances Research Innovation and Productivity
A12 DO NO HARM, UNLESS THE AI SAYS Without Perpetuating Bias or Impacting Privacy
OTHERWISE - AI ETHICS 10:25 AI Enhances Research Innovation and Productivity
Committee on Ethics and Conflict of Interest Without Perpetuating Bias or Impacting Privacy

9:15 A.M. - 10:45 A.M. 10:37 Questions/Discussion

Target Audience
All providers and researchers who interact with electronic health BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
records that utilize or could utilize artificial intelligence as well as
researchers who evaluate or create proposals that utilize or MEDICAL EDUCATION SEMINAR
could utilize artificial intelligence
ME101 COMMUNICATING AND TEACHING
Objectives
ABOUT UNCERTAINTY IN CLINICAL,
At the conclusion of this session, the participant will be able to:
EDUCATION, AND RESEARCH
• apply structured ethical frameworks to assess the risks and SETTINGS
benefits of AI tools in clinical and research contexts, including
transparency, accountability, and equity Assemblies on Behavioral Science and Health Services
Research
• identify ethical challenges unique to different AI applications
(e.g., diagnostic, informatic, analytic), and distinguish when 10:45 A.M. - 11:45 A.M.
traditional ethical oversight (e.g. clinical ethics committee or Target Audience
institutional review board) may require modernization Clinicians, investigators, educators, public health professionals,
• choose individual AI applications to use in specific scenarios, trainees, nurses, APPs
based on understanding of opportunities and ethical Objectives
challenges, that will benefit the patient in front us without At the conclusion of this session, the participant will be able to:
introducing bias or propagating disparities • By the end of this MTE session, learners will be able to define
• AI tools are being implemented at a dizzying pace, yet the uncertainty, distinguish it from confidence, and describe how it
decision-making processes of these tools are not necessarily impacts patient care, research, and scientific communication.
bound to the personal, societal, and professional ethics of • By the end of this MTE session, learners will be able to apply
human healthcare providers and researchers. This creates new skills and techniques to mitigate diagnostic uncertainty, by
questions we must answer including who is responsible when learning about how both medical and non-medical
AI recommendations cause harm, when and how do we tell professionals manage uncertainty.
patients that AI was involved in their care, how should clinical
ethics committees and IRBs evaluate bias in AI tools, and how • By the end of this MTE session, learners will be able to employ
are ethical principles integrated in learning algorithms. This new skills and techniques to communicate about diagnostic

ATS 2026 Advance Conference Program • Orlando, FL

26 Click on the session title to view the speakers SUNDAY • MAY 17

uncertainty to (a) patients and families, (b) other clinicians, and CLINICAL
(c) the general public.
Uncertainty is rampant in medicine following the pandemic and in PEDIATRIC CLINICAL CORE CURRICULUM
the current socio-political environment where everything from PCC1 PEDIATRIC CLINICAL CORE
Medicaid to NIH funding changes daily. In this interactive
CURRICULUM
session, learners will be able to define uncertainty and distinguish
it from confidence, review literature on its relevance to critical SCALe: Core Curriculum Committee
care, learn strategies used by other professions who deal 12:00 P.M. - 1:00 P.M.
routinely with uncertainty (e.g. engineers, meteorologists,
military, and public health experts), and employ techniques on Target Audience
how to manage uncertainty. Participants will leave the session Advanced Practice Providers,Clinicians,Medical Educators
with skills in communicating with patients and families, trainees, Objectives
and the public which will facilitate their roles as advocates and At the conclusion of this session, the participant will be able to:
[Link] • define new strategies to manage pediatric patients with
pulmonary disease and critical illness
CLINICAL • better counsel pediatric patients and families on new treatment
options for pulmonary disease and critical illness
ADULT CLINICAL CORE CURRICULUM
• better counsel pediatric patients and families on treatment
CC1 ADULT SLEEP CORE CURRICULUM options available for management of pulmonary diseases and
critical illness.
SCALe: Core Curriculum Committee
The goal of the core is to support clinicians who are engaged in
11:30 A.M. - 1:00 P.M.
maintenance of certification activities by providing updates on
Target Audience subjects included in recertification requirements.
Practicing physicians, trainees, students, Advanced Practice
12:00 Pediatric Bronchiectasis: A Comprehensive
Providers
Approach
Objectives
12:25 Cystic Fibrosis: The Latest Therapeutic Advances
At the conclusion of this session, the participant will be able to:
12:50 Panel Discussion
• Identify new strategies to manage patients with sleep
disordered breathing
• better counsel patients and families on treatment options for
sleep disordered breathing
• identify knowledge gaps in the treatment of patients with sleep
disordered breathing.
The goal of the core is to support clinicians who are engaged in
maintenance of certification activities by providing updates on
subjects included in recertification requirements.
11:30 OSA, PH, ILD, OH MY!
11:55 Show Me the Data: Cardiovascular Disease and
OSA
12:20 COMISA: Two Diseases Too Much?
12:45 Panel Discussion

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 27

11:45 a.m. - 1:15 p.m.

DIVERSITY FORUM
The annual ATS Diversity Forum celebrates diversity
within the fields of pulmonary, critical care, and sleep
medicine and research. All ATS members are invited to
attend this inspiring event, which provides valuable career
insights and networking opportunities.
This year's theme is "Resilience in a Time of Challenge."
We are thrilled to welcome our featured speaker, Jennifer
Taylor-Cousar, MD, ATSF, who will bring this theme to life
in a truly impactful way.
We also honor the recipients of the Underrepresented
Trainee Development Scholarships (UTDS). These Sunday Mid-Day, May 17
scholarships are designed to help increase diversity
among underrepresented trainees in medicine by
sponsoring attendance at the ATS International
Conference. Recipients are selected based on the quality BASIC • TRANSLATIONAL
of the science presented in their submitted abstracts,
along with other criteria. MID-DAY SYMPOSIUM
The recipient of the ATS Fellowship in Health Equity and
Diversity will also be recognized during the forum. These MD1 RED JOURNAL IN ACTION 1: EARLY
fellowships support senior fellows, postdoctoral trainees, CAREER LUNG RESEARCH
and junior faculty in advancing health equity through HIGHLIGHTS
research, clinical care, education, and policy initiatives for
patients with respiratory diseases, critical illness or injury, American Journal of Respiratory Cell and Molecular
and sleep-disordered breathing. Biology;
The Diversity Forum is organized and presented by the 12:00 P.M. - 1:00 P.M.
ATS Health Equity and Diversity Committee. This year's
event will be hosted by the committee's chair, Stephanie Target Audience
Lovinsky-Desir, MD, MS. The Underrepresented Trainee Individuals interested in in basic science research of lung
Development Scholarships and the Health Equity and disease and development; Individuals who publish mechanistic
Diversity Fellowship award are supported by the American translational research; Individuals interested in the peer review
Thoracic Society and editorial process; Early career researchers

R Pre-registration and an additional fee are required. Objectives

$45 members/non-members At the conclusion of this session, the participant will be able to:
ATS thanks • describe new findings about emerging breakthroughs of
Genentech molecular and cellular mechanisms for lung disease as
for their generous support of the Diversity Forum. reported in American Journal of Respiratory Cell and
Molecular Biology
• better understand the peer review process, in particular the
most effective approaches to address comments from reviews
and how associate editors facilitate author-reviewer
interactions.
• better understand the features of mechanism-deciphering lung
pathobiology research, and elements that create potential for
future impact in the field.

ATS 2026 Advance Conference Program • Orlando, FL

28 Click on the session title to view the speakers SUNDAY • MAY 17

This is a continuation of an annual series started in 2023. The strategies-to enhance competitiveness in an unstable funding
audience-interactive session will include early career researchers environment
who authored exemplary articles on basic mechanisms of lung Periods of fiscal uncertainty and shifting priorities pose significant
disease published in the May Issue of the American Journal of challenges for clinician-scientists and researchers seeking to
Respiratory Cell and Molecular Biology. The session highlights sustain impactful programs of work. This one-hour session brings
the individual review process for these articles, with Associate together research funders and successful awardees representing
Editors highlighting novelty and relevance of the work alongside federal funding agencies, professional societies, philanthropic
critical comments from reviewers. Authors present the study and organizations, and healthcare systems to explore creative,
highlight how they addressed reviewer comments to achieve strategic approaches to pursuing research support in an unstable
acceptance. funding environment.
12:00 Overview of Session 12:00 Introduction
12:05 Introduction of First Paper 12:05 Federal Perspectives: What Endures When Paylines
12:10 First Highlighted Research Paper Tighten
12:26 Q&A 12:13 Building Momentum and De-Risking Ideas: Lessons
12:31 Introduction of Second Paper from an ATS Awardee

12:36 Second Highlighted Research Paper 12:21 Patient-Centered Perspective: Letting Your “Why”
Drive Competitiveness
12:52 Q&A
12:29 Foundation Perspective: Story, Mission, and
12:57 Closing Remarks Catalytic Funding
12:37 Leveraging Institutional Support through Clinical &
Translational Science Awards (CTSAs): Sustaining
Impact Beyond Grant Cycles
MID-DAY SYMPOSIUM
12:45 Moderated Panel Discussion
MD2 CREATIVE APPROACHES IN AN
UNSTABLE FUNDING ENVIRONMENT:
TRANSLATIONAL
TIPS AND TRICKS FOR SUCCESS
12:00 P.M. - 1:00 P.M. MID-DAY SYMPOSIUM
Target Audience MD3 THE COLLABORATION CATALYST:
Students, trainees, early-career investigators, mid-career faculty, ACCELERATING CLINICAL IMPACT
and senior clinician-scientists with clinical, academic, research, THROUGH ACADEMIC-INDUSTRY
and/or funding responsibilities who seek pragmatic guidance for
SYNERGY
navigating today’s complex funding landscape
Assemblies on Allergy, Immunology and Inflammation,
Objectives
Clinical Problems, Environmental, Occupational and
At the conclusion of this session, the participant will be able to:
Population Health, Respiratory Structure and Function;
• compare how funding priorities and decision-making Drug, Device, Discovery and Development Committee;
processes differ across federal agencies, professional
12:00 P.M. - 1:00 P.M.
societies, foundations, and healthcare systems during periods
of fiscal constraint Target Audience
Physicians, scientists, trainees, fellows, industry professionals,
• apply cross-sector strategies to align research goals with
clinicians, and government representatives
funder missions while maintaining scientific rigor and personal
or programmatic purpose Objectives
At the conclusion of this session, the participant will be able to:
• identify creative approaches-including alternative funding
pathways, partnerships, and visual communication

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 29

• recognize and optimize opportunities to advance research • learn about the importance of the ILO system for classifying
through academic-industry collaborations while addressing chest radiographs for findings of pneumoconiosis, the role of
potential challenges to ensure ethical partnerships the B Reader in performing classifications, and how to become
• describe the possible role(s) and opportunities for academic a B Reader
physicians and scientists in multiple work environments, • learn about the potential for using artificial intelligence
including industry, governmental agencies and biotechnology methods to evaluate chest radiographs for findings of
companies pneumoconiosis and recent NIOSH efforts in this area
• develop strategies to build and sustain productive The session will provide attendees with useful new information
academic-industry partnerships that align with scientific goals, relevant to occupational respiratory disease including updates
institutional values, and patient-centered outcomes from the NIOSH Health Hazard Evaluation and B Reader
This symposium will explore topics of critical relevance to programs, and emerging information about using artificial
academic translational investigators and industry professionals, intelligence to evaluate (“classify”) chest radiographs for findings
emphasizing the pivotal role of academia-industry collaboration in of pneumoconiosis.
advancing scientific discoveries into clinical practice. Four 12:00 Introduction to Session
focused presentations will be followed by dynamic panel 12:03 NIOSH Health Hazard Evaluation Program Update
discussions and audience engagement, fostering debate and
knowledge exchange. The session will highlight successful 12:22 NIOSH B Reader Program Update
models of collaborative innovation, with a focus on accelerating 12:41 Classification of Chest Radiographs for Findings of
therapeutic development and expanding career pathways for the Pneumoconiosis Using Artificial Intelligence
next generation of physician-scientists and translational
researchers.
CLINICAL
12:00 Academia-Industry Collaboration: Potential for
Innovation and Pitfalls to Avoid MID-DAY SYMPOSIUM
12:10 The Future Career Paths of Physician Scientists
MD5 UPDATES ON ARDS, PNEUMONIA,
12:20 Opportunities for Physicians and Scientists in the AND SPESIS PHENOTYPING
Medtech, Biotech and Pharma Sectors CONSORTIUM
Division of Lung Disease, National Heart, Lung, and Blood
CLINICAL • TRANSLATIONAL Institute, National Institutes of Health;
MID-DAY SYMPOSIUM 12:00 P.M. - 1:00 P.M.
Target Audience
MD4 NIOSH OCCUPATIONAL providers of lung health, investigators in lung physiology and
RESPIRATORY DISEASE UPDATES pathophysiology, specific patient groups or multiple stakeholder
CDC - National Institute for Occupational Safety and Health; groups

12:00 P.M. - 1:00 P.M. Objectives

At the conclusion of this session, the participant will be able to:
Target Audience
Providers of lung health; those interested in preventing • learn about the APS Phenotype Consortium. Updates and
occupational respiratory disease progress made.
Objectives • understand the APS phenotype consortium center-specific
At the conclusion of this session, the participant will be able to: projects
• learn about the NIOSH Health Hazard Evaluation Program, its NHLBI and NIGMS awarded the ARDS, Pneumonia, and Sepsis
utility in sentinel surveillance, how to engage the program in (APS) consortium on May 1, 2023. APS Consortium goals are to
evaluating potential work-related outbreaks of respiratory 1) understand the heterogeneity and underlying mechanisms of
disease, and about recent examples of Health Hazard critical illness syndromes and recovery, specifically in adults
Evaluations w/ARDS, pneumonia, and/or sepsis, as well as the relationship

ATS 2026 Advance Conference Program • Orlando, FL

30 Click on the session title to view the speakers SUNDAY • MAY 17

and biological overlap among these syndromes; 2) collect and pulmonary fibrosis before the development of extensive
disseminate data and biospecimens as a resource to the broader scarring of the lung
research community. It consists of one coordinating center and In 11/2020, VHA embarked on a 5-year lung cancer program
six clinical centers that plan to enroll 4000 patients and conduct called LPOP, one goal of which was to improve early detection
consortium-wide studies as well as center-specific studies. The through screening. The program has grown to include 118 VA
session will highlight/showcase research goals, scopes, novel facilities nationally, making it an outstanding venue for research
findings and advocate the resource for the broader community to aimed at improving outcomes. This session will describe
advance research and knowledge in this field. research studies with the following goals: to better understand
12:00 Progress on APS consortium the impact of pre-screening health status on outcomes; to
12:07 Description of first 500 participants data and incorporate risk factors beyond age and smoking in patient
biospecimens selection; to use artificial intelligence for risk stratifying screening
cohorts; and to characterize the impact of early detection of
12:14 Initial preliminary results and publications (1) interstitial lung abnormalities and pulmonary fibrosis in screening
12:21 Initial preliminary results and publications (2) programs.
12:28 Initial preliminary results and publications (3) 12:00 Outcomes for Early-Stage Lung Cancer in Screened
Veterans by Pre-screening Health Status
12:35 Initial preliminary results and publications (4)
12:15 Expanding Lung Cancer Screening Criteria in
12:42 Initial preliminary results and publications (5)
Veterans
12:49 Q & A Session
12:30 Evaluation of an AI-Based Assessment of Lung
Cancer Risk from a Single Low-Dose CT Scan
BEHAVIORAL • CLINICAL • TRANSLATIONAL 12:45 AI Surveillance for Timely Detection of Pulmonary
Fibrosis and Care Pathway Optimization
MID-DAY SYMPOSIUM
MD6 VHA LUNG PRECISION ONCOLOGY
BASIC • TRANSLATIONAL
PROGRAM: KEY FINDINGS FROM
SCREENING RESEARCH MID-DAY SYMPOSIUM
VHA Office of Research and Development; MD7 ENVIRONMENTAL EXPOSURES AND
12:00 P.M. - 1:00 P.M. CHRONIC PULMONARY MORBIDITY
Target Audience National Institute of Environmental Health Science;
Providers of lung health serving patients at high risk for lung
12:00 P.M. - 1:00 P.M.
cancer; those engaged in administering lung cancer screening
programs or conducting research relating to such programs; all Target Audience
lung health providers who are VA-based Basic science researchers, clinicians, medical educators
Objectives Objectives
At the conclusion of this session, the participant will be able to: At the conclusion of this session, the participant will be able to:
• assess a patient’s candidacy for lung cancer screening • gain knowledge from the emerging studies demonstrating how
through use of objective criteria, such as CAN scores and acute exposure depending on the lifestage contributes to
Elixhauser Comorbidity indices, to assess pre-screening long-term consequences in respiratory health
health status • gain comprehensive understanding on the utility of integrating
• assess whether use of Sybil would permit risk stratifying those multiomics analyses in developing potential biomarkers of
in a screening cohort, thus improving the efficiency of the exposure and response to predict effects on chronic
screening program pulmonary morbidity
• have a better understanding of how AI algorithms can assist The NIEHS supported research to understand the impacts of
screening programs improve early detection of idiopathic environmental pollutants, especially inhaled air pollutants over

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 31

the past five decades. The research findings from these efforts • have new strategies to manage the care of patients with long
contributed to regular evaluation and updating ambient air quality COVID by applying evidence-based approaches, improving
standards. Though the ambient levels of fine particulate matter, early referral, and incorporating multidisciplinary resources to
ozone and other toxic chemicals are under current standards in enhance patient outcomes and quality of life.
most parts of the US, there is accumulating evidence of their Recent research leveraging the NIH RECOVER and C4R cohorts
impacts on pulmonary morbidity. Additionally, exposure to air has revealed persistent pulmonary and immune complications in
pollutants during childhood are found to impact later in life. This long COVID. Studies identify ongoing respiratory symptoms,
session will provide a snapshot on our current understanding on declines in lung function, and both restrictive and obstructive
exposure-induced chronic respiratory morbidity. defects, with radiographic evidence of lung injury. SARS-CoV-2
12:00 Introduction can disrupt airway integrity, impair mucociliary clearance, and
12:05 Early Life Exposure to Particulate Matter Air promote chronic inflammation. Immunological research
Pollution Affects Epigenome and Transcriptome demonstrates sustained elevation of pro-inflammatory cytokines
Later in Life and altered T-cell responses, contributing to fatigue and
breathlessness. These findings highlight the heterogeneity of
12:22 Naphthalene Metabolism and Genotoxicity: Early long COVID and the need for integrated, longitudinal
Indicators of Lung Cancer Potential assessment, guiding targeted interventions to improve outcomes
12:39 Exposure to the Air Pollutant Ozone and Adverse for affected individuals.
Respiratory Health Effects: Results from Studies 12:00 Introduction: RECOVER and C4R Resources for
with Genetically Diverse Mice Ancillary Studies
12:56 Moderated Discussion 12:10 Understanding Long COVID: Insights from the
RECOVER Adult Cohort Study and Clinical Trials
BASIC • CLINICAL 12:20 From Mechanism to the Clinic: Characterizing Long
COVID in Children and Adolescents in RECOVER
MID-DAY SYMPOSIUM
12:30 Epidemiologic Features of Recovery From
MD8 NIH RECOVER AND C4R COHORTS: SARS-CoV-2 Infection from the C4R Cohort
PULMONARY COMPLICATIONS AND 12:40 Characteristics and Determinants of Pulmonary
IMMUNE DYSFUNCTION IN Long COVID
LONG-COVID ACROSS THE LIFESPAN 12:50 Panel Discussion
Division of Lung Disease, National Heart, Lung, Blood
Institute, National Institutes of Health;
BASIC • CLINICAL • TRANSLATIONAL
12:00 P.M. - 1:00 P.M.
Target Audience
MID-DAY SYMPOSIUM
Fellow/Junior / Established Professional MD9 GENERIC DRUG DEVELOPMENT FOR
Objectives RESPIRATORY PRODUCTS, US FOOD
At the conclusion of this session, the participant will be able to: AND DRUG ADMINISTRATION UPDATE
• learn new findings about the risk factors and mechanisms US Food and Drug Administration;
underlying long COVID (PASC) identified through the NIH
RECOVER and C4R cohorts, with a focus on pulmonary and 12:00 P.M. - 1:00 P.M.
immune dysfunction. Target Audience
Clinicians in practice, researchers, pharmaceutical industry
• be better able to diagnose and characterize long COVID
representatives, international drug regulators
complications in diverse patient populations by integrating
objective clinical measures, symptom indices, and Objectives
phenotyping strategies developed by leading investigators. At the conclusion of this session, the participant will be able to:

ATS 2026 Advance Conference Program • Orlando, FL

32 Click on the session title to view the speakers SUNDAY • MAY 17

• recognize key aspects of the generic drug regulatory approval Target Audience
process, and how the Office of Generic Drugs (OGD) Basic and Clinical researchers interested in understanding the
evaluates comparative clinical information to support latest developments for PE
bioequivalence for complex inhaled generic drug products Objectives
• describe product-specific guidances for generic drug products At the conclusion of this session, the participant will be able to:
recently posted by the Office of Generic Drugs (OGD), with a • understand the shortcomings of current PE diagniosis and
focus on how these can inform complex orally inhaled and treatment
nasal generic drug development
• learn about novel preclinical models that are helping
• articulate how emerging technologies and innovative researchers study PE
approaches are being utilized for FDA-funded research, FDA
guidance development, and regulatory decision-making • improve outcomes of PE patients by integrating treatment
options.
This session will describe respiratory product development of
generic drugs within the US, focusing on paths forward to bring Pulmonary embolism (PE) presents significant challenges,
safe and effective generic respiratory products to the American necessitating improved diagnostic and therapeutic strategies to
public. A general overview will summarize the generic drug address acute complications like hemodynamic shock and RV
approval process, including demonstration of bioequivalence and dysfunction and long-term issues such as pulmonary fibrosis and
therapeutic equivalence utilizing comparative clinical information. recurrence. This session increases knowledge of issues with
Discussion of recent generic product approvals and posted presentations that seek to improve 1) competence in identifying
regulatory guidance will provide the audience a greater at-risk patients, 2) understanding of limitations of plasmin-based
understanding of the generic approval process, and how the use therapies and introducing a potentially more effective treatment,
of emerging technologies and outcomes of research projects and 3) refining treatment protocols to reduce right ventricular
contribute to scientific understanding for these complex orally dysfunction efficiently. Collectively, this symposium introduces
inhaled and nasal drug products to inform regulatory actions. recent advances that will help refine PE treatment strategies,
mitigate complications, and improve patient outcomes,
12:00 Introduction addressing a significant health challenge.
12:03 Update for Generic Orally Inhaled and Nasal Drug 12:00 Investigating Pulmonary Embolism Biology with
Products Targeted Molecular Imaging and Inflammation
12:20 Emerging Concepts and New Technologies for Profiling
Bioequivalence of Orally Inhaled and Nasal Drug 12:15 Plasmin-Independant Thrombolytic Agent for the
Products Treatment of PE
12:37 Comparative Clinical Considerations in the 12:30 Advances in the Diagnosis and Treatment of Acute
Determination of Sameness Pulmonary Embolism
12:54 Questions/Answers 12:50 Open Discussion (all presenters)

BASIC • CLINICAL • TRANSLATIONAL CLINICAL • TRANSLATIONAL

MID-DAY SYMPOSIUM MID-DAY SYMPOSIUM
MD10 ADVANCES IN THE DIAGNOSIS , RISK MD11 STUDY UPDATES FROM THE
STRATIFICATION AND TREATMENT AMERICAN LUNG ASSOCIATION’S
OF PULMONARY EMBOLISM AIRWAY CLINICAL RESEARCH
Division of Lung Disease, National Heart, Lung, and Blood CENTERS NETWORK
Institute, National Institutes of Health; American Lung Association Airways Clinical Research
12:00 P.M. - 1:00 P.M. Centers;
12:00 P.M. - 1:00 P.M.

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 33

Target Audience • learn about rare and common variant analysis related to lung
Physicians, clinical scientists, nurses, paraprofessionals, and heart phenotypes across all five WSPH groups.
educators, health care providers
• learn about DNA methylation biomarkers and RNA-based
Objectives groupings of pulmonary hypertension, how they provide insight
At the conclusion of this session, the participant will be able to: into disease mechanisms, and how they relate to prognosis.
• describe the role of oxidative stress and circulating Pulmonary hypertension (PH) has no cure, and PH research
mitochondrial DNA in predicting which emphysema patients remains a high priority for NHLBI. The current PH classification is
will show progression or regression of emphysema. difficult to apply clinically for precision medicine therapy. In 2014,
• define new strategies to care for people with emphysema NHLBI launched a multi-center clinical study named: Redefining
through dietary interventions. Pulmonary Hypertension through Pulmonary Vascular Disease
Phenomics (PVDOMICS), which includes 1 Data Coordinating
• improve the quality of life in adolescents and young adults with Center & 7 clinical centers to conduct an observational study in
asthma through effective telehealth strategies PH patients. The overall goal of the PVDOMICS is to perform
The purpose of the session is to discuss ongoing research deep phenotyping across all PH groups and intermediate
initiatives within the American Lung Association Airways Clinical phenotypes to reconstruct the traditional classification and define
Research Centers network. new meaningful subclassifications. 1193 participants were
12:00 Introduction enrolled, and clinical and omics results from these subjects will
be presented at this Mid-day session.
12:05 MATCH Design and Recruitment
12:00 Clinical Clustering Reveals Novel Phenotypes of
12:15 MATCH Primary Results Pulmonary Hypertension
12:25 Urinary Mitochondrial DNA Copy Number Predicts 12:15 Whole Genome Sequence Analysis Across All Five
Emphysema Progression in Female COPD Patients WSPH Group
12:35 Influence of Inflammation-Resolving Compounds 12:30 Comprehensive Characterization of Blood DNA
on Respiratory Outcomes in Patients with Methylation Landscape for Pulmonary Hypertension
Emphysema
12:45 Clustering Across Pulmonary Hypertension Using
12:45 Questions Blood RNA Profiles

BASIC • CLINICAL • TRANSLATIONAL

MID-DAY SYMPOSIUM
MD12 CLINICAL AND OMICS FINDINGS
FROM PVDOMICS PATIENTS WITH
PULMONARY HYPERTENSION
Division of Lung Disease, National Heart, Lung, and Blood,
Institute, National Institutes of Health;
12:00 P.M. - 1:00 P.M.
Target Audience
Health providers, trainees, and researchers
Objectives
At the conclusion of this session, the participant will be able to:
• learn about new clinical groupings of pulmonary hypertension
and how they relate to prognosis.

ATS 2026 Advance Conference Program • Orlando, FL

34 Click on the session title to view the speakers SUNDAY • MAY 17

2:25 Emerging Research on Bronchopulmonary

Dysplasia and Pulmonary Hypertension
2:45 Updates on Pulmonary Function Testing
3:05 Clinical and Translational Advances on Childhood
Interstitial Lung Diseases
3:25 New Perspectives on the Origins and Management
of Childhood Asthma

SCIENTIFIC SYMPOSIUM

Sunday Afternoon, May 17 A82 CLINICAL TRIALS SESSION

2:15 P.M. - 3:45 P.M.
Check ATSConference365 for the
CLINICAL • TRANSLATIONAL latest information as it becomes available

SCIENTIFIC SYMPOSIUM Click Here

A81 PEDIATRIC YEAR IN REVIEW

CLINICAL
Assembly on Pediatrics
2:15 P.M. - 3:45 P.M. CLINICAL TOPICS IN PULMONARY MEDICINE
Target Audience A83 GREAT CASES: CLINICAL,
This session will appeal to physicians, trainees, advanced RADIOLOGIC, AND PATHOLOGIC
practice providers, nurses, and respiratory therapists who care CORRELATIONS BY MASTER
for children with chronic lung diseases, as well as researchers in
CLINICIANS
pediatric pulmonary medicine.
Council of Chapter Representatives
Objectives
At the conclusion of this session, the participant will be able to: 2:15 P.M. - 3:45 P.M.
• review emerging research on bronchopulmonary dysplasia and Target Audience
pulmonary hypertension All clinical practitioners in adult and pediatric pulmonary and
critical care medicine
• discuss new perspectives on the origins and management of
childhood asthma and updates on pulmonary function testing Objectives
At the conclusion of this session, the participant will be able to:
• evaluate clinical and translational advances on childhood
interstitial lung diseases • improve recognition of clinical findings of patients in correlation
with rare and common pulmonary diseases using a
Pediatric Year in Review is one of the most popular sessions
multidisciplinary approach
organized by the ATS Assembly on Pediatrics. It features four
timely and clinically relevant topics that highlight recent • apply clinical reasoning approaches to formulate differential
advancements in both clinical practice and research. This year, diagnoses from complex patient presentations from real-time
the session will include presentations on the following topics: 1) sharing of clinical knowledge, correlations, and inclusive of
bronchopulmonary dysplasia and pulmonary hypertension, 2) radiologic, and pathologic assessment by Master Clinicians
pulmonary function testing, 3) childhood interstitial lung diseases, • increase clinical knowledge of management and treatment
and 4) childhood asthma. approaches of pathologies presented
2:15 Introduction to This Year’s Pediatric Year In Review

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 35

Residents, fellows, and early career physicians present This session will critically examine the growing use of terms like
diagnostically difficult and interesting cases to a multidisciplinary PRISm (Preserved Ratio Impaired Spirometry), GOLD 0, and
expert panel consisting of adult and pediatric pulmonologists, Pre-COPD to describe individuals with respiratory symptoms,
thoracic radiologists, and pulmonary pathologists to demonstrate structural abnormalities, or early functional impairment who do
a collaborative team approach to diagnosing and managing not meet classic COPD diagnostic criteria. We will explore the
challenging cases. This session enhances audience medical clinical relevance, prognostic value, and potential pitfalls of these
knowledge, and diagnostic and management skills as you get the labels. Are they helpful for early detection and intervention, or do
opportunity to work through multiple case studies with a team they risk medicalizing uncertain findings? Drawing on evidence
master clinicians. from large cohorts and imaging studies, this session will debate
2:15 Radiological Findings whether these emerging categories advance clinical care-or
complicate it.
2:33 Pathology Findings
2:15 Beyond Obstruction: Has the GOLD Era Reached Its
2:51 Master Clinician Limit?
3:09 Master Clinician 2:30 PRISm, Pre-COPD, and GOLD 0: What Does the
3:27 Master Clinician Genome Tell Us?
2:45 COPD in Progress: What Lung Tissue Teaches Us
About Its Beginnings
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
3:00 Imaging the Gray Zone: Are Early COPD
CLINICAL TOPICS IN PULMONARY MEDICINE Phenotypes Truly Distinct?
A84 PRISM, GOLD 0, AND PRE-COPD: 3:15 Natural History of Pre-Obstructive COPD: What Are
USEFUL CONCEPTS OR DIAGNOSTIC We Really Preventing?
OVERREACH? 3:30 Intervening Early: Therapeutic Development for
Pre-Obstructive COPD
Assemblies on Clinical Problems, Allergy, Immunology and
Inflammation, Environmental, Occupational and Population
Health, Respiratory Cell and Molecular Biology, Respiratory BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
Structure and Function
2:15 P.M. - 3:45 P.M. CRITICAL CARE TRACK
Target Audience A86 ILLNESS & IDENTITY: SYSTEMIC
Basic and translational scientists and clinicians with interest in OPPRESSION & THE ETHICS OF CARE
COPD
Assemblies on Critical Care, Behavioral Science and Health
Objectives Services Research, Critical Care, Nursing; Health Equity and
At the conclusion of this session, the participant will be able to: Diversity Committee; LGBTQIA+ Interest Group
• define and differentiate between the terms Pre-COPD, PRISm, 2:15 P.M. - 3:45 P.M.
and GOLD 0, and understand their diagnostic criteria and
clinical significance Target Audience
Clinicians, advocates; educators, clinical researchers; clinical
• understand the historical evolution and current debates ethics consultants; health policy researchers; administrative
surrounding the use of Pre-COPD, PRISm, and GOLD 0 in leaders; translational researchers
clinical practice and research
Objectives
• recognize the spirometric and imaging features that At the conclusion of this session, the participant will be able to:
differentiate early COPD phenotypes-such as PRISm and
• summarize analytic frameworks for understanding systemic
GOLD 0-from classic obstructive COPD, and evaluate how
oppression — such as racism, sexism, ableism, and LGBTQIA
these classifications may inform patient management and
stigma — as a critical factor influencing illness experiences and
clinical trial design
outcomes in acute & critical illnesses.

ATS 2026 Advance Conference Program • Orlando, FL

36 Click on the session title to view the speakers SUNDAY • MAY 17

• discuss the evidence for disparities in access and outcomes in 2:15 P.M. - 3:45 P.M.
critical & acute illness among racialized minorities, LGBTQIA+ Target Audience
patients, neurodiverse people and patients with poorly Clinicians and scientists with an interest in pathophysiology of
understood medical conditions such as Long COVID disease, novel therapies and biomarker
• facilitate interdisciplinary discussions aimed at actionable Objectives
strategies to improve the study of systemic oppression and their At the conclusion of this session, the participant will be able to:
impact on outcomes in critical & acute illnesses
• summarize and interpret current epidemiological and
This symposium highlights the ways in which structural oppression interventional data that link macro- and micronutrient patterns,
shapes the lived experience of illness and contributes to health obesity, and life-stage nutrition to lung development, function,
inequities in pulmonary and critical care medicine. Drawing on and the course of major pediatric and adult respiratory
interdisciplinary frameworks, clinical insights, and empirical data, disorders
this session will move beyond a general disparities lens to provide
advanced perspectives on how power, knowledge, and • better counsel and more appropriately refer patients and
embodiment intersect in the ICU and beyond. The session is at-risk groups to multidisciplinary nutrition and lifestyle
designed to engage both newcomers and experienced scholars in programs, substantiating earlier intervention that enhances
health equity and offers strategies to promote justice-centered care long-term pulmonary function and quality of life
practices in pulmonary and critical care medicine. Modern lifestyles have led to rising obesity rates, now a major
2:15 Welcome and Introductions global health concern linked to chronic diseases, including
respiratory conditions. Nutrition plays a dual role: while
2:20 On the Ethics of Identity: From Patient to Research high-calorie diets and maternal obesity contribute to lung
Coordinator disease, specific nutrients (e.g., DHA, vitamin E, retinoic acid)
2:32 Embodied Inequality: Analytic Frameworks for may support lung development and immune function. Emerging
Understanding Stress, Stigma and Health evidence highlights complex interactions between diet, obesity,
Outcomes in Marginalized Communities and the pulmonary microenvironment across the lifespan. This
symposium brings together clinical and basic science experts to
2:44 The Legacy of Race-Based Oppression and the
explore how macro- and micronutrients shape lung health,
Microbiome
identify key knowledge gaps, and assess the potential of
2:56 Delays, Dismissals & Disregard: Identity, Illness & nutritional strategies in preventing and treating chronic lung
Epistemic Injustice diseases.
3:08 From Disability to Difference: Confronting Ableism 2:15 How Obesity Tips the Scales in Lung Disease
and Embracing Neurodiversity in Critical Care
2:33 Metabolic Signals Shaping Lung Development and
3:20 Queerly Healing: Resistant Imaginations & Radical Disease
Solidarity
2:51 Feeding the Flame: Western Diet Sensitizes the
3:32 Panel Discussion Lung to Smoke
3:09 Calories, Carbs, and Chronic Lung Disease:
BASIC • TRANSLATIONAL Metabolic Therapies in a New Light
3:27 From Diet to Disease Prevention: Translating
SCIENTIFIC SYMPOSIUM Lung-Phenotype Insights into Public Health Action
A87 YOU BREATHE WHAT YOU EAT -
EFFECTS OF NUTRITION ON LUNG
HEALTH AND DISEASE
Assemblies on Respiratory Cell and Molecular Biology,
Allergy, Immunology and Inflammation, Environmental,
Occupational and Population Health, Respiratory Structure
and Function

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 37

BASIC • CLINICAL • TRANSLATIONAL 3:10 Patient Selection for Pharmacotherapy in OSA:

Who, When, and How? (10 mins, 5 mins Q&A)
SCIENTIFIC SYMPOSIUM 3:25 Future Directions: Toward a Pharmacologic
A88 PHARMACOLOGIC THERAPIES FOR Toolbox for OSA (10 min + 10 min Q&A)
OSA: A NEW FRONTIER
Assemblies on Sleep and Respiratory Neurobiology, Sleep CLINICAL
and Respiratory Neurobiology
SCIENTIFIC SYMPOSIUM
2:15 P.M. - 3:45 P.M.
A89 REDEFINING CARE: STRATEGIES FOR
Target Audience
Pulmonary and sleep medicine providers as well as pulmonary EFFECTIVE PATIENT_CENTERED
and sleep medicine trainees/fellows clinician-researchers in MANAGEMENT ACROSS THE
sleep apnea, respiratory physiology, and obesity CONTINUUM IN SERIOUS
Objectives RESPIRATORY ILLNESS
At the conclusion of this session, the participant will be able to: Assemblies on Nursing, Clinical Problems
• describe novel pharmacologic mechanisms being investigated for 2:15 P.M. - 3:45 P.M.
the treatment of OSA, targeting metabolic modulation, ventilatory
Target Audience
control, airway patency via upper airway tone modulation
Physicians, nurses, allied health professionals and advanced
• understand trial evidence and safety considerations for agents practice providers
such as GLP-1 receptor agonists and other metabolic modulators, Objectives
AD109 and upper airway tone modulators, and carbonic At the conclusion of this session, the participant will be able to:
anhydrase inhibitors in OSA management
• integrate patient-centered care with new referrals to palliative
• apply emerging pharmacotherapy and combination therapy care and hospice
options to personalize care in patients with OSA, especially those
who are PAP-intolerant or have specific mechanistic and • refer to pulmonary rehabilitation earlier during a patient’s
phenotypic features journey living with serious respiratory illness
The treatment landscape for obstructive sleep apnea (OSA) is rapidly • improve the quality of life/health status of this patient by early
evolving. While positive airway pressure (PAP) remains the and evidence-guided initiation of supplemental oxygen in
cornerstone therapy, new pharmacologic approaches are expanding serious respiratory illness
our options beyond PAP therapy. This session will explore the Centering care around the patient during new referrals is crucial
rationale, mechanisms, and emerging evidence for pharmacotherapy to have uptake of additional services by patients living with
in OSA, including GLP-1 receptor agonists, carbonic anhydrase serious respiratory illness. Initiating supplemental oxygen,
inhibitors, and novel agents targeting upper-airway muscle pulmonary rehabilitation, palliative care, and hospice should be
responsiveness. We will highlight how these treatments target directed by the patient and their caregiver to promote quality of
specific endotypes and may offer alternatives or combination therapy life.
options for patients with poor adherence or residual symptoms, while
2:15 Optimizing Oxygen: Best Practices for Initiation of
addressing the potential for truly personalized OSA management.
Supplemental Oxygen Therapy
2:15 Why Pharmacotherapy for OSA, and Why Now?
2:45 The Physiology and Power of Early Referral in
2:25 Obesity and Metabolic Modulation for OSA Serious Respiratory Illness
treatment (10 min + 5 min Q&A)
3:05 Supporting the Whole Patient: Palliative Care as a
2:40 Pharmacologic Neuromuscular Modulation of Upper Core Component of Serious Respiratory Illness
Airway Tone in OSA (10 min + 5 min Q&A)
3:25 Evidence-Based Hospice Care for Serious
2:55 Carbonic Anhydrase Inhibitors in OSA: Respiratory Illness: Guidelines and Gaps
Mechanisms and Emerging Evidence

ATS 2026 Advance Conference Program • Orlando, FL

38 Click on the session title to view the speakers SUNDAY • MAY 17

BASIC • CLINICAL • TRANSLATIONAL TRANSLATIONAL

SCIENTIFIC SYMPOSIUM SCIENTIFIC SYMPOSIUM
A90 ONE AIRWAY, MANY OUTCOMES: A91 AIR POLLUTION AND CLEAN AIR
RETHINKING ASTHMA AND COPD ZONES: NATURAL EXPERIMENTS FOR
ACROSS THE LIFESPAN RESPIRATORY HEALTH IN THREE
Assemblies on Allergy, Immunology and Inflammation, GLOBAL CITIES
Clinical Problems, Pediatrics, Respiratory Cell and Assemblies on Environmental, Occupational and Population
Molecular Biology, Respiratory Structure and Function Health, Environmental, Occupational and Population Health,
2:15 P.M. - 3:45 P.M. Pediatrics
Target Audience 2:15 P.M. - 3:45 P.M.
Basic and translational scientists and clinicians with interest in Target Audience
asthma and COPD environmental and occupational health researchers, pediatric
Objectives pulmonologists, public health professionals, and clinicians
At the conclusion of this session, the participant will be able to: managing asthma and other respiratory diseases.

• differentiate the key pathobiological features of asthma and Objectives

COPD, and identify areas of mechanistic and clinical overlap At the conclusion of this session, the participant will be able to:

• evaluate recent clinical trial data, including the use of biologics • describe new findings about the respiratory health impacts of
such as dupilumab, and their implications for treating COPD Clean Air Zones and congestion pricing policies, including
with type 2 inflammation effects on asthma exacerbations, lung function and growth,
and health disparities
• apply current knowledge to improve diagnostic accuracy
including imaging outcomes and biomarkers • apply knowledge of natural experiment methodologies and
real-world evaluations to critically assess the effectiveness of
This session challenges the traditional dichotomy between environmental interventions in reducing respiratory disease
asthma and COPD by exploring their overlapping features and burden across diverse urban populations
shared mechanisms. While historically treated as distinct
diseases, recent research highlights common pathways in • improve the quality of life and respiratory health of patients by
inflammation, airway remodeling, and immune response. The talk incorporating air quality awareness and clean-air policy
will examine clinical, molecular, and imaging data that blur the advocacy into clinical practice, patient counseling, and
boundaries between the two conditions, and discuss how a more community engagement
integrated understanding could reshape diagnosis, treatment, This session explores the respiratory health impacts of Clean Air
and research strategies. Zones (areas where vehicle access is restricted or priced)
2:15 Developmental Origins and Diverging Pathways in through natural experiments in cities including Stockholm,
Chronic Obstructive Lung Diseases London, and New York. Presentations will highlight changes in air
pollution and links to asthma exacerbations and lung growth in
2:30 From Childhood Asthma to Adult COPD: Evidence children, using diverse study designs including hospital data,
from Longitudinal Cohorts longitudinal cohorts, and exposure modelling. The symposium
2:45 Same Storm, Different Skies: Understanding will also examine health equity, urban policy design, and
Inflammation Across Asthma and COPD behavioural shifts such as increased physical activity. Attendees
will gain practical insights into how policy-level environmental
3:00 Shared Scars: What Imaging Reveals About Asthma
interventions can improve respiratory outcomes and reduce
and COPD
health disparities in urban populations worldwide.
3:15 The Airway Transcriptome Doesn’t Care About
2:15 Chair Introduction
Labels
2:25 From Traffic to Triage: Early Health Insights from
3:30 From Wheeze to Obstruction: Is it Possible to
New York’s Clean Air Zone
Integrate Asthma and COPD Guidelines?

ATS 2026 Advance Conference Program • Orlando, FL

SUNDAY • MAY 17 Click on the session title to view the speakers 39

2:45 Reducing Pediatric Asthma Hospitalizations 2:15 Introduction

Through Urban Policy: A Natural Experiment from 2:20 Shifting Epidemiology of Pulmonary Mycoses:
Stockholm Global Patterns and Local Implications
3:05 Impact of London’s Ultra Low Emission Zone on 2:35 Pulmonary Mycobiome in Health and Disease: A
Lung Development in Children: the Children’s New Frontier in Fungal Pneumonia
Health in London and Luton (CHILL) Cohort Study
2:50 Mechanisms of Antifungal Resistance in Candida
3:25 Concluding Remarks and Q&A Auris: Genomic Drivers and Clinical Impact
3:05 Novel Antifungal Targets and Agents: Advances in
CLINICAL Mechanism-Driven Therapy

SCIENTIFIC SYMPOSIUM 3:20 ATS Fungal Infection Guidelines 2026: Translating

Evidence Into Practice
A92 FUNGAL INFECTIONS IN PULMONARY 3:35 Q&A
AND CRITICAL CARE: UPDATES ON
EPIDEMIOLOGY, MYCOLOGY, AND
MANAGEMENT CLINICAL
Assembly Pulmonary Infections and Tuberculosis ADULT CLINICAL CORE CURRICULUM
2:15 P.M. - 3:45 P.M. CC2 ADULT CRITICAL CARE CLINICAL
Target Audience CORE CURRICULUM
Clinicians in pulmonary and critical care practice both in the
academic and private sector, clinical pharmacists, SCALe: Core Curriculum Committee
epidemiologists, microbiologists 2:15 P.M. - 3:45 P.M.
Objectives Target Audience
At the conclusion of this session, the participant will be able to: Advanced Practice Providers,Clinicians,Medical Educators
• understand the contemporary global epidemiology of fungal Objectives
lung infections and its impact on local practice. At the conclusion of this session, the participant will be able to:
• appreciate current trends in the approach to treatment of • integrate new critical care practice guidelines in to clinical
invasive candidiasis and invasive pulmonary aspergillosis, practice.
including the role of novel antifungal agents. • identify knowledge gaps in the treatment of patients with
• recognize the global health threat posed by candida auris and critical illness.
become familiar with the mechanisms that underlie its • better counsel patients on treatment options available for
resistance profile. critical illness.
For something so frequently encountered in pulmonary and The goal of the core is to support clinicians who are engaged in
critical care medicine, fungal infections are perhaps one of the maintenance of certification activities by providing updates on
least publicized and most poorly understood entities. Fungal subjects included in recertification requirements
infections span the entire scope of this discipline, from the
critically ill to pulmonary outpatients and from the 2:15 High-Flow Nasal Cannula: Best Practices in the ICU
immunocompromised host to those with hyper-reactive immunity. 2:40 Use Of Non-Invasive Ventilation: Best Practices in
Fungal infection is a dynamic field with evolving diagnostic and the ICU
therapeutic options and thus it has been the subject of recent
3:05 Strategies to Improve Outcomes During Intubation
ATS guideline updates, the latest of which was published at the
end of 2024. The objective of this symposium is to discuss five 3:30 Panel Discussion
cutting-edge issues pertaining to fungal infection that ought to
inform pulmonary and critical care practice in 2026.

ATS 2026 Advance Conference Program • Orlando, FL

40 Click on the session title to view the speakers MONDAY • MAY 18

MTE24 CHALLENGES IN THE MANAGEMENT OF

TUBERCULOSIS IN LUNG TRANSPLANT PATIENTS
MTE25 HOSPITAL SLEEP MEDICINE: BENCH TO BEDSIDE
MTE26 PRACTICAL APPROACHES TO INCORPORATING
NOVEL AI TECHNIQUES INTO
CLINICAL/TRANSLATIONAL RESEARCH

KEYNOTE SERIES

8:00 a.m. -8:45 a.m.

K2 JUDICIAL IMPACT ON
Monday Morning, May 18 HEALTHCARE
The ATS Keynote Series focuses on timely topics
of high relevance to the pulmonary, critical care,
MEET THE EXPERT SEMINARS and sleep medicine community. Keynote lectures
feature leaders who have made major contributions
R Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
10:45 a.m. - 11:45 a.m.
MTE14 IMPROVING REPRESENTATIVENESS IN
in the important themes programmed at the 2026
conference and are unopposed by any other
programming.
Keynote Speaker: Stephen Vladeck, JD
PROSPECTIVE RESEARCH
MTE15 POTENTIAL AND PITFALLS OF AI FOR CLINICIANS Moderator: Josh Fessel, MD, PhD, ATSF
AND EDUCATORS
MTE16 TEACHING IN THE TRENCHES: MASTERING
BEDSIDE EDUCATION IN HIGH-ACUITY SETTINGS
MTE17 COPD AND HOMEBASED NIV — INTRODUCTION
TO THE NEW CMS COVERAGE DETERMINATION
YEAR IN REVIEW

MTE18 FACILITATING SLEEP DURING CRITICAL ILLNESS B1 CLINICAL YEAR IN REVIEW

AND BEYOND 9:15 A.M. - 10:45 A.M.
MTE19 LUNG CANCER SCREENING ADHERENCE: A DEEP Target Audience
DIVE INTO AN IMPORTANT QUALITY METRIC Pulmonary, critical care, and sleep providers
MTE20 STORIES IN EVERY BREATH: USING NARRATIVE Objectives
MEDICINE TO STRENGTHEN PHYSICIAN IDENTITY At the conclusion of this session, the participant will be able to:
MTE21 MANAGEMENT OF PULMONARY HYPERTENSION • be able to apply new clinical research knowledge to clinical
IN PATIENTS WITH OBESITY practice
MTE22 UNRAVELING THE STORM: MANAGING ACUTE • learn new findings about key conditions in pulmonary, critical
EXACERBATIONS OF INTERSTITIAL LUNG care and sleep
DISEASES
• have new strategies to manage the care of common conditions
MTE23 FROM SURVIVING TO THRIVING: in pulmonary, critical care, and sleep
POST-TRAUMATIC GROWTH FOR HEALTH
PROFESSIONALS & TRAINEES IN HIGH-ACUITY This program has been developed to include core topics in
SETTINGS pulmonary, critical care, and sleep medicine. The goal of the
session is to discuss critical state-of-the-art topics and evolving

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 41

concepts. The learner will be exposed to a carefully curated 9:15 Introduction

review of the current literature by emerging leaders in the field. 9:20 Lived Experience of Pulmonary Fibrosis Care:
After the course, participants will better understand novel Barriers and Patient Priorities
concepts in each specific domain that we hope will translate to
improved patient care. 9:30 Disparities in Pulmonary Fibrosis: Exploring Racial,
Socioeconomic, and Geographic Inequities
9:15 ARDS/AHRF
9:45 Extending ILD Expertise into the Community:
9:37 Critical Care Telehealth, Remote Monitoring, and Local
10:00 Sepsis Partnerships
10:23 Post-ICU Care / ICU rehab 10:00 Team-Based Care in ILD: Empowering Allied Health
Professionals to Improve Outcomes

CLINICAL 10:15 Bridging the Gap: Expanding Access and

Participation in Pulmonary Fibrosis Clinical Trials
CLINICAL TOPICS IN PULMONARY MEDICINE 10:30 Panel Discussion with Q & A
B2 ACHIEVING EQUITY IN PULMONARY
FIBROSIS: FROM PATIENT VOICES TO CLINICAL
PRACTICE INNOVATION
CLINICAL TOPICS IN PULMONARY MEDICINE
9:15 A.M. - 10:45 A.M.
Target Audience B3 CHEST MATCH: A PRO/CON DEBATE IN
Academic pulmonologists and ILD specialists, community NON-MALIGNANT PLEURAL DISEASE
pulmonologists, nurses, RTs, and allied health professionals, as MANAGEMENT
well as clinical trialists and implementation scientists, trainees,
and health equity advocates Assemblies on Clinical Problems, Clinical Problems

Objectives 9:15 A.M. - 10:45 A.M.

At the conclusion of this session, the participant will be able to: Target Audience
Advanced practice providers, clinicians, interventional
• recognize the barriers faced by patients with pulmonary fibrosis
pulmonologists, medical educators, early career professionals,
in accessing timely, high-quality care
pharmacists
• describe how racial, socioeconomic, and geographic disparities
Objectives
affect outcomes and clinical trial representation in PF
At the conclusion of this session, the participant will be able to:
• identify strategies to expand ILD expertise beyond academic
• evaluate the evidence on safety, optimal dosing, duration and
centers through telehealth and community engagement and
patient selection for intrapleural enzyme therapy in pleural
discuss innovative approaches to broaden clinical trial access
infection, and recognize scenarios where protocol adaptation
and participation
is appropriate
Pulmonary fibrosis (PF) care remains fragmented and inequitable,
• define the pleural physiology and apply evidence for
particularly for patients facing racial, socioeconomic, and
pneumothorax management once a chest tube is in place
geographic barriers. This session brings together voices from
across the PF community - including patients, clinicians, and allied • describe evidence informing the utilization, timing, and efficacy
health professionals - to explore how structural disparities shape of medical thoracoscopy in an undiagnosed exudative pleural
access to care and research, and to present practical, scalable effusion
solutions. Through a combination of lived experience, health equity This session will delve into three common clinical scenarios and
data, implementation models, and workforce perspectives, this have experts debate pros and cons. The three scenarios include
symposium will highlight how interdisciplinary and pneumothorax, empyema, and recurrent transudative effusions
community-driven approaches can close gaps in diagnosis, and the management intricacies associated.
treatment, and trial participation for individuals living with PF.

ATS 2026 Advance Conference Program • Orlando, Florida

42 Click on the session title to view the speakers MONDAY • MAY 18

9:15 Pro: I Always Give 6 Doses of tPA/Dornase when Language does more than convey information among clinicians,
Performing Intrapleural Enzyme Therapy for patients, and families, it shapes meaning, relationships, and care
Empyema as per the MIST-II Protocol delivery in less obvious ways. Drawing on insights from palliative
9:30 Con: I Always Give 6 Doses of tPA/Dornase when medicine and linguistic anthropology, speakers will present
Performing Intrapleural Enzyme Therapy for leading-edge work on how language, both intentionally and
Empyema as per the MIST-II Protocol unintentionally, influences ICU care and uncovers ingrained
clinical patterns and practices, using common ICU words and
9:45 Pro: When Managing an Inpatient Chest Tube, I phrases as real-world examples. This session will also address
Always Use Suction to Promote Pleural Apposition, challenges and solutions to promoting equitable care for patients
Even if Patients Tolerate Water Seal who cannot speak or speak different languages. Participants will
10:00 Con: When Managing an Inpatient Chest Tube, I gain new understanding of ICU language across populations and
Always Use Suction to Promote Pleural Apposition, learn evidence-based language alternatives for clinical practice.
Even if Patients Tolerate Water Seal 9:15 Words Matter: An Introduction to the Scientific
10:15 Pro: Medical Thoracoscopy for Non-Malignant Symposium
Pleural Disease is Dead 9:18 Reconstructing Ethical Problems in Critical Care:
10:30 Con: Medical Thoracoscopy for Non-Malignant Insights from Linguistic Anthropology
Pleural Disease is Dead 9:32 Rethinking the Use of “Need”
9:46 Banishing “Never” Statements
BEHAVIORAL • CLINICAL 10:00 The “Treatable” Trap: When Treatment Discussions
Mislead
SCIENTIFIC SYMPOSIUM
10:14 Language as a Lens into Health Equity
B4 WORDS MATTER: THE POWER OF
10:28 Q&A
LANGUAGE IN SHAPING CRITICAL
CARE
Assemblies on Critical Care, Behavioral Science and Health BASIC • TRANSLATIONAL
Services Research, Nursing; Aging Interest Group BASIC SCIENCE CORE
9:15 A.M. - 10:45 A.M.
B5 NOVEL INSIGHTS INTO THE
Target Audience
COMPLEMENT INFLUENCE ON LUNG
All interprofessional ICU team members (APPs/physicians,
chaplains, respiratory therapists, nurses, pharmacists, palliative MICROENVIRONMENT IN ACUTE AND
care, rehabilitation professionals, social workers, other allied CHRONIC DISEASE
health professionals); Health services/clinical researchers Assemblies on Respiratory Cell and Molecular Biology,
Objectives Allergy, Immunology and Inflammation, Critical Care,
At the conclusion of this session, the participant will be able to: Pulmonary Circulation, Pulmonary Infections and
Tuberculosis
• describe how language functions in critical care and
contributes to ethical complexities in clinician-patient-family 9:15 A.M. - 10:45 A.M.
communication Target Audience
• unearth how commonly used clinical phrases shape meaning, Students, residents, fellows, basic/translational scientists at all
influence patient/family experiences and decision-making, and career levels (physician- and PhD scientists) interested in
offer literature-supported alternatives immunology, ILD, pulmonary hypertension, acute lung injury,
cellular biology, lung transplant, pneumonia, lung repair
• identify challenges and strategies for promoting equity,
particularly for patients who cannot speak or speak languages Objectives
other than English At the conclusion of this session, the participant will be able to:

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 43

• understand lung specific complement, the benefit of a normally TRANSLATIONAL

functioning complement system, and effects of complement
dysregulation in lung disease. Specifically in ARDS, pulmonary CRITICAL CARE TRACK
fibrosis, pulmonary arterial hypertension, and lung transplant
B6 OMICS TO ACTION: REDESIGNING
• evaluate advances in technology that can be used to study
TRIALS AND CARE IN RESPIRATORY
complement activation and how these techniques can be used
at the bench and the bedside to study both canonical and
MEDICINE
non-canonical complement function in pulmonary patients Assemblies on Allergy, Immunology and Inflammation
• promote awareness of complement as a potential contributor 9:15 A.M. - 10:45 A.M.
to a wide array of pulmonary diseases, with the goal of
Target Audience
encouraging additional research that might lead to drug trials Clinicians, clinical trialists, omics researchers, systems
for complement inhibitors for pulmonary diseases biologists, computational scientists, and industry professionals
Complement is considered a hepatic protein that operates in working across asthma, COPD, ILD, bronchiectasis, and broader
circulation. However, studies demonstrate complement is respiratory health
produced in the lung by respiratory epithelia, immune cells, and Objectives
fibroblasts and is important for regulation of pulmonary immunity, At the conclusion of this session, the participant will be able to:
tissue repair, and endothelial function. However critical gaps in
our understanding for what happens when this multifunctional • describe strategies for integrating multi-omics (genetics,
system becomes dysregulated during lung injury and fibrosis transcriptomics, proteomics, metabolomics, microbiome) into
remain. This session explores mechanisms of complement respiratory research and clinical care
promotion of ARDS, IPF, and PAH, and how lung transplant • recognize how real-world data can be used for addressing
outcomes are influenced by increased levels. It will also address implementation issues for polygenic risk scores and to validate
if genetic variants in complement regulation alter phenotypes in drug repurposing candidates and novel trial endpoints
lung disease. Finally, we will discuss therapeutic interventions • discuss approaches and best practices in translating
and the role of complement inhibition in lung disease. biomarker discoveries into next-generation trials and precision
9:15 Living with Lung Disease - Patient Perspectives and care models
Call for Research Multi-omics technologies are rapidly transforming respiratory
9:21 Introduction to Complement and Techniques for science. These methods can predict disease risk, poor
Assessing Complement Activation in the Lungs outcomes, reveal distinct molecular pathways, and identify
9:35 Complement Dysregulation is a Hallmark of ARDS endotypes. However, translating these findings into clinical trials
and clinical care remains limited and inconsistent. This
9:49 Complement and IPF - Current Understanding, symposium will highlight how integrated omics, spanning
Genetic Associations, and Future Directions genomics, transcriptomics, proteomics, metabolomics, and the
10:03 Complement-Mediated Vascular Dysfunction and Its microbiome, can inform trial design and real-world
Role in Lung Aging and Disease implementation. Speakers will present work on Omics-guided trial
enrichment, patient stratification, real-world endpoint validation,
10:17 The Role of Complement in Graft Dysfunction
novel clinical trial designs, and multi-omic biomarker translation.
Following Lung Transplant
The session will conclude with a panel discussion offering
10:31 Complement Inhibition as Treatment for Acute and perspectives on embedding these innovations into clinical
Chronic Pulmonary Disease: Past, Present, and workflows and trial frameworks.
Future
9:15 Introduction
9:17 From Prediction to Practice: Integrating Polygenic
Risk Scores into Pulmonary Practice
9:32 Advancing Precision Trials in Critical Illness
through Multi-Omics and Real-World Data

ATS 2026 Advance Conference Program • Orlando, Florida

44 Click on the session title to view the speakers MONDAY • MAY 18

9:47 Novel Clinical Trials with Omics to Understand 9:30 Screening Tuberculosis in Immigrant Populations
COPD Exacerbations 9:42 Who Watches the Watchers? Dignity for
10:02 Leveraging Airway Microbiome Profiles to Enrich Institutionalized Patients
Clinical Trials in Respiratory Health 9:54 Towards a Humane Immigration Policy
10:17 Using Real-World Evidence to Inform Clinical Trials 10:21 Post-Tuberculous Lung Disease
in Respiratory Health
10:33 Summary
10:32 Panel Discussion
10:36 Discussion

BEHAVIORAL • CLINICAL
CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
SCIENTIFIC SYMPOSIUM
B7 CARE OF THE UNDOCUMENTED
MIGRANT B8 PULMONARY REHABILITATION IN
NON-COPD PATIENTS: UPDATES ON
Assemblies on Behavioral Science and Health Services THE EVIDENCE, CLINICAL INDICATIONS
Research, Behavioral Science and Health Services
AND PHYSIOLOGY
Research, Pulmonary Infections and Tuberculosis; Health
Equity and Diversity, Health Policy, Ethics Assemblies on Pulmonary Rehabilitation, Nursing
9:15 A.M. - 10:45 A.M. 9:15 A.M. - 10:45 A.M.
Target Audience Target Audience
All healthcare providers or researchers, including medico-legal Multidisciplinary: Physicians, residents and fellows, nurses,
interfaces, interested in patient-centered care, and equity physiotherapists, exercise physiologists, researchers and allied
health professionals in all stages of their careers who care for
Objectives
patients with lung diseases
At the conclusion of this session, the participant will be able to:
Objectives
• describe how the specialize challenges of working with
At the conclusion of this session, the participant will be able to:
undocumented patients reinforces essential skillsets in the
high-quality care of all patients • advance the knowledge pertaining to Pulmonary Rehabilitation
in non-COPD patients for clinicians, physiotherapists, exercise
• evaluate clinical spaces for their safety and efficacy to
physiologists and researchers
undocumented persons
• discuss pulmonary rehabilitation interventions to prevent,
• distinguish between high- and low-efficacy practices in dealing with
manage and improve outcomes related to chronic illnesses
undocumented migrant or historically disadvantaged populations for
including asthma, interstitial lung disease, pulmonary
clinical care or research
hypertension, bronchiectasis, Cystic Fibrosis and asthma
Both local and global politics have been riveted by immigration-related
• identify and apply strategies for advocating for the timely
debates. In medicine, these patients present challenges unique in their
referral of eligible patients to pulmonary rehabilitation
acuity or social context, which can importantly impact population
programs, improving access to care and decreasing inequities
health. However, the nature of the problems raised are fundamental,
broadly applicable principles of high-quality care. In this session, we Pulmonary rehabilitation is an evidence-based intervention that
explore best practices for the care of undocumented migrants as a lens improve symptoms, quality of life and exercise capacity in
for improving the quality of direct clinical care and research across all individuals with chronic lung disease. In non-COPD conditions,
populations. A dynamic slate of early career speakers is featured to evidence for the benefits of pulmonary rehabilitation continues to
capture a range of interests across the ATS. This symposium is evolve and will be highlighted through presentations on interstitial
complimentary to the immigration keynote. lung disease, pulmonary hypertension, cystic fibrosis,
bronchiectasis and asthma. The presentation will go beyond the
9:15 Introduction
ATS 2023 PR guidelines that primarily focused on COPD, with
9:18 Building Trust in Marginalized Populations less discussion of interstitial lung disease and pulmonary

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 45

hypertension. It will include a patient speaker and a diverse respiratory diseases. Speakers will address the latest evidence
group of chairs and speakers including clinicians, researchers, linking PFTs to outcomes, and highlight knowledge in asthma,
physiotherapists, early career professionals and senior cystic fibrosis, sickle cell disease, and primary ciliary dyskinesia.
professionals. A cross-cutting theme will examine the impact of social
9:15 Patient Speaker to Share Their Lived Experiences determinants on lung function, and a final talk will examine
childhood lung function trajectories into adulthood, highlighting
9:20 Pulmonary Rehabilitation in Interstitial Lung the lifelong implications of pediatric respiratory health.
Disease
9:15 Introduction
9:40 Pulmonary Rehabilitation in Pulmonary
Hypertension 9:17 Lung Clearance Index and the Small Airways in
Childhood Disease
9:55 Pulmonary Rehabilitation in Bronchiectasis and in
Cystic Fibrosis 9:34 Oscillometry in Severe Asthma: Ready for
Primetime?
10:15 Pulmonary Rehabilitation in Asthma
9:51 What Does Exercise Challenge Testing Tell Us
10:30 Panel Discussion + Q&A about Exercise Safety in Children with Sickle Cell
Disease?
CLINICAL 10:08 Social Determinants of Lung Function in Childhood
10:25 Lung function trajectories in childhood and adult
SCIENTIFIC SYMPOSIUM
outcomes
B9 PULMONARY FUNCTION IN 10:42 Conclusion
CHILDHOOD RESPIRATORY DISEASE:
EVIDENCE, SOCIAL DETERMINANTS,
AND TRAJECTORIES BEHAVIORAL • CLINICAL

Assembly on Pediatrics SCIENTIFIC SYMPOSIUM

9:15 A.M. - 10:45 A.M. B10 RESPIRATORY HEALTH, POLICY, AND
Target Audience THE ENVIRONMENT IN THE 2026
Providers of pediatric pulmonology and adult pulmonology POLITICAL CLIMATE
Objectives Assemblies on Environmental, Occupational and Population
At the conclusion of this session, the participant will be able to: Health, Pediatrics; 1. Health Equity and Diversity Committee
• Describe new findings about the utility and limitations of lung 2. Environmental Health Policy Committee
clearance index, oscillometry, exercise testing, and spirometry 9:15 A.M. - 10:45 A.M.
in pediatric respiratory diseases.
Target Audience
• Apply emerging evidence to better interpret pulmonary Adult, pediatric pulmonologists, critical care physicians,
function data in children, with attention to social determinants clinicians, researchers, nurses, respiratory therapists, public and
on lung function, which includes an understanding of the global health professionals, and ATS members interested in
importance of race-neutral reference equations. health equity and advocacy
• Integrate pediatric pulmonary function trajectories into clinical Objectives
care and research design by identifying early-life factors that At the conclusion of this session, the participant will be able to:
contribute to lung function declines over time • describe the national and international threats to
Pulmonary function testing (PFT) in children offers critical insight environmental health, including policy changes in the current
into pediatric respiratory disease, yet questions remain about its political climate.
predictability. This session highlights the evolving role of • more appropriately, understand how vulnerable populations,
spirometry, lung clearance index, oscillometry, and including socioeconomically disadvantaged communities, face
cardiopulmonary exercise testing across a spectrum of childhood

ATS 2026 Advance Conference Program • Orlando, Florida

46 Click on the session title to view the speakers MONDAY • MAY 18

an increased risk of lung disease under these environmental Objectives

threats, and identify research needs in this area. At the conclusion of this session, the participant will be able to:
• apply learned knowledge, including tools provided, to advocate • Define new strategies of care for patients with CAP based on
and influence environmental policies to benefit all, but patient-specific endotypes.
especially vulnerable and marginalized communities. • Improve patient quality of life by addressing patient-specific
Climate change, environmental policy, and lung health intersect acute and post-acute outcomes of interest.
as respiratory illnesses intensify globally. Vulnerable • Integrate new guidelines into current practice, including
populations-such as children, the elderly, historically determining appropriate populations for application.
marginalized, and socioeconomically disadvantaged
communities-experience disproportionate exposure to air This session will explore critical controversies in managing
pollutants, heat, and allergens, compounding health inequities. In hospitalized pneumonia patients. Emphasizing evolving patient
March 2025, the Environmental Protection Agency (EPA) priorities and scientific advances in short- and long-term
announced 31 actions to roll back various rules and programs outcomes, it will address the profound heterogeneity observed in
protecting lung health from pollution. Environmental and Health clinical management and outcomes that is driven by differences
Organizations, including the ATS, have released statements in microbiological etiology and patient-intrinsic characteristics.
opposing these actions. This symposium will discuss the current Experts from the PITB Pneumonia Advisory Group will discuss
environmental threats to lung health, including recent policy the urgent need for updated clinical research to bridge knowledge
changes in the US and climate change globally, and provide tools gaps and inform evidence-based practices for this large patient
to advocate and influence policy. population. Through dynamic presentations and discussions, this
session aims to advance understanding and guide future
9:15 Introduction- Lung Health and the Environment in research to optimize pneumonia care.
2026: An Overview of Clinical, Educational and
Policy Themes 9:15 What is CAP, Anyway? Differentiating Between a
Disease and a Syndrome in Diagnosis and
9:20 Pollution, and Respiratory Health: Current Policies Management
Reshaping Respiratory Health
9:30 What Drives CAP Heterogeneity? Recognizing
9:45 Extreme Weather Events and the Impact of Pneumonia Endotypes in Pathogenesis and
Environmental Hazards on Historically Marginalized Management
Populations
9:45 What CAP Outcomes Really Matter? Short- and
10:05 Air Pollution and Climate Change and its Global Long-Term Patient Priorities Beyond Mortality
Impact on the Respiratory Health of Workers
10:00 What Else Can We Do? The Future of Host-Directed
10:25 Pulmonologists as Advocates: How to Testify, Therapies in CAP
Lobby, and Influence Policy
10:15 Who Else Can We Help? Applying CAP Guidelines
to Immunocompromised Patients
BASIC • CLINICAL • TRANSLATIONAL 10:30 What Have CAP Trials Taught Us? Lessons Learned
SCIENTIFIC SYMPOSIUM and Research Priorities in CAP

B11 QUESTION EVERYTHING: RETHINKING

CONVENTIONAL APPROACHES TO CAP
Assemblies on Pulmonary Infections and Tuberculosis, SCIENTIFIC SYMPOSIUM
PITB Pneumonia Advisory Group
B12 PRESIDENT'S SYMPOSIUM
9:15 A.M. - 10:45 A.M.
9:15 A.M. - 10:45 A.M.
Target Audience
Clinicians caring for patients with pneumonia; clinical pneumonia Check ATSConference365 for the
researchers; basic/translational pneumonia researchers latest information as it becomes available
Click Here

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 47

CLINICAL
COMMITTEE-SPONSORED ADULT CLINICAL CORE CURRICULUM
B13 NEJM/JAMA PULMONARY SESSION CC3 ADULT SLEEP CORE CURRICULUM
11:15 A.M. – 1:15 P.M. SCALe: Core Curriculum Committee
Check ATSConference365 for the 11:30 A.M. - 1:00 P.M.
latest information as it becomes available Target Audience
Click Here PCCM and CCM Trainees, physicians and advanced practice
providers caring for adults with critical illness
Objectives
BEHAVIORAL • CLINICAL
At the conclusion of this session, the participant will be able to:
MEDICAL EDUCATION SEMINAR • identify new strategies to manage patients with sleep
disordered breathing
ME102 ICU ROUNDS AS LEARNING LABS:
PRACTICAL STRATEGIES FOR THE • better counsel patients and families on new treatment options
ICU EDUCATOR for critical illness
• identify knowledge gaps in the treatment of patients with sleep
Assemblies on Behavioral Science and Health Services
disordered breathing.
Research
The goal of the core is to support clinicians who are engaged in
10:45 A.M. - 11:45 A.M.
maintenance of certification activities by providing updates on
Target Audience subjects included in recertification requirements.
Academic medicine practitioners, including those still in training
or in related interdisciplinary fields. 11:30 The Computer Will See You Now: Impact of AI Tools
in the Sleep Field
Objectives
At the conclusion of this session, the participant will be able to: 11:55 Sleepless For Two: Pregnancy and Sleep

• Identify strategies to enhance clinical reasoning during ICU rounds 12:20 Planes, Trains and ...CPAP? Transportation and
by applying evidence-based frameworks that promote diagnostic Medicine
thinking and team-based decision-making. 12:45 Panel Discussion
• Demonstrate methods to meaningfully incorporate patients into
ICU rounds through bedside teaching techniques that prioritize CLINICAL
patient engagement, communication, and education.
• Design a structured approach to ICU rounding that leverages PEDIATRIC CLINICAL CORE CURRICULUM
pre-rounding preparation and post-rounding reflection to improve
PCC2 PEDIATRIC CLINICAL CORE
learning outcomes, care coordination, and team efficiency.
CURRICULUM
This interactive session will focus on three key areas of ICU teaching
rounds: enhancing clinical reasoning, incorporating patients through SCALe: Core Curriculum Committee
bedside teaching, and optimizing pre- and post-rounding activities. 12:00 P.M. - 1:00 P.M.
Brief presentations will introduce each topic, followed by small-group Target Audience
discussions that promote idea sharing between faculty and Advanced Practice Providers,Clinicians,Medical Educators
attendees. Participants will leave with practical, peer-generated
strategies to enhance their bedside [Link] Objectives
At the conclusion of this session, the participant will be able to:
• define new strategies to manage pediatric patients with
pulmonary disease and critical illness

ATS 2026 Advance Conference Program • Orlando, Florida

48 Click on the session title to view the speakers MONDAY • MAY 18

• better counsel pediatric patients and families on ne treatment

options for pulmonary disease and critical illness
• identify knowledge gaps in the care of pediatric patients with
pulmonary disease including bronchiectasis.
The goal of the core is to support clinicians who are engaged in
maintenance of certification activities by providing updates on
subjects included in recertification requirements.
12:00 Primary Ciliary Dyskinesia: Understanding the
Basics and Beyond
12:25 Aspiration and Bronchiectasis: The Aerodigestive
Team's Role
12:50 Panel Discussion
Monday Mid-day, May 18

BASIC • TRANSLATIONAL
11:45 a.m. - 1:15 p.m. MID-DAY SYMPOSIUM
ATS WOMEN’S FORUM MD13 RED JOURNAL IN ACTION 2: LUNG
REPAIR MODELS AND MECHANISMS
The annual ATS Women's Forum recognizes the
achievements and supports the advancement of American Journal of Respiratory Cell and Molecular Biology
women in pulmonary, critical care, and sleep 12:00 P.M. - 1:00 P.M.
medicine and research. The forum provides a
valuable opportunity for women to find value in the Target Audience
inspirational messages and career insights the Basic and translational researchers interested in cellular repair
speakers share. mechanisms and cell-based therapies for lung disease.

This year, the Women’s Forum will offer a Objectives

moderated, conversational panel with brief opening At the conclusion of this session, the participant will be able to:
remarks, guided discussion, and audience Q&A. • describe new findings on concepts of lung cell plasticity and its
The panelists will be: role in lung disease progression.
Annie Pardo, PhD • define new strategies that are being developed and tested for
Mary Rice, MD, MPH cell-based therapy of lung disease.
Kathleen Lindell, PhD, RN, ATSF • describe new findings related to lung repair mechanisms and
The Elizabeth A. Rich Awardee research models that are featured in a special collection
R Pre-registration and an additional fee are required. featured in the american journal of respiratory cell and
$45 members/non-members molecular biology.
ATS thanks This session features work that aligns with the American Journal
United Therapeutics and Genentech of Respiratory Cell and Molecular Biology call for papers on
for their generous support of the Women's Forum “Lung Repair Models and Mechanisms: Stem Cells, Cell
Therapy, and Bioengineering.” The featured speakers will discuss
recent advances in understanding processes of injury, repair, and
cellular plasticity in lung development, and lung disease. The
potential and advances in using cell-based therapies in the lung
will be featured. Particular focus on pulmonary fibrosis,
bronchopulmonary dysplasia and pulmonary hypertension.

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 49

12:00 Introduction and Overview BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

12:05 Alveolar Epithelial Type II (AT2) Cell Plasticity Gone
Wrong in Lung Fibrosis MID-DAY SYMPOSIUM
12:27 Questions and Answers MD15 WHEN THE FUNDING STOPS:
12:32 Cell Therapies for Pediatric Lung Disease: Are We NAVIGATING RESEARCH IN A
There Yet? SHIFTING LANDSCAPE
12:54 Questions and Answers Health Equity and Diversity Committee, Centers for Disease
Control, ALA Foundation, COPD Foundation
12:59 Closing Remarks
12:00 P.M. - 1:00 P.M.
Target Audience
BEHAVIORAL • CLINICAL
International and interprofessional pulmonary-critical care and
MID-DAY SYMPOSIUM palliative care researchers (nurses, therapists, physicians, social
workers), and scientists, medical educators, and trainees
MD14 ATS SCHOLAR: SUCCESSFUL (fellows, residents, medical students)
PUBLICATION IN MEDICAL Objectives
EDUCATION At the conclusion of this session, the participant will be able to:
ATS SCHOLAR • identify strategies to adapt or reposition research programs in
12:00 P.M. - 1:00 P.M. response to changing funding priorities

Target Audience • apply practical tools to explore new funding opportunities

Medical educators in the health professions through interdisciplinary or community-based collaborations

Objectives • formulate next steps for mentoring junior investigators during

At the conclusion of this session, the participant will be able to: times of funding uncertainty

• understand foundational concepts focused on key learning As funding priorities shift, many investigators face the challenge
methods in medical education of sustaining research programs that no longer align with sponsor
interests. This session brings together experts from academia,
• select the best submission category based on their educational federal agencies, industry, and medical foundations to share
intervention and understand what educational elements should strategies for maintaining research relevance, reframing scientific
be included for each category narratives, and identifying alternative funding pathways.
• understand and address common pitfalls that can impact Speakers will present real-world examples of successful pivots,
successful publication on novel topics within medical education institutional advocacy, and cross-sector partnerships that have
kept important science moving forward. The session will
This session is designed to provide an overview of novel topics for
conclude with an interactive panel discussion offering practical,
publication within medical education. The learner will gain an
actionable guidance for investigators at all career stages who are
understanding of what makes for successful publication within
navigating a rapidly changing funding landscape.
novel submission categories such as Patient Education, How I
Teach, Narrative Medicine, Video Submissions, and On the Fly 12:00 Pivot or Persevere? Making Strategic Shifts Without
submissions. A submission published in Scholar in each topic will Losing Your Scientific Identity
be provided as an example, with discussion of each. 12:12 Adapting Federal Research Priorities: Insights from
12:00 Keeping Our Patients Informed - Publishing CDC’s Environmental Health Science and Practice
Impactful Patient Education 12:24 Industry Insights: Building Strategic Partnerships
12:15 Tell and Compel - The Importance of Narrative to Sustain Research
Medicine 12:36 From Bridge Grants to Big Wins: How Foundations
12:30 Making Your Teaching Come to Life Keep At-Risk Science Funded
12:45 We All Want to Learn! - Teach Us How You Teach

ATS 2026 Advance Conference Program • Orlando, Florida

50 Click on the session title to view the speakers MONDAY • MAY 18

BASIC • TRANSLATIONAL 12:45 Near Real Time Air Quality Forecasts using the
NASA GEOS Model
MID-DAY SYMPOSIUM
MD16 USING NASA SATELLITE DATA TO CLINICAL
GUIDE NOVEL AIR QUALITY
MID-DAY SYMPOSIUM
APPLICATIONS
NASA Earth Action Program MD17 FUNDAMENTALS OF
HIGH-RESOLUTION CT OF THE
12:00 P.M. - 1:00 P.M.
LUNGS
Target Audience
Physicians; nurses; allied health professionals; public health Society of Thoracic Radiology
practitioners; community health educators; researchers who are 12:00 P.M. - 1:00 P.M.
interested in using Earth observation data for environmental and
occupational health research applications Target Audience
Pulmonologists, radiologists, advanced practice providers who
Objectives focus on ILD
At the conclusion of this session, the participant will be able to:
Objectives
• present an overview of the NASA Health and Air Quality At the conclusion of this session, the participant will be able to:
Program activities that showcase cross-cutting environmental
• describe the key findings and patterns of a variety of diffuse
health applications of interest to clinicians and researchers
lung diseases on high-resolution chest CT of the lungs, with a
• analyze at least three examples where NASA satellite data focus on the most specific patterns and correlating the HRCT
can help examine the global health risks of air pollution results with clinical factors
• inform clinicians and researchers about relevant scientific • discuss the multi-disciplinary approach to diffuse lung disease
resources on air quality monitoring as well as training and the role of HRCT compared to clinical and histologic
opportunities for applying remote sensing data for air quality findings
topics
• understand both the spectrum of both typical and atypical
Each day, Earth-observing satellite missions collect terabytes of HRCT manifestations of a variety of common and rare diffuse
spatial and temporal data related to environmental indicators of lung diseases
public health importance. This session will highlight how NASA
This session will provide a practical, clinically focused approach
satellite data can support novel applications guiding health and
to the interpretation of diffuse lung diseases using high-resolution
policy decision-making related to Earth’s changing systems. It will
chest CT, with a particular emphasis on the key diagnostic
describe updates to NASA projects and missions, such as NASA
patterns.
ASIA-AQ and other airborne campaigns, the NASA GEOS
Model, the Tropospheric Emissions: Monitoring of Pollution 12:00 Algorithmic Approach to Diffuse Nodular Lung
(TEMPO) satellite, and the Multi-Angle Imager for Aerosols Disease
(MAIA) satellite. Each incorporate valuable community 12:15 Imaging of Fibrotic Lung Disease: 2026 Update
stakeholder partnerships examining adverse health risks related
to harmful air pollution exposure. 12:30 Mosaic Attenuation: Significance and Differential
Diagnosis
12:00 Using NASA Satellite Data to Examine Respiratory
Health Risks: An Overview of NASA Health and Air 12:45 Cystic Lung Diseases: Classic HRCT Appearances
Quality Applications
12:15 The Role of Airborne Measurements for Better
Understanding Air Quality Challenges
12:30 The NASA TEMPO Mission: Unprecedented Hourly
Daytime Air Pollution Observations from Space for
Enhanced Health and Air Quality Applications

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 51

BASIC • CLINICAL CLINICAL

MID-DAY SYMPOSIUM MID-DAY SYMPOSIUM
MD18 NEW RESULTS FROM THE MD19 PULMONARY UPDATE FROM THE US
SUBPOPULATIONS AND FOOD AND DRUG ADMINISTRATION
INTERMEDIATE OUTCOMES IN COPD U.S. Food and Drug Administration
STUDY (SPIROMICS ) FAMILY OF
STUDIES 12:00 P.M. - 1:00 P.M.
Target Audience
Division of Lung Disease, National Heart, Lung, and Blood Clinicians in practice, academic researchers, pharmaceutical
Institute industry representatives, international regulators
12:00 P.M. - 1:00 P.M. Objectives
Target Audience At the conclusion of this session, the participant will be able to:
Researchers, medical trainees, those interested in origins and
• better understand how regulatory science is applied in the
subtypes of COPD
review of new drug applications
Objectives
• describe new safety findings and how these were evaluated in
At the conclusion of this session, the participant will be able to:
the context of regulatory science
• understand “pre-copd” as well as plans to investigate early
The most recent FDA approvals in the pulmonary disease space,
copd
research endeavors, safety issues and other hot topics navigated
• understand associations between copd and cardiovascular over the past year in the Division of Pulmonology, Allergy, and
phenotypes Critical Care in the Office of New Drugs at FDA.
• understand molecular markers associated with copd 12:00 Regulatory Considerations for Clinical Development
phenotypes Programs in Pulmonary Fibrosis
SPIROMICS is a clinical observational study intended to identify 12:20 Regulatory Considerations for Clinical Development
different subpopulations of individuals with COPD and ultimately Programs in Non-Cystic Fibrosis Bronchiectasis
define endotypes within this heterogeneous disease that are (NCFB)
responsive to mechanism-specific interventions. The ongoing
12:40 Updates in Cystic Fibrosis
study is performing intensive longitudinal phenotyping of a cohort
that consists of individuals with smoking history with and without 12:55 Panel Discussion
COPD, and control participants without smoking history.
SPIROMICS has launched a family of studies, including
SOURCE, a cohort designed to investigate the origins of COPD, BASIC • TRANSLATIONAL
and SPIROMICS Heart Failure, which is collecting cardiovascular MID-DAY SYMPOSIUM
measures in a subset of the SPIROMICS cohort. During this
session, investigators will discuss recent results from all three of MD20 LEVERAGE HUMAN-BASED
these studies. APPROACHES TO STUDY LUNG
12:00 Early results from the SOURCE Study RESILIENCE AND DISEASE
12:15 Report from the COPDGene-SPIROMICS Multiomics Division of Lung Disease, National Heart, Lung, and Blood
workshop Institute, National Institutes of Health
12:30 Cell-Free DNA Levels and Tissue Profiles 12:00 P.M. - 1:00 P.M.
Associated with Severe COPD Exacerbations Target Audience
12:45 Myocardial Fibrosis in CPFE in the SPIROMICS Researchers, students and trainees, clinicians, other healthcare
Heart Failure study providers, industry experts, policymakers, public health officials,
and health advocates who are interested in lung biology,
resilience and diseases, advanced human-based technologies

ATS 2026 Advance Conference Program • Orlando, Florida

52 Click on the session title to view the speakers MONDAY • MAY 18

Objectives TRANSLATIONAL
At the conclusion of this session, the participant will be able to:
• master emerging technologies: understand advanced MID-DAY SYMPOSIUM
human-based, physiologically relevant experimental systems. MD21 IMMUNE AND EPITHELIAL
select and integrate technologies into their research. enhance
PREDICTORS OF ASTHMA RISK:
relevance and impact of their studies
LESSONS FROM EARLY LIFE
• innovative research designs: develop research incorporating COHORT STUDIES
new approach methods (nams). discover cutting-edge
technologies to propel advancements in understanding lung National Institute of Allergy and Infectious Disease
disease pathogenesis, improve therapy testing, and optimize 12:00 P.M. - 1:00 P.M.
drug screening.
Target Audience
• foster collaboration and networking: increase networking Clinicians, basic and clinical researchers
opportunities, foster collaboration among lung disease
Objectives
researchers and engineering fields. facilitate interdisciplinary
At the conclusion of this session, the participant will be able to:
partnerships and innovative research initiatives.
• review data demonstrating divergent patterns of nasal gene
This scientific program aims to promote the use of human-based
expression pathways over the first year of life in a birth cohort
emerging technologies and New Approach Methods (NAMs),
at increased risk of asthma, & assess the potential of distinct
such as lung organoids, lung-on-chips, bioprinted lungs, and ex
patterns to influence the development of subsequent disease
vivo tissue preparations (e.g., perfused human lungs,
precision-cut lung slices) in lung research. By equipping • describe single-cell transcriptomic data from early childhood
participants with essential knowledge, skills, and networking suggesting that airway epithelium in children with wheeze may
opportunities, the program encourages innovative research be developmentally reprogrammed, altering susceptibility to
strategies to advance our understanding of lung resilience, respiratory viral infections and later asthma development
disease mechanisms, and drug development through • describe differences in microbial composition in mothers and
collaborative efforts. Inspired by NHLBI’s 2022 Notice of Special children recruited for a binational cohort, and assess the
Interest (NOT-HL-22-030), this program supports NIH initiatives association between microbiome features and symptoms
that prioritize human-based research technologies during infancy, as well airway epithelial barrier function in vitro
12:00 Use of Explanted Cystic Fibrosis Lung Tissues to This session will highlight emerging data generated by
Discover Mucociliary Transport Enhancers NIAID-funded birth and early life cohorts describing early life
12:12 Engineering Vascularized Lung Organoids: immune and epithelial developmental pathways that may underlie
Decoding Human Development and Disease in a risk for asthma development.
Dish 12:00 Early Life Upper Airway Immune Development
12:24 Human-Relevant Crystal Ribcage Models for Trajectories
Multiscale Visualization of Lung Remodeling in 12:20 Early Life Respiratory Viral Infection, Pulmonary
Health and Disease Epithelial Development and Asthma
12:36 The Biology of Mechanical Stretch and 12:40 The Role of Maternal and Infant Microbiome in the
Compression in Human Lung Organoids Development of Pulmonary Immune and Epithelial
12:48 Microphysiological Systems and Bioinspired Function
Robotics for Modeling Human Lung Pathobiology
and Mechanics

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 53

BASIC • CLINICAL • TRANSLATIONAL BASIC • TRANSLATIONAL

MID-DAY SYMPOSIUM MID-DAY SYMPOSIUM
MD22 THE NHLBI LUNG TRANSPLANT MD23 INTERROGATING INTERACTIONS
CONSORTIUM BETWEEN IMMUNITY, MECHANICS,
Division of Lung Disease, National Heart, Lung, and Blood AND ORGAN SYSTEMS IN
Institute, National Institutes of Health PULMONARY FIBROSIS
12:00 P.M. - 1:00 P.M. Division of Lung Disease, National Heart, Lung, and Blood
Institute, National Institutes of Health
Target Audience
Those with research interests involving the study of lung 12:00 P.M. - 1:00 P.M.
transplant donors or recipients. Target Audience
Objectives Fellow/Junior / Established Professional
At the conclusion of this session, the participant will be able to: Objectives
• learn about the impact of certain clinical practices on, and the At the conclusion of this session, the participant will be able to:
value of collecting particular data elements to inform, donor • understand the role of immune system and interaction
lung utilization and early post-transplant outcomes in lung between immune cell subtypes in pulmonary fibrosis.
transplant recipients.
• better understand and apply new findings to the identification
• increase awareness among the broader lung transplant and development of novel therapeutic targets and diagnostics
research community of the availability of the consortium’s in pulmonary fibrosis
resources to support ancillary studies
• learn new findings about the application of novel models and
• more appropriately design and control for clinical variables technologies of pulmonary fibrosis
during the conduct of multi-site research studies involving lung
transplant donors or recipients. Pulmonary fibrosis is a terminal hallmark of various lung
diseases, resulting in significant morbidity, and mortality. It
The Lung Transplant Consortium (LTC) is an NHLBI-funded frequently coincides with fibrosis in other organs, such as the
multi-site clinical research network aimed at improving lung heart, skin, and kidneys, in conditions like systemic sclerosis,
transplant outcomes. By standardizing data and biospecimen lupus, RA, and sarcoidosis. This session will highlight
collection across Clinical Centers (CCs), the LTC evaluates NHLBI-supported studies that explore fibrogenesis mechanisms,
selection criteria and management strategies, focusing on innovative strategies, monitoring tools for disease progression,
complications like primary graft dysfunction (PGD) and acute and therapeutic strategies . By examining the common
lung allograft dysfunction (ALAD). Supported by a Data determinants of fibrosis across organ systems, we aim to
Coordinating Center (DCC), the consortium also conducts enhance research awareness, expand knowledge, and refine
hypothesis-driven studies and facilitates future clinical trials. therapeutic techniques and drugs for pulmonary fibrosis and
Each CC features multidisciplinary teams collaborating to related disorders.
enhance donor lung utilization and post-transplant outcomes
through shared research protocols and innovative observational 12:00 Crystal Ribcage: A Platform for Probing Real-Time
and mechanistic studies. Lung Mechanobiology and Mechano-Immunity in
Health and Disease
12:00 The PROMISE-LUNG Study
12:12 Dendritic Cell Regulation of Lung Fibrosis and
12:26 Clinical and Biological Factors Predicting Lung Exacerbations
Transplant Textbook Outcomes
12:24 Sex-Specific Differences in Scleroderma Lung
12:43 Peri-Operative Factors That Drive Cell-Free Disease
Hemoglobin-Mediated Primary Graft Dysfunction
12:36 Opportunities to Pharmacologically Target
Mechanotransduction in Pulmonary Fibrosis
12:48 Discussion

ATS 2026 Advance Conference Program • Orlando, Florida

54 Click on the session title to view the speakers MONDAY • MAY 18

BASIC • TRANSLATIONAL
MID-DAY SYMPOSIUM
MD24 LUNGMAP PHASE 3- NOVEL
TECHNOLOGY, DATA SCIENCE, AND
RESOURCES
Division of Lung Disease, National Heart, Lung, and Blood
Institute
12:00 P.M. - 1:00 P.M.
Target Audience
Basic and clinical researchers interested in lung biology,
developmental biology, lung disease mechanisms, multi-omics,
bioinformatics, and systems biology Monday Afternoon, May 18
Objectives
At the conclusion of this session, the participant will be able to:
• learn the innovative technologies for single-cell multiomics, YEAR IN REVIEW
spatial multiomics, and data analysis of the lung
• learn the newest discoveries from lungmap that could inform B81 NURSING YEAR IN REVIEW:
lung research NAVIGATING CARE TRANSITIONS IN
PULMONARY, CRITICAL CARE, AND
• learn how to access and use the lungmap resources
SLEEP
The overall goal of LungMAP is to build a molecular and cellular
atlas of the human lung to serve as a reference to better Assembly on Nursing
understand both normal biology and disease pathobiology. 2:15 PM - 3:45 PM
LungMAP Phase 3 aims to utilize the power of single-cell omics
Target Audience
and other innovative technologies to identify the pathogenic Multidisciplinary clinical and research audiences; any training
mechanisms of lung disease at cellular resolution, including cell level; those involved in care transitions for patients and families
types critical to disease initiation and progression, aberrant
molecular pathways in abnormal and diseased cell states, and • Apply evidence-based strategies from recent literature to
targets for novel lung disease therapies. Speakers will describe enhance continuity, communication, and outcomes during
cutting-edge technology platforms, e.g., spatial transcriptomics, transitions, with the goal of improving patient recovery and
LungMAP data pipeline, data analysis tools, and LungMAP quality of life.
resources. • Describe recent findings on gaps in transitional care and how
12:00 LungMAP Flight Simulators: Pairing in Vivo with In these impact patient outcomes, caregivers, and opportunities
Vitro Human Disease Modeling for system-level improvement.

12:15 AI for Multi-Omic Single-Cell and Spatial Analysis in • Understand the role of family-centered approaches and
[Link] interdisciplinary collaboration in improving the quality and
safety of care transitions.
12:30 Lung Cell Nomenclature Integration and BRINDL
Repository This symposium provides a focused review of current literature
on care transitions within pulmonary, critical care, and sleep
12:45 Tools for Generating Molecular and Cellular medicine. Topics include evidence-based approaches to care
Hypotheses From the LungMap Data Distillery transitions after critical illness, palliative and end-of-life care
transitions, tobacco and vaping cessation across the lifespan,
and family-centered models of transitional care. Presenters will
synthesize recent findings, highlight key gaps, and discuss

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 55

implications for clinical practice and future research to improve decisions for individual patients. However, work by
patient and caregiver outcomes during transitional periods. epidemiologists and implementation scientists consistently
2:15 Introduction demonstrates that we often fall short in delivering
evidence-based care for patients with common deadly conditions
2:25 Critical Crossroads: Advancing Recovery Through like sepsis and ARDS. This session will highlight the tension
Post-ICU Care Transitions between approaches that seek to personalize care versus those
2:40 Family Matters: Strengthening Transitions Through that focus on delivering the best care for populations. Formatted
Collaborative Care as a series of pro/con-style debates followed by expert
discussions, the session aims to move beyond apparent conflict
2:55 Bridging Care and Compassion: Improving
towards an integrated, nuanced approach to important topics in
Palliative Care and End-of-Life Transitions Across
critical care.
Settings
2:15 Introduction
3:10 From First Puff to Final Quit: Supporting Tobacco
and Vaping Cessation Across the Lifespan 2:18 Personalized Ventilator Strategies Are the Future
3:25 Session Q & A 2:25 Population-Level Ventilator Protocols Are Needed
First
2:32 Ventilator Management Discussion
BEHAVIORAL • CLINICAL
2:37 Sepsis Bundles Are the Problem
CRITICAL CARE TRACK
2:44 Sepsis Bundles Are the Solution
B82 PRECISION VS PRAGMATISM: 2:51 Sepsis Bundles Discussion
STRIKING BALANCE IN THE ICU
2:56 Balanced Fluid for the Right Patient
Assemblies on Critical Care, Behavioral Science and Health 3:03 Balanced Fluid for Everybody
Services Research, Clinical Problems, Environmental,
Occupational and Population Health, Pulmonary Infections 3:10 Fluids Discussion
and Tuberculosis 3:15 We Need Precise Trials
2:15 P.M. - 3:45 P.M. 3:22 We Need Pragmatic Trials
Target Audience 3:29 Critical Care Trials Discussion
Physicians, researchers, nurses, and allied health professionals
3:34 Panel Discussion
at all stages of career who care for or research critically ill
patients
Objectives
At the conclusion of this session, the participant will be able to:
SCIENTIFIC SYMPOSIUM
• explore benefits and potential pitfalls of individualized
approaches to care for critically ill patients and review tools B83 NEJM/JAMA CRITICAL CARE SESSION
that are available to guide personalization in clinical care,
2:15 P.M. - 4:15 P.M.
where applicable
Check ATSConference365 for the
• evaluate current research methods used to study critical
latest information as it becomes available
illness and understand how these methods incorporate
personalized vs pragmatic approaches to evaluating Click Here
interventions
• facilitate discussion among panelists and audience members
about how to integrate personalized and population-level
strategies in research and clinical practice
Recent critical care research has focused on
personalization-using cutting-edge methods to optimize treatment

ATS 2026 Advance Conference Program • Orlando, Florida

56 Click on the session title to view the speakers MONDAY • MAY 18

BEHAVIORAL • CLINICAL • TRANSLATIONAL 2:57 Con: ILA/ILD Screening

3:06 Audience Discussion & Introduction to Next Topic
CLINICAL TOPICS IN PULMONARY MEDICINE
3:16 Pro:BIP
B84 CONTROVERSIES IN INTERSTITIAL 3:25 Con: BIP
LUNG DISEASE: A PRO-CON
3:34 Audience Discussion & Wrap Up
Assembly on Clinical Problems
2:15 P.M. - 3:45 P.M.
BASIC • TRANSLATIONAL
Target Audience
ILD clinicians, ILD translational scientists, general BASIC SCIENCE CORE
pulmonologists, rheumatologists, pathologists, radiologists,
trainees B85 BEYOND -OMICS: CONNECTING
MOLECULAR BIOLOGY TO CELL
Objectives
At the conclusion of this session, the participant will be able to:
PATHOPHYSIOLOGY USING
SPATIO-TEMPORAL MULTI-MODAL
• analyze the evidence supporting immunosuppressant therapy IMAGING
and antifibrotic agents as first-line treatment options for
non-IPF ILD, including identifying patient populations most Assemblies on Respiratory Structure and Function, Allergy,
likely to benefit from each therapeutic approach Immunology and Inflammation, Respiratory Cell and
Molecular Biology, Respiratory Structure and Function
• evaluate the implications of implementing the 2025 ATS
recommendations for ILA/ILD screening, weighing the 2:15 P.M. - 3:45 P.M.
potential benefits of early detection against radiation exposure Target Audience
risks and healthcare system burden Those interested in basic to translational pulmonary research
• apply an evidence-based decision-making framework to across the broad spectrum of pulmonary pathobiology
controversial areas in ILD diagnosis and management, Objectives
incorporating both clinical evidence and patient-specific factors At the conclusion of this session, the participant will be able to:
when consensus is lacking
• increase awareness of the spectrum of available advanced
This interactive symposium features three pro-con debates multimodal imaging techniques and associated approaches
addressing the most controversial topics in current ILD practice. relevant to pulmonary biology
Attendees will engage with expert pulmonologists,
• learn how the available imaging techniques are used and best
rheumatologists, and radiologists on whether
applied, and their specific limitations
immunosuppression should constitute first-line therapy for
non-IPF ILD, examine the benefits and burdens of the new ATS • acquire information on available resources to gain access to
screening recommendations for interstitial lung abnormalities, these advanced molecular imaging tools and techniques
and explore the paradigm shift from etiology-based to This session will feature exciting, innovative, and cutting-edge
morphology-based diagnosis with the publication of the new research methods in pulmonary basic/translational research.
interstitial pneumonia guidelines. Through structured debates and High-yield multimodal imaging methodologies are transforming
audience participation, the learner will develop a framework for how we conduct research and our fundamental understanding of
navigating clinical uncertainty and making evidence-based pulmonary disease pathogenesis. These advanced imaging
decisions in evolving areas of ILD diagnosis and management. techniques address the cellular microenvironment and tissue
2:15 Introduction & Overview context, some using real-time spatiotemporal resolution. The
talks have broad appeal across different pulmonary diseases
2:20 Pro: Immunosuppression
(e.g., asthma, COPD, emphysema, ILD, fibrosis, remodeling,
2:29 Con: Immunosuppression pulmonary vascular disease, etc.) and will cover complementary
2:38 Audience Discussion & Introduction to Next Topic approaches. This aligns with the basic science theme
“Understanding the Lung Microenvironment in Disease,” and will
2:48 Pro: ILA/ILD Screening

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 57

increase awareness about approaches that will continue to 2:33 Disease Diagnosis: Making Sense of the Alphabet
revolutionize pulmonary research. Soup
2:15 Brief Introduction to the Symposium 2:51 Evaluation and Treatment of Non Type 2
2:20 Spatial Transcriptomics and its Use in Pulmonary Inflammation in COPD
Disease Research 3:09 Cardiovascular Disease in COPD: Does Treating the
2:37 Real-Time Spatiotemporal Imaging Using Lungs Make the Heart Better?
Biosensors 3:27 Is Emphysema Reversible
2:54 Spatial Metabolomics Using Mass Spectrometry
Imaging CLINICAL • TRANSLATIONAL
3:11 Molecular Imaging of Pulmonary Fibrosis
SCIENTIFIC SYMPOSIUM
3:28 The Extracellular Matrix as a Driver of Chronic Lung
Diseases B87 WHEN TREATMENT HURTS:
RETHINKING CPAP IN OBSTRUCTIVE
SLEEP APNEA THROUGH A PRECISION
CLINICAL • TRANSLATIONAL
MEDICINE LENS
CLINICAL TOPICS IN PULMONARY MEDICINE Assemblies on Sleep and Respiratory Neurobiology, Clinical
B86 NEW AND HOT CONCEPTS IN COPD Problems, Critical Care, Sleep and Respiratory
Neurobiology
Assembly on Clinical Problems
2:15 P.M. - 3:45 P.M.
2:15 P.M. - 3:45 P.M.
Target Audience
Target Audience Clinicians, researchers, policy makers
Physicians, nurse practitioners, physician assistants, nurses,
Objectives
respiratory therapists
At the conclusion of this session, the participant will be able to:
Objectives
• apply physiologic phenotyping to stratify risk and tailor CPAP
At the conclusion of this session, the participant will be able to:
treatment in clinical practice
• learn about impact of using the new COPD diagnostic schema and
• describe how CPAP may cause harm in specific OSA
how to differentiate this from Pre-COPD and PRISm, strengths and
subgroups and recognize key mechanisms including vascular
limitations and practical considerations for clinical practice
inflammation, lung stretch, and sleep disruption
• learn about which patients may derive cardiac benefits from using
• evaluate evidence for intermittent hypoxia-induced
COPD medications, with immediate implications for clinical practice
cardioprotection and how CPAP may interfere with this
• learn about how to recognize predominant non type 2 inflammation adaptive process
and treat the exacerbator phenotype with this inflammatory
This session will explore why CPAP may not benefit all patients
endotype
with obstructive sleep apnea (OSA) and may even cause harm in
There have been several advances in the understanding of COPD certain subgroups. Learners will gain insight into potential
pathobiology, diagnosis and therapeutics in the past few years. In this mechanisms of harm, including vascular inflammation, sleep
session, key new and hot topics will be discussed using the most disruption, and loss of cardioprotective intermittent hypoxia. The
recent evidence, including the new concept of disease stability in symposium will emphasize emerging evidence supporting a
COPD, the new multidimensional COPD diagnostic schema and its precision medicine approach to CPAP treatment. Attendees will
implications for Pre-COPD and PRISm, emerging ideas about whether learn how to apply physiologic phenotyping to identify which
emphysema is reversible, cardiac benefits of COPD medications, and patients may benefit the most from therapy. The session will
the evaluation of and new treatments for non type-2 inflammation in conclude with discussion on future research needs and
COPD. implications for clinical guidelines and trial design.
2:15 Disease Stability in COPD

ATS 2026 Advance Conference Program • Orlando, Florida

58 Click on the session title to view the speakers MONDAY • MAY 18

2:15 Introduction - Why Have CPAP Trials Been targeted peptides-focusing on translational challenges and
Negative? strategies from bench to bedside. The session will also draw on
2:31 Rethinking CPAP: Who Benefits? lessons from other monogenic lung diseases, such as cystic
fibrosis, and from fetal gene therapy, to inform future
2:47 CPAP, Angiopoietin-2, and Vascular Inflammation approaches. Attendees will leave with a deeper understanding of
3:03 Are Mild Intermittent Hypoxia and OSA emerging technologies, their therapeutic potential, and the level
Cardioprotective? of evidence supporting their use in pulmonary vascular disease
treatment and drug development.
3:19 Future Directions: Linking OSA Phenotypes to
Potential CPAP Harm 2:15 From Mutation to Medicine: Lessons in Gene
Therapy and Delivery from Cystic Fibrosis
3:35 Audience Q&A and Panel Discussion
2:30 Smart Bombs for Sick Vessels: EC-Targeted
Nanotherapies for Pulmonary Vascular Diseases
BASIC • TRANSLATIONAL
2:45 SORT-of-a-Breakthrough: Targeting the
SCIENTIFIC SYMPOSIUM Endothelium with Lipid Nanoparticles
3:00 From Bench-to-BARRIER-to-Bedside: The Status of
B88 REWRITING THE CODE: PRECISION Adenoviral Targeting of the Endothelium
DELIVERY VECTORS AND GENE
THERAPY FOR PULMONARY 3:15 Precision Targeting: CAR-Nanopeptides for
Vascular Lesion-Directed Therapy in PAH
VASCULAR DISEASES
3:30 The Next Frontier: In-Utero Gene and Molecular
Assemblies on Pulmonary Circulation, Respiratory Cell and
Therapy for Developmental Diseases
Molecular Biology, Respiratory Structure and Function
2:15 P.M. - 3:45 P.M.
BASIC • CLINICAL • TRANSLATIONAL
Target Audience
Clinicians, translational researchers, and biotech/pharma SCIENTIFIC SYMPOSIUM
professionals interested in bench-to-bedside gene therapy,
delivery vectors, and the clinical translation of targeted therapies B89 FROM BENCH TO THRIVING: RECENT
for pulmonary vascular diseases BREAKTHROUGHS IN CHILDHOOD
Objectives INTERSTITIAL LUNG DISEASES
At the conclusion of this session, the participant will be able to: Assembly on Pediatrics
• describe new findings about gene delivery platforms-including 2:15 P.M. - 3:45 P.M.
viral vectors, lipid nanoparticles, extracellular vesicles, and
targeted peptides-and their potential application to pulmonary Target Audience
vascular diseases Pediatric pulmonologists, geneticists, clinical/translational and
basic science researchers studying ILD or pediatric advanced
• incorporate lessons from gene therapy successes in cystic lung disease, adult ILD specialists, interdisciplinary professionals
fibrosis and fetal interventions to improve the development and involved in the care of these patients
clinical translation of novel therapies for patients with
• Objectives
pulmonary vascular diseases
At the conclusion of this session, the participant will be able to:
• apply knowledge of delivery barriers and cell-specific targeting
• incorporate new guidelines for the diagnosis and classification
strategies to evaluate or design translational approaches for
of childhood interstitial lung disease into clinical practice
gene therapy in pulmonary arterial hypertension and related
vascular disorders • describe new and upcoming diagnostic and therapeutic
advances in the genetics of childhood interstitial lung disease
This session is designed for clinicians, scientists, and industry
professionals interested in gene therapy and delivery vectors for • describe radiographic and pathologic findings that suggest the
pulmonary vascular diseases. Speakers will highlight current diagnosis of pulmonary fibrosis and to explore potential
platforms-including viral vectors, intravenous nanoparticles, and treatment strategies

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 59

We will provide a series of talks that highlight recent research • learn about the role of immune profiling and biomarker
findings and connect them with clinical updates in childhood discovery in understanding host responses to bacterial lung
interstitial lung diseases. This will include an update on the new infections
ATS clinical practice guideline on diagnosis of children 2 years • compare traditional and next-generation model
and topical talks highlighting recent data and new treatment systems-including animal models, lung-on-a-chip, and ex vivo
paradigms. This session will be of interest to a general pediatric platforms-for their utility in replicating human pneumonia
pulmonary clinical audience, pediatric pulmonologists specializing pathophysiology and guiding translational research
in childhood interstitial lung diseases, trainees, researchers, and
interdisciplinary care team members. This session will provide learners with an integrated perspective
on bacterial pneumonia by highlighting advances in human
2:15 Introduction clinical studies, immunologic profiling, and innovative modeling
2:20 Patient Voice systems. Attendees will explore how animal models, organoids,
2:25 New ATS Clinical Practice Guidelines: Diagnosis of and lung-on-a-chip platforms complement human research and
ChILD in Children Under Two inform therapeutic strategies. Designed for clinicians, scientists,
and trainees, the symposium emphasizes the importance of
2:45 Advances in Genetic Mechanisms of ChILD translational approaches in understanding disease mechanisms
3:05 Gene Therapy for ChILD: Disorders of Surfactant and developing precision medicine tools. Learners will gain
Metabolism insight into biomarker development, immune responses, and
model refinement, with a focus on bridging experimental findings
3:25 Fibrosis in ChILD: Radiologic Diagnosis and
to patient care in pneumonia and sepsis. This session fosters
Potential Treatment Approaches
cross-disciplinary learning and collaborative exploration.
2:15 Pneumonia in the Precision Medicine Era: Insights
BASIC • CLINICAL • TRANSLATIONAL from Longitudinal Human Cohorts and
Interventional Trials
SCIENTIFIC SYMPOSIUM
2:33 Biomarkers and Translational Immunology in
B90 DECODING BACTERIAL PNEUMONIA: Human Pneumonia
INTEGRATING HUMAN TRIALS, 2:51 Refining Animal Models of Bacterial Pneumonia:
TRANSLATIONAL IMMUNOLOGY, AND Mimicking Human Disease and Immune Dynamics
NEXT-GEN MODELING TO ADVANCE
3:09 Beyond the Mouse: Using ALI Cultures,
PRECISION MEDICINE Lung-on-a-Chip, Organoids, and EVLP to Model
Assemblies on Pulmonary Infections and Tuberculosis, Human Lung Infection
Allergy, Immunology and Inflammation, Critical Care, 3:27 From Animals and Chips to Bedside: Integrative
Pediatrics, Respiratory Cell and Molecular Biology; PhD Modeling to Advance Human Pneumonia Care
Basic Translational Science Group
2:15 P.M. - 3:45 P.M.
CLINICAL • TRANSLATIONAL
Target Audience
Clinicians and researchers in pneumonia, immunology, and SCIENTIFIC SYMPOSIUM
translational modeling, including those using animal and ex vivo
systems, and appeals to anyone advancing precision medicine B91 INTEGRATING PRAGMATIC CLINICAL
and biomarkers in lung infection and sepsis TRIALS INTO INTERVENTIONAL
Objectives PULMONARY OUTCOMES RESEARCH
At the conclusion of this session, the participant will be able to: Assemblies on Thoracic Oncology, Interventional
• learn how human studies and clinical trials contribute to Pulmonary Working Group
precision medicine approaches in bacterial pneumonia and 2:15 P.M. - 3:45 P.M.
sepsis
Target Audience
Pulmonologists interested in clinical research; thoracic oncology

ATS 2026 Advance Conference Program • Orlando, Florida

60 Click on the session title to view the speakers MONDAY • MAY 18

and interventional pulmonary providers, researchers, Target Audience

coordinators, and research administrators Health care providers, tobacco and e-cigarette researchers,
patient educators and health care advocates
Objectives
At the conclusion of this session, the participant will be able to: Objectives
At the conclusion of this session, the participant will be able to:
• describe challenges of traditional randomized controlled trials
in advanced diagnostic bronchoscopy • describe new findings about the health concerns of nicotine
analogues including 6-methyl nicotine
• apply the definition of diagnostic yield in advanced diagnostic
bronchoscopy research • better counsel patients, families, policy advocates, and
decision makers about the harms of electronic tobacco
• incorporate pragmatic clinical trial data to patient care
products
Advanced diagnostic bronchoscopy and adjunct tools to biopsy
• advocate for strategies to better manage to tobacco and
pulmonary lesions have rapidly evolved over the last several
e-cigarette epidemic in the US
years. Often, new technologies are rushed to market and
integrated into clinical practice despite a paucity of supportive Nicotine analogues are being promoted as not subject to FDA
evidence. Particularly, comparative effectiveness and regulations on nicotine. More is being learned about the toxicity
randomized controlled trials have been difficult to execute and of electronic cigarette (vaping) products, with much of it from
given the lack of funding and rapid pace of technologic animal models. New flavored tobacco products are being
development, leaving technologies outdated by the time a trial introduced in Latin American and are becoming popular with
could be completed. This session will discuss the major barriers young people. This session will help you to know what the NEW
to randomized controlled trials in advanced bronchoscopy and tobacco and vaping products are that young people are using,
how pragmatic trials have potential to expedite patient their toxicity, and how they are being used to addict a new
recruitment, study completion, and increase external validity. generation.
2:15 Study Design and Ethical Challenges with 2:15 Introduction
Pragmatic Clinical Trials 2:17 Global Trends in New Tobacco Products -
2:35 Clinical and Patient Centered Outcomes for Implications for Public Health
Pragmatic Clinical Trials in Bronchoscopy 2:31 6-Methyl Nicotine and Neotame: What Are These
2:55 Recent Pragmatic Trials from the Interventional and Why Should We Worry?
Pulmonary Outcome Group 2:45 Vaping Research in Translation: From Laboratory
3:15 Funding Considerations for Comparative Models to Human Studies
Effectiveness Trials 2:59 E-Cigarette Vapor Amplifies Inflammation and
3:35 Discussion Proteolytic Extracellular Vesicles in Response to
Secondary Insults
3:13 Selling Vapes to Children and Adolescents - Holes
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
in Current Enforcement and How it Needs to
SCIENTIFIC SYMPOSIUM Change
3:27 The Science Education and Research on Vaping
B92 ESCALATING USE, EMERGING
and Interventions for Community Engagement
SCIENCE: VAPE/SMOKE INDUCED (SERVICE) Guide
LUNG DISEASE
3:41 Conclusions and Next Steps
Assemblies on Pediatrics, Behavioral Science and Health
Services Research, Environmental, Occupational and
Population Health, Respiratory Cell and Molecular Biology;
Tobacco Action Committee also co-sponsoring
2:15 P.M. - 3:45 P.M.

ATS 2026 Advance Conference Program • Orlando, Florida

MONDAY • MAY 18 Click on the session title to view the speakers 61

BASIC • TRANSLATIONAL 2:45 Fungal Triggers of Fibrosis: Immune-Fibroblast

Interactions in the Chronically-Exposed Lung
SCIENTIFIC SYMPOSIUM 2:59 Granuloma Microenvironments in Tuberculosis:
B93 LIVING LANDSCAPES: HOW LUNG Spatial Immune Regulation in the Lung
MICROENVIRONMENTS ORCHESTRATE 3:13 Spatially Resolved Immune Landscapes in the
HOST RESPONSE DURING LUNG Infected Lung
INFECTIONS 3:27 Cystic Fibrosis Host Response to Bacterial
Infections in the Lung
Assemblies on Respiratory Cell and Molecular Biology,
Allergy, Immunology and Inflammation, Clinical Problems, 3:41 Conclusion
Pediatrics, Pulmonary Infections and Tuberculosis; PBTS
(PhD, Basic and Translational Science) Working Group
CLINICAL
2:15 P.M. - 3:45 P.M.
Target Audience ADULT CLINICAL CORE CURRICULUM
Basic and translational researchers; clinical scientists; fellows
CC4 ADULT CRITICAL CARE CLINICAL
Objectives CORE CURRICULUM
At the conclusion of this session, the participant will be able to:
SCALe: Core Curriculum Committee
• describe how distinct lung microenvironments influence
immune responses to diverse pathogens, including viruses, 2:15 P.M. - 3:45 P.M.
parasites, fungi, and mycobacteria Target Audience
• identify the mechanisms by which pathogens reshape Advanced Practice Providers,Clinicians,Medical Educators
epithelial, immune, and stromal cell interactions in the lung to Objectives
promote inflammation, persistence, or fibrosis At the conclusion of this session, the participant will be able to:
• evaluate emerging tools such as spatial transcriptomics and • integrate new critical care guidelines in to clinical practice.
single-cell profiling for uncovering immune-epithelial-stromal • identify knowledge gaps in the treatment of patients with
interactions during infection and repair critical illness.
This session will examine how diverse lung microenvironments • better counsel patients on treatment options available for
influence immune responses, infection outcomes, and tissue critical illness
repair. Speakers will highlight how viruses, helminths, fungi, and
mycobacteria reshape local immune, stromal, and epithelial The goal of the core is to support clinicians who are engaged in
niches. Topics include type 2 immunity, fibrosis, maintenance of certification activities by providing updates on
immunometabolism, and granuloma formation. Cutting-edge subjects included in recertification requirements
tools such as spatial transcriptomics and advanced imaging will 2:15 Lung Protective Ventilation Targets and
be discussed to illustrate how lung microenvironments Optimization Of Peep
orchestrate inflammation and disease progression. Together,
2:40 Dyssynchronies and Complications of Mechanical
these talks will provide a multidimensional view of how the
Ventilation
infected lung evolves across space and time-and how these
dynamic landscapes inform pathogenesis and recovery. 3:05 Weaning From Mechanical Ventilation: When and
How?
2:15 Introduction
3:30 Panel Discussion
2:18 T2-biased Lungs and Influenza: a
Microenvironmental Perspective
2:31 Metabolic Reprogramming in the Lung During
Parasitic Infection

ATS 2026 Advance Conference Program • Orlando, Florida

62 Click on the session title to view the speakers TUESDAY • MAY 19

MTE36 PH RELATED TO ILD: CURRENT EVIDENCE AND

OUTSTANDING QUESTIONS
MTE37 THE CELLULAR LANDSCAPE OF COPD: NOVEL
INSIGHTS FROM GENOMICS AND CELL BIOLOGY

KEYNOTE SERIES

8:00 a.m. -8:45 a.m.

K3 Speaker and Topic:
To Be Announced

Tuesday Morning, May 18

MEET THE EXPERT SEMINARS YEAR IN REVIEW

R Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
10:45 a.m. - 11:45 a.m.
MTE27 FROM FLATLINE TO FIRST DRAFT: A NARRATIVE
C1 CLINICAL YEAR IN REVIEW
9:15 A.M. - 10:45 A.M.
Target Audience
RESUSCITATION WORKSHOP FOR BURNOUT Pulmonary, critical care and sleep providers
RECOVERY
Objectives
MTE28 PERSONALIZED SLEEP HEALTH: A METABOLIC At the conclusion of this session, the participant will be able to:
MEDICINE FRONTIER
• apply new clinical research knowledge to clinical practice
MTE29 UPDATED BRONCHIECTASIS GUIDELINES:
• learn new findings about key conditions in pulmonary, critical
INTEGRATING INTO CLINICAL PRACTICE
care and sleep
MTE30 MAKING WAVES: OSCILLOMETRY BASICS AND
• have new strategies to manage the care of common conditions
INTERPRETATION FOR CLINICAL AND RESEARCH
in pulmonary, critical care, and sleep
APPLICATION
This program has been developed to include core topics in
MTE31 USE OF SOTATERCEPT IN THE REAL WORLD -
pulmonary, critical care, and sleep medicine. The goal of the
WHAT HAVE WE LEARNED SO FAR
session is to discuss critical state-of-the-art topics and evolving
MTE32 MODELING THE DISEASED LUNG concepts. The learner will be exposed to a carefully curated
MICROENVIRONMENT: EXPERIMENTAL review of the current literature by emerging leaders in the field.
STRATEGIES FOR COMPLEX CO-MORBID After the course, participants will better understand novel
CONDITIONS concepts in each specific domain that we hope will translate to
MTE33 NAVIGATING INFANT SLEEP APNEA: WHAT TO DO improved patient [Link] • TRANSLATIONAL
WITH AN OAHI 5 9:15 Cystic Fibrosis / Non-CF bronchiectasis
MTE34 TO PNEUMONITIS AND BEYOND: A 9:37 Interstitial Lung Disease
COMPREHENSIVE REVIEW OF DYSPNEA FROM
10:00 Lung Transplant
IMMUNE CHECKPOINT INHIBITORS
10:23 Occupational / Environmental Lung Disease
MTE35 FROM FEATHERS TO ANTIFIBROTICS:
EXPOSURES, DIAGNOSIS, AND TREATMENT IN
HYPERSENSITIVITY PNEUMONITIS

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 63

BASIC • TRANSLATIONAL 9:30 RGC-32 Regulation of EndoMT and Inflammation in

PAH
BASIC SCIENCE CORE 9:40 Regulatory T Cells Preserve Lung Endothelial
C2 IMMUNE ACTIVATION AND FIBROSIS Integrity and Prevent Pulmonary Hypertension in
Bronchopulmonary Dysplasia
WITHIN THE PULMONARY VASCULAR
MICROENVIRONMENT 9:50 Alternative Polyadenylation in Macrophages and
their Contribution to Lung Injury
Assembly on Pulmonary Circulation
10:00 Immune Regulation of Vascular Remodeling in
9:15 A.M. - 10:45 A.M. Pulmonary Hypertension Associated with Systemic
Target Audience Sclerosis
Pulmonary clinicians, researchers, and trainees interested in 10:10 Cytokine-Cellular Microenvironment Interactions
vascular disease, fibrosis, and inflammation, including
Driving Perivascular Fibrosis in Pulmonary
immunologists and cell biologists studying immune-vascular
Hypertension
crosstalk in lung pathogenesis
10:20 Single-Cell Dissection of Immune-Driven Neointimal
Objectives
Fibrosis in Pulmonary Hypertension
At the conclusion of this session, the participant will be able to:
10:30 Discussion
• describe new findings about how macrophages, regulatory T
cells, and redox signaling contribute to immune-driven 10:40 Final Remarks
vascular remodeling and fibrosis in pulmonary diseases
• define new strategies to manage the care of patients with CLINICAL • TRANSLATIONAL
ARDS, pulmonary hypertension, COPD by recognizing
immune-mediated mechanisms that sustain vascular injury, CLINICAL TOPICS IN PULMONARY MEDICINE
even after initial environmental exposures resolve
C3 PEDIATRIC CLINICAL CHEST ROUNDS
• apply knowledge of immune-endothelial and immune-epithelial
interactions to improve translational research design and Assembly on Pediatrics
identify novel therapeutic targets in pediatric and adult 9:15 A.M. - 10:45 A.M.
pulmonary vascular disease
Target Audience
This session focuses on immune mechanisms that contribute to Physicians, trainees, advanced practice providers, nurses, and
fibrosis and vascular remodeling in pulmonary diseases, respiratory therapists who care for children with chronic lung
including pulmonary hypertension, COPD, and diseases, as well as researchers in pediatric pulmonary medicine
bronchopulmonary dysplasia. Presentations will cover alternative Objectives
polyadenylation, redox signaling, epithelial-immune interactions, At the conclusion of this session, the participant will be able to:
and regulatory T cell function. Speakers will discuss how immune
responses influence endothelial health, fibroblast behavior, and • review the case selected among the highest-ranked case
structural changes in the vasculature. The session includes data reports submitted to the ATS Assembly on Pediatrics
from both pediatric and adult models. Attendees will gain • based on the case selected among the highest-ranked case
practical knowledge of inflammatory pathways involved in reports submitted to the ats assembly on pediatrics
vascular pathology and how they may be targeted to modify
• based on the case selected among the highest-ranked case
disease progression across diverse forms of acute and chronic
reports submitted to the ATS Assembly on Pediatrics.
lung disease
Pediatric Clinical Chest Rounds is one of the most popular
9:15 Introduction
sessions organized by the ATS Assembly on Pediatrics. It
9:20 Smoke-Driven p73-SIgA Axis Failure Fuels Chronic showcases four clinically challenging or intriguing cases involving
Inflammation and Fibrotic Airway Remodeling in pediatric lung diseases. These cases are selected from the
COPD highest-ranked case reports submitted to the assembly. Each
case is presented by a trainee and followed by an expert-led

ATS 2026 Advance Conference Program • Orlando, Florida

64 Click on the session title to view the speakers TUESDAY • MAY 19

discussion that highlights relevant literature and key clinical exacerbation phenotypes, and the role of inhaled corticosteroid
insights. inhalers in cardiovascular disease risk reduction. The session
9:15 Introduction to this year’s Pediatric Clinical Chest provided valuable insights into the complexities of COPD
Rounds management and the ongoing discussions in the medical
community.
9:17 Case #1 - Presentation by Trainee
9:15 Opening Remarks
9:29 Case #1 - Discussion by Expert
9:18 Patient Perspective
9:39 Case #2 - Presentation by Trainee
9:25 Pro: High Risk COPD Exacerbation Phenotype Is
9:51 Case #2 - Discussion by Expert Defined as 2 Moderate or 1 Severe Exacerbation
10:01 Case #3 - Presentation by Trainee within Past 1 Year
10:13 Case #3 - Discussion by Expert 9:35 Con: High Risk COPD Exacerbation Phenotype Is
Defined as Any Exacerbation withing Past 1 Year
10:23 Case #4 - Presentation by Trainee
9:45 Question and Answer Topic #1
10:35 Case #4 - Discussion by Expert
9:50 Pro: All COPD Patients with History of 2 Moderate
or 1 Severe Exacerbation Should Be Treated with
CLINICAL Triple Inhaler Therapy
CLINICAL TOPICS IN PULMONARY MEDICINE 10:00 Con: Only COPD Patients with 2 Moderate or 1
Severe Exacerbation with Greater than 100 Blood
C4 CONTENTIOUS TOPICS IN COPD CARE: Eosinophiles Should Be Treated with Triple Inhaler
A PRO/CON DEBATE Therapy
Assemblies on Clinical Problems, Clinical Problems 10:10 Question and Answer Topic #2
9:15 A.M. - 10:45 A.M. 10:15 Pro: Inhaled Corticosteroids Should Be Considered
a Cardiovascular Risk Reduction Therapy
Target Audience
Clinicians caring for patients living with COPD, patients living 10:25 Con: Inhaled Corticosteroids Are Not Yet Ready To
with COPD and their families Be Considered a Cardiovascular Risk Reduction
Therapy
Objectives
At the conclusion of this session, the participant will be able to: 10:35 Question and Answer Topic #3
• better diagnose what defines the high risk COPD exacerbation 10:40 Closing Remarks
phenotype. Improved diagnosis could lead to improved
counseling to patients on their personalized preventative
treatment options CLINICAL
• define a personalized inhaler treatment strategy to optimize CRITICAL CARE TRACK
the care of patients with COPD who suffer from 2 moderate or
1 severe exacerbation(s) with or without elevated blood C5 FROM CANNULAS TO CONCEPTS: THE
eosinophils PRACTICE, EVIDENCE AND SCIENCE
• describe new findings that support inhaled corticosteroids as a OF VV-ECMO
cardiovascular risk reduction therapy in contrast to prior Assembly on Critical Care
evidence which did not support this treatment indication
9:15 A.M. - 10:45 A.M.
The scientific symposium on contentious topics in COPD care
Target Audience
covered various perspectives on exacerbation risk, treatment, Clinicians, medical trainees, advance practice providers,
and cardiovascular disease. Key topics included the debate on pharmacists, nurses, physical therapists, respiratory therapists,
whether all COPD patients with a history of exacerbations should and ECMO specialists involved in the care for patients with
receive triple inhaler therapy, the definition of high-risk COPD ARDS and / or supported on VV-ECMO

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 65

Objectives Target Audience

At the conclusion of this session, the participant will be able to: ILD providers general pulmonologists interested in advancing
ILD knowledge translational researchers clinical trialists
• assess patients with advanced respiratory failure for
designing ILD studies Industry developing ILD diagnostics and
VV-ECMO candidacy for acute respiratory distress syndrome therapeutics trainees seeking cutting-edge ILD knowledge
and for less traditional indications
Objectives
• distill best practices, based on increased experience and At the conclusion of this session, the participant will be able to:
evidence, for supporting patients with VV-ECMO as a bridge to
lung transplantation • apply molecular endotyping concepts to critically evaluate
current ILD diagnostic categories and determine when
• appraise evolving evidence around common management traditional “lumping versus splitting” approaches may
issues for VV-ECMO including sedation and anti-coagulation inappropriately delineate patients who share similar underlying
and design new research initiatives to help answer remaining biological pathways
questions about the care of patients supported on VV-ECMO
• describe new findings regarding radiologic features associate
The use of veno-venous extracorporeal membrane oxygenation with treatment response in autoimmune interstitial lung
(VV-ECMO) has steadily increased over the past 25 years. It is disease, challenging existing paradigms and supporting a
now widely utilized as a bridge to lung transplantation and as a molecularly based assessment in these conditions beyond
bridge to recovery for patients with advanced respiratory failure. imaging biomarkers
Despite this increased use, emerging evidence guiding care for
patients on VV-ECMO remains specialized and not widely known • define new strategies to manage the care of ILD patients by
to many intensivists. This session will present exciting new incorporating imaging-molecular correlations into treatment
advances and evolving knowledge around indications, areas of decision-making and clinical trial design, moving toward
evolving best practices, and methods for future research for the precision medicine approaches in ILD
use of VV-ECMO. Current ILD diagnosis relies on subjective interpretation creating
9:15 Introduction to Session artificial boundaries that constrain therapeutic advances. This
session demonstrates how molecular technologies can transcend
9:20 Moving the Needle: Society Guidelines and traditional diagnostic categories to identify biologically meaningful
VV-ECMO for ARDS endotypes. Speakers present: BAL proteomics revealing
9:32 VV-ECMO Beyond EOLIA molecular convergence across ILD subtypes, endobronchial OCT
9:44 Best Practices in VV-ECMO for Bridge to Lung providing objective microscopic assessment, circulating
Transplantation biomarkers democratizing molecular insights, insights from tissue
based-diagnostic tools like cryobiopsy and imaging-molecular
9:56 Insuring Equity and Access to VV-ECMO integration guiding treatment selection. These complementary
10:08 Drugs and the Circuit: Anti-Coagulation and approaches offer a pathway from historical nomenclature toward
Sedation on VV-ECMO precision medicine, transforming ILD care by matching patients
to targeted therapies based on underlying biology rather than
10:20 The Future of VV-ECMO Research
subjective classification.
10:32 Question and Answer Panel
9:15 Chairs Introduction
9:25 Circulating Molecular Signatures: High-Throughput
CLINICAL • TRANSLATIONAL Discovery of ILD Endotypes
SCIENTIFIC SYMPOSIUM 9:41 Endobronchial OCT: Real-time Microscopic
Phenotyping Beyond Histologic Patterns
C6 EVOLVING FROM SUBJECTIVE
9:57 The Role of Advanced Tissue Diagnosis in
DIAGNOSTIC CATEGORIES TO Treatment Decisions in ILD: Cryobiopsy
MOLECULAR ENDOTYPES
10:13 BAL Systems Biology: Molecular Endotypes of the
Assembly on Clinical Problems Lung Microenvironment
9:15 A.M. - 10:45 A.M.

ATS 2026 Advance Conference Program • Orlando, Florida

66 Click on the session title to view the speakers TUESDAY • MAY 19

10:29 Imaging-Molecular Integration: From Target 9:53 Pipeline Therapies for Chronic Cough
Discovery to Treatment Prediction 10:13 Nonpharmacologic Strategies to Address Chronic
Cough
BEHAVIORAL • CLINICAL 10:33 Patient Perspectives on Chronic Cough

PUBLIC ADVISORY ROUNDTABLE SYMPOSIUM

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
C7 NEW APPROACHES TO THE PATIENT
WITH CHRONIC PRODUCTIVE COUGH SCIENTIFIC SYMPOSIUM
Assembly on Public Advisory Roundtable C8 SEEING THE DIFFERENCE: USING
9:15 A.M. - 10:45 A.M. IMAGING TO DEFINE COPD
Target Audience SUBGROUPS
Providers of respiratory care including clinicians and adjunct care Assemblies on Respiratory Structure and Function, Clinical
team members; basic science and clinical researchers; patient Problems, Respiratory Cell and Molecular Biology
advocacy representatives; patients and patient caregivers
9:15 A.M. - 10:45 A.M.
Objectives
At the conclusion of this session, the participant will be able to: Target Audience
Basic and translational scientists and clinicians with interest in
• describe current knowledge gaps in the diagnosis of chronic COPD
cough and describe evidence-based strategies to improve
Objectives
diagnostic accuracy
At the conclusion of this session, the participant will be able to:
• improve and address the quality of life of patients impacted by
• identify key imaging phenotypes of COPD-including
chronic cough by illuminating the physical and mental health
airway-predominant disease, emphysema, mucus plugs, and
impacts upon the patient and the importance of addressing
small airway dysfunction-and their clinical implications
both in clinical care
• evaluate how imaging-based stratification can inform
• define new strategies to provide effective pharmacologic and
personalized treatment approaches and guide future research
nonpharmacologic interventions for chronic cough as well as
and clinical trials in COPD
practical approaches to integrate these therapies into patient
care plans • describe how advanced imaging techniques (e.g., CT, MRI)
reveal structural lung abnormalities in COPD beyond what
In the PAR Symposium, “New Approaches to the Patient with
spirometry detects
Chronic Cough,” attendees will learn from a panel of experts
representing clinical, research, and patient experience. This session explores how advanced imaging techniques-such as
Presentations will address the diverse causes of a chronic cough quantitative CT and MRI-are transforming our understanding of
- from environmental triggers to a range of respiratory diseases COPD heterogeneity. By visualizing structural changes like
including asthma, cystic fibrosis, non-CF bronchiectasis, and emphysema, airway remodeling, and small airway disease,
COPD-chronic bronchitis. Considerations in diagnosing the root imaging allows us to identify distinct patient subgroups that may
cause will be addressed. The significant negative impacts of not be evident through spirometry alone. The session will
chronic cough will be addressed, including both physical and highlight insights from large cohorts, discuss how imaging
mental health complications. Strategies to address chronic biomarkers can guide personalized therapy, and examine the
productive cough - including nonpharmacologic interventions - future role of imaging in precision medicine for COPD.
will be addressed, as well as therapies in the pipeline. 9:15 Imaging the Divide: Airways vs. Alveoli in COPD
9:15 Welcome Remarks Phenotyping
9:23 PAR Award Presentation 9:30 Mucus Plugs in COPD: Markers of Type 2
Inflammation or More?
9:33 Diverse Causes of Chronic Cough and How
Diagnosed 9:45 Vascular Pruning: A New Imaging Biomarker for
Personalized COPD Care?

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 67

10:00 Imaging or Obstruction: Which Tells the True Story 10:24 Integrating Social and Medical Care to Improve
of COPD Pathogenesis? Patient-Centered Outcomes
10:15 Lung MRI for COPD: Redefining Diagnostic 10:36 Group Reflection and Discussion
Boundaries
10:30 Is Imaging the Key to Smarter COPD Trials? CLINICAL
SCIENTIFIC SYMPOSIUM
BEHAVIORAL • CLINICAL
C10 PULMONARY REHABILITATION
SCIENTIFIC SYMPOSIUM AROUND THE WORLD: LEARNING
C9 SOCIAL DETERMINANTS OF FROM THE FRONTLINES
RECOVERY Assembly on Pulmonary Rehabilitation
Assemblies on Behavioral Science and Health Services 9:15 A.M. - 10:45 A.M.
Research
Target Audience
9:15 A.M. - 10:45 A.M. All clinical providers and trainees from medicine, nursing,
Target Audience physiotherapy, exercise physiology, and respiratory therapy
Professionals who care for or conduct research concerning Objectives
patients who are critically ill or have survived critical illness At the conclusion of this session, the participant will be able to:
Objectives • understand how PR is delivered in low and middle-income
At the conclusion of this session, the participant will be able to: countries, and learn from these strategies
• provide an overview of the current evidence on how social • appreciate culturally sensitive adaptations to the components
determinants of health affect patients’ ability to recover from of PR that can be adopted in their own PR programs
critical illness
• use PR “add-ons” to enhance patient outcomes, access to,
• discuss the tools currently available to clinicians and health and implementation of PR globally
systems to mitigate disparities in recovery resulting from these
Pulmonary Rehabilitation (PR) is standard of care for patients
factors, and how these tools are currently accessed and
with chronic lung disease. The core components include aerobic
utilized
exercise training and disease self-management education.
• explore new novel models of care integration to promote Components have been adapted globally to be culturally
recovery and reduce disparate outcomes from social appropriate and various “add-ons” have been used in low to
determinants in ICU survivors middle income settings. Identifying strategies to improve access
Our speakers will use contemporary evidence, clinical to PR is a top research priority globally to reduce health
experience, and specialized research expertise to discuss the inequities. This session will examine lessons learned from
influence of particular social determinants of health on the ability adaptations based on cultures, private vs. public healthcare
of patients to recover from acute and critical illnesses. systems, and socioeconomic status, and their impacts on the PR
models delivered on the frontlines of care. This session will
9:15 Differences in Healthcare Delivery as a Social provide options to facilitate PR program development and
Determinant of Recovery implementation globally. The speakers provide PR on the
9:27 Recovery in Place: How Neighborhoods Influence frontlines of clinical care.
Recovery and Rehabilitation 9:15 Introduction
9:39 Financial Toxicity after Acute and Critical Illness 9:23 Global Reach of Pulmonary Rehabilitation
9:51 The Patient and Family Journey to Recovery 9:35 Brazil
10:00 Critical Measurement of Social Determinants of 9:47 Saudi Arabia
Health
9:59 Hong Kong
10:12 Tools to Support Patients After Discharge

ATS 2026 Advance Conference Program • Orlando, Florida

68 Click on the session title to view the speakers TUESDAY • MAY 19

10:11 South Korea each of these in research, therapeutic discovery and equitable
10:23 Australia clinical care.

10:35 Questions and Answers 9:15 The Growing Imperative in Lung Health: Spotlight
on Social Determinants and the Promise of Omics
9:25 The Growing Threat: Climate Change and Lung
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL Health Disparities
SCIENTIFIC SYMPOSIUM 9:45 Neighborhood Matters: Food, Location and Stress
as Drivers of Lung Disparities
C11 GLOBAL DISPARITIES AND SOCIAL
10:05 Race Neutral Spirometric Equations and Lung
DETERMINANTS: INNOVATIVE
Health Equity
INTERVENTIONS FOR LUNG HEALTH
10:25 Sex, Gender and Hormones: The Triumvirate of
Assemblies on Environmental, Occupational and Population Lung Health
Health, Allergy, Immunology and Inflammation, Clinical
Problems, Pediatrics; Systems Genetics and Genomics
Section BASIC • TRANSLATIONAL
9:15 A.M. - 10:45 A.M. SCIENTIFIC SYMPOSIUM
Target Audience
Clinicians and researchers at all levels as well as industry C12 MYCOBACTERIA RE-IMAGINED:
partners engaged in understanding how to better develop GAME-CHANGING DISCOVERIES IN TB
therapies for global populations across a range of lived AND NTM SCIENCE
experiences
Assembly on Pulmonary Infections and Tuberculosis
Objectives
At the conclusion of this session, the participant will be able to: 9:15 A.M. - 10:45 A.M.
Target Audience
• describe new findings about various social determinants and
TB and NTM researchers and physician-scientists
how to include for clinical practice and research. At the end of
the seesion the learner will be able to identify social Objectives
deteminants of lung health At the conclusion of this session, the participant will be able to:
• improve understanding about biologic(sex, ancestry) and • describe new insights into T-cell subsets, humoral correlates,
social constructs (gender, race) and the intersectionality with and innate-adaptive immunity in TB and NTM to enhance
environments. At the end of the session the learner will be understanding of disease mechanisms and inform clinical and
able to consider different constructs driving disparities research applications
• integrate concepts of local (neighborhood) and global (climate) • apply advanced imaging, animal models, and pharmacology
environments into lung health. The learner will understand the approaches to improve TB and NTM drug and vaccine
threat of neighborhood (eg food scarcity) and climate change development and research translation
(eg temperature) on lung health and disease risk • integrate knowledge of malnutrition’s impact on immunity to
This symposium will explore social determinants and lung health optimize patient care and design effective TB interventions in
and will highlight global needs to improve lung health across a endemic settings
range of lived experiences. Experts will present state-of-the-art This symposium highlights cutting-edge discoveries and
approaches to evaluating race-neutral spirometry, consideration paradigm-shifting advances in tuberculosis (TB) and
of local neighborhood and climate change, and will present a nontuberculous mycobacteria (NTM) research. It will explore the
framework for sex/gender consideration. Epigenomic plasticity evolving immunopathogenesis of TB and NTM, focusing on T-cell
related to social determinants will be proposed as a targetable subset specialization, humoral correlates of protection,
feature for therapeutic intervention. At the end of this session the innate-adaptive immune interactions, and the impact of
learners will understand the understudied aspects of social malnutrition on host immunity in TB-endemic settings. Attendees
determinants of lung disease and actionable ways to address will also learn about advanced imaging techniques, novel animal

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 69

models, and pre-clinical drug development strategies. This session will use a series of case vignettes to describe the
Emphasizing both basic and translational research, the program ways that pregnancy can be complicated by airways disease,
provides a comprehensive view of the science shaping the future pulmonary vascular disease, transplantation, sleep, and critical
of TB and NTM research. illness. It will also cover the obstetric approach to the pregnant
9:15 Advancing T Cell Immunity: Emerging Insights and patient with pulmonary disease or critical illness and will touch
Innovations in TB and NTM Vaccines upon the ways that policy changes have impacted pregnant
patients who are cared for by the ATS community.
9:30 Expanding the Immune Paradigm: The Role of
Humoral and Innate Responses in Tuberculosis 9:15 Lessons Learned from a Case Study of Pregnancy
in Airways Disease
9:45 Advanced Imaging Approaches for TB and NTM
Infections 9:25 Lessons Learned from a Case Study of Pregnancy
in Lung Transplantation
10:00 Model-Informed Strategies for Optimizing
Preclinical Drug Development in TB and NTM 9:35 Lessons Learned from a Case Study of Sleep
Disorders in the Pregnant Patient
10:15 Nutritional Influences on Host Immunity:
Implications for TB Pathogenesis and Treatment 9:45 Lessons Learned from a Case Study of Pregnancy
in Pulmonary Vascular Disease
10:30 General Discussion
9:55 Lessons Learned from Case Studies of the Critically
Ill Pregnant Patient
CLINICAL 10:05 Approaching the Pregnant Patient with Critical
Illness and Lung Disease from the Obstetric
SCIENTIFIC SYMPOSIUM
Perspective
C13 WHAT TO EXPECT WHEN YOUR 10:15 Impact of Policy Decisions on the Pregnant Patient
PATIENT IS EXPECTING: PREGNACY IN with Lung Disease and Critical Illness
PCCM 10:25 Question and Answer
Assemblies on Clinical Problems, Critical Care, Pulmonary
Circulation, Sleep and Respiratory Neurobiology; Medical
Education Section & Patient and Family Education BEHAVIORAL • CLINICAL
Committee; Health Policy Committee MEDICAL EDUCATION SEMINAR
9:15 A.M. - 10:45 A.M.
ME103 BLENDING TRADITION AND TECH:
Target Audience
NAVIGATING LEARNING RESOURCES
Anyone interested in clinical care, advocacy, and the impact of
policy decision making on health in pulmonary, critical care, IN THE DIGITAL AGE
sleep, and pediatrics Assemblies on Behavioral Science and Health Services
Objectives Research
At the conclusion of this session, the participant will be able to: 10:45 A.M. - 11:45 A.M.
• better counsel patient who are considering pregnancy on the Target Audience
impact pregnancy may have on their respiratory health Pulmonary Physicians, Critical Care Physicians, Physicians
• more appropriately counsel patients who have lung disease on In-Training, Advanced Practice Providers, Medical Students, ICU
the safety of pregnancy and to be able to have treatment plans Nurses, Respiratory Therapists
in place before pregnancy develops Objectives
• advocate for improved access to pre-natal care for the At the conclusion of this session, the participant will be able to:
pregnant patient with lung disease and improved access to • identify and gain insights into current resources available to
providers familiar with lung disease in pregnancy learn pulmonary and critical care medicine including but not
limited to ebooks, apps, podcasts, ai chatbots and other
platforms that enhance clinical knowledge and patient care.

ATS 2026 Advance Conference Program • Orlando, Florida

70 Click on the session title to view the speakers TUESDAY • MAY 19

• review the utility of medical print and online textbooks (ebooks)

and journal articles in the digital age.
• provide strategies for educators to guide in developing
curricula for trainee education in the current dynamic
environment.
This session will explore the integration of different learning tools
and resources in pulmonary critical care medicine. Participants
will: (1) Identify and gain insights into current resources available
to learn pulmonary and critical care medicine including but not
limited to ebooks, apps, podcasts, AI chatbots and other
platforms that enhance clinical knowledge and patient care. (2)
Review the utility of medical print and online textbooks (ebooks)
and journal articles in the digital age. (3) Provide strategies for
educators to guide trainees through this dynamic environment Tuesday Afternoon, May 18
and to develop curricula for fellow education and fellowship
programs. By the end of the session, learners will be equipped
with practical strategies to optimally utilize all the tools presented CLINICAL • TRANSLATIONAL
for learningFacultyFaculty CLINICAL TOPICS IN PULMONARY MEDICINE
C81 NON-TOBACCO COPD - CLASSIFYING
11:45 a.m.- 1 p.m.
DISEASE, IDENTIFYING EXPOSURES
AND CLINICAL TRIAL CONSIDERATIONS
PLENARY SESSION Assemblies on Clinical Problems, Environmental,
Occupational and Population Health; EHPC, HEDC
The Plenary Session is open to all registered attendees
and will also include the ratification of the 2026-2027 slate 2:15 P.M. - 3:45 P.M.
of leaders, as well as remarks from outgoing president Target Audience
Raed A. Dweik, MD, MBA, ATSF, and incoming president Clinicians, basic and translation science researchers,
Michelle Ng Gong, MD, MS, ATSF. epidemiologists, advanced healthcare practitioners, medical
educators, nurses, respiratory therapists
Objectives
At the conclusion of this session, the participant will be able to:
• describe the clinical classification of non-tobacco forms of
COPD
• understand differences in molecular mechanisms of
non-tobacco vs. tobacco related COPD
• conceptualize approaches to clinical trial design in
non-tobacco COPD taking into account both the heterogeneity
and global nature of this disease entity
In this session, you will explore the distinct challenges of
non-tobacco COPD, from identifying at-risk populations to
developing targeted therapies. You will gain a deeper
understanding of environmental and occupational exposures,
their role in disease progression, and strategies for early
screening. Experts will discuss molecular mechanisms, how they
differ from tobacco-related COPD, and implications for treatment.

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 71

You will also learn about clinical trial design, addressing gaps in approaches, and consider their relevance for their own
research, and strategies to expand global outreach, particularly in research
underserved regions. This session will provide you with This session explores key drivers of lung fibrosis across the age
actionable insights to improve diagnosis, treatment, and research span, from environmental and genetic risk factors to cellular and
for this underrecognized COPD population. extracellular mechanisms. Talks will highlight how environmental
2:15 Classifying Non-Tobacco COPD exposures contribute to fibrogenesis and how preventive
2:27 Identifying “At Risk”/"Exposed" Populations strategies may mitigate risk; genetic predispositions and
advances in gene therapy; the role of epithelial aging and cell
2:39 Environmental Exposures - Impact on Lung Health death in disease onset; and how targeting fibroblasts and fibrotic
& Development matrix may halt progression. By bridging pediatric and adult
2:51 Approach to Therapy in Non-Tobacco COPD perspectives, the session will showcase emerging opportunities
for prevention and intervention across the continuum of lung
3:03 Approach to Clinical Trial Design
fibrosis.
3:15 Global Clinical Trial Design to Optimize Outreach
2:15 Environmental and Occupational Triggers of
3:27 Panel Discussion Fibrosis: A Call for Prevention
2:30 Genetic Drivers of Lung Fibrosis: Moving from Risk
BASIC • CLINICAL • TRANSLATIONAL to Pluripotent Stem Cell Therapies
2:45 Molecular Mechanisms of Rare Interstitial Lung
BASIC SCIENCE CORE Diseases: Pediatrics Perspective
C82 LUNG FIBROSIS ACROSS THE 3:00 Dysregulated Epithelial Proteostasis at the
LIFESPAN: EMERGING Mechanistic Intersection of Pediatric and Adult
OPPORTUNITIES FOR INTERVENTION Interstitial Lung Disease
Assemblies on Respiratory Cell and Molecular Biology, 3:15 Targeting Fibroblasts and Matrix: Breaking the
Clinical Problems, Environmental, Occupational and Cycle of Fibrosis
Population Health, Pediatrics; PhD and Basic and 3:30 Panel Discussion
Translational Scientists (PBTS) Working Group
2:15 P.M. - 3:45 P.M.
CLINICAL
Target Audience
Basic, translational, and clinical scientists with an interest in CLINICAL TOPICS IN PULMONARY MEDICINE
age-spanning mechanisms and emerging preventive and
therapeutic strategies across pediatric and adult pulmonary C83 TREATMENT CHALLENGES IN
fibrosis SARCOIDOSIS
Objectives Assembly on Clinical Problems
At the conclusion of this session, the participant will be able to: 2:15 P.M. - 3:45 P.M.
• understand how environmental and occupational exposures Target Audience
contribute to the initiation and progression of pulmonary Clinicians that take care of patients with sarcoidosis, as well as
fibrosis, and how this knowledge can inform prevention sarcoidosis clinical and translational researchers
strategies across the lifespan
Objectives
• describe new findings about the role of genetic and cellular At the conclusion of this session, the participant will be able to:
factors, including telomere biology, epithelial aging, and
alveolar epithelial cell dysfunction, in driving fibrogenesis in • define new strategies to manage the care of pulmonary
both pediatric and adult lung disease sarcoidosis including minimizing or avoiding the use of
prednisone in treating pulmonary sarcoidosis
• acknowledge emerging antifibrotic strategies, including gene
therapy, senescence modulators, and matrix-targeting

ATS 2026 Advance Conference Program • Orlando, Florida

72 Click on the session title to view the speakers TUESDAY • MAY 19

• better counsel patients on the treatment of fibrotic pulmonary • describe recent advances in endothelial biology with
sarcoidosis, incorporating evidence and underlying implications for the treatment of critical illness syndromes
mechanisms to support a shared decision making process including sepsis, ARDS, trauma, and AKI
• incorporate into practice the most recent data regarding • integrate endothelial specific biomarkers and bedside imaging
treatment of pulmonary and extra pulmonary sarcoidosis, techniques into design of critical care studies
including use of advanced imaging and recognition of other • define effective clinical trial designs to successfully target
symptoms of sarcoidosis such as fatigue and multiorgan endothelial dysfunction in critically ill patients
involvement
Targeting endothelial dysfunction is an emerging strategy to
Sarcoidosis is a challenging disease with many unknowns. improve outcomes in critically ill patients with ARDS, sepsis,
Patients can have a highly variable clinical course and decisions trauma, and AKI. This session will explore the clinical and
around treatment including whether to initiate therapy, duration of translational implications of endothelial injury and activation,
treatment, and choice of agent are often not straightforward. This including glycocalyx degradation and disruption of the
clinically focused session will review the most recent data, Angiopoietin-Tie2 signaling axis. Speakers will highlight emerging
explore the evolving treatment paradigms in sarcoidosis and biomarkers and novel imaging techniques available to detect
examine specific challenges in treating patients with sarcoidosis. dysfunction, as well as therapeutic strategies aimed at restoring
2:15 Introduction vascular homeostasis. Attendees will gain insight into how
2:25 The Beginning of the End for Prednisone? Evolving advances in endothelial biology are driving a more precise,
Treatment Paradigms in Sarcoidosis mechanism-based approach to the diagnosis, monitoring, and
treatment of critical illness.
2:45 How Much is Too Much? The Role of FDG PET and
Other Advanced Imaging in the Assessment and 2:15 Endothelium Unveiled: Unified Mechanisms of
Treatment of Sarcoidosis Endothelial Dysfunction in Critical Illness

3:05 The Chicken or the Egg: How Mechanism Drives 2:27 Advances in Bedside Detection of Endothelial
Treatment Decisions in Fibrotic Pulmonary Dysfunction: Biomarkers and Emerging Bedside
Sarcoidosis Technologies

3:25 Exploring Subtypes of Fatigue in Sarcoidosis: 2:39 Endothelial Fragility and the Brain: A Novel
Implications for Treatment Contributor to Poor Critical Illness Outcomes in
Older Adults
2:51 Endothelial Injury in the Lung: The Role of Cell-free
CLINICAL • TRANSLATIONAL Hemoglobin and Disruption of Microvascular
Endothelial Cell Barrier in Lung Injury
CRITICAL CARE TRACK
3:03 Endothelial Dysfunction in the Kidney: Lung and
C84 ENDOTHELIAL DYSFUNCTION IN Kidney Cross-talk in Perpetuating Organ Injury
CRITICAL ILLNESS: FROM
3:15 Resetting and Restoring the Endothelium:
MECHANISMS TO THERAPIES Therapeutic Targets and Clinical Trials
Assemblies on Critical Care, Pulmonary Circulation, 3:27 Panel Discussion on Endothelial Dysfunction in
Pulmonary Infections and Tuberculosis, Respiratory Cell Critical Illness
and Molecular Biology
2:15 P.M. - 3:45 P.M.
Target Audience
Clinicians and researchers who care for or conduct research on
adult patients with critical illness.
Objectives
At the conclusion of this session, the participant will be able to:

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 73

CLINICAL 3:09 Pro-Screening for ILA/ILD

3:22 Con-Screening for ILA/ILD
SCIENTIFIC SYMPOSIUM
3:35 Questions: Screening for ILA/ILD
C85 ATS GUIDELINES AND CLINICAL
STATEMENTS: CONTROVERSIES IN
RESPIRATORY FAILURE AND ILA/ILD BASIC • CLINICAL • TRANSLATIONAL

Documents Development and Implementation Committee; SCIENTIFIC SYMPOSIUM

Pulmonary Function Testing Committee; Quality
C86 VASCULOPATHIES IN PULMONARY
Improvement and Implementation Committee
DISEASE ? THE DARK SIDE OF THE
2:15 P.M. - 3:45 P.M. LUNG
Target Audience
Assemblies on Pulmonary Circulation, Allergy, Immunology
Clinicians caring for patients with respiratory failure, ILA/ILD
and Inflammation, Clinical Problems, Pediatrics, Respiratory
Objectives Cell and Molecular Biology, Respiratory Structure and
At the conclusion of this session, the participant will be able to: Function; PhD, Basic, and Translational Scientists Working
• understand how evidence is used to inform diagnostic and Group (PBTS WG)
treatment recommendations 2:15 P.M. - 3:45 P.M.
• improve patient outcomes by applying recommendation from Target Audience
recently published clinical practice guidelines and clinical Providers of lung health care (pediatrics and adult), basic and
statements translational researchers, and clinical researchers
• learn new strategies in the management of acute respiratory Objectives
failure and in the identification and monitoring of individuals at At the conclusion of this session, the participant will be able to:
risk for interstitial lung disease • describe new scientific findings regarding the biochemical and
This session is proposed as the 11th annual scientific symposium immunological mechanisms responsible for pulmonary
sponsored by the Documents Development and Implementation vasculopathies
Committee. This symposium will focus on controversial topics in • understand new strategies to manage pulmonary vascular diseases
recently published clinical practice guidelines and statements, with a deeper insight into the molecular mechanisms at play
with presentations of pro and con positions on recommendations
related to interstitial lung abnormalities (ILAs)/interstitial lung • describe new clinical research findings and better counsel their
disease (ILD) and acute respiratory failure. patients on new treatment options and educational resources for
patients suffering from pulmonary vasculopathies
2:15 Welcome and Introduction
This session will provide insights into how vascular alterations interact
2:18 ATS CPG on Management of Noninvasive with/shape the lung microenvironment in disease progression. The
Respiratory Support for Acute Respiratory Failure talks included in this scientific symposium will explore recent findings
(Part 1) regarding the mechanisms and treatment of pulmonary vasculopathies.
2:22 ATS CPG on Management of Noninvasive Speakers will discuss the molecular mechanisms responsible for
Respiratory Support for Acute Respiratory Failure detrimental vascular changes in pulmonary hypertension and chronic
(Part 2) obstructive pulmonary disease, providing an overview of recent
2:26 Pro-HFNO in Hypercapnic Respiratory Failure pre-clinical and clinical studies on vasculopathies and fostering
discussion on ongoing scientific and clinical efforts.
2:39 Con-HFNO in Hypercapnic Respiratory Failure
2:15 The Role of Imaging in Non-Invasive Assessment of
2:52 Questions: HFNO in Hypercapnic Respiratory the Pulmonary Vasculature
Failure
2:33 Understanding Endothelial-to-Mesenchymal
3:02 ATS Clinical Statement on the Evaluation and Transition in Pulmonary Vascular Remodeling
Management of Interstitial Lung Abnormalities

ATS 2026 Advance Conference Program • Orlando, Florida

74 Click on the session title to view the speakers TUESDAY • MAY 19

2:51 Cigarette Smoke and Air Pollution Compromise 2:18 Resilience in Transition: Rethinking Global Health
Epithelial-Endothelial Interactions Research
3:09 Molecular Mechanisms of Vascular Remodeling in 2:33 Perspectives on the Federal Trajectory in Health
Pulmonary Hypertension Research
3:27 Insights from Precision-Cut Lung Slices: Pulmonary 2:48 Building a Funding Roadmap: Strategic
Hypertension Mechanisms and Novel Therapeutics Opportunities for Early-Career Investigators
3:03 Lessons from International Collaborations and NGO
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL Funders
3:18 Sustaining Research through NGO Innovation
SCIENTIFIC SYMPOSIUM
3:33 Discussion
C87 ADAPTING TO AN EVOLVING
RESEARCH FUNDING ENVIRONMENT:
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
A MULTI-NATIONAL APPROACH
Assemblies on Behavioral Science and Health SCIENTIFIC SYMPOSIUM
ServicesResearch; Health Policy Committee, Research
C88 BREATHING NEW LIFE INTO YOUR
Advocacy, Committee, International Health Committee ;
CAREER: THRIVING THROUGH
Health Equity and Diversity Committee
TRANSITIONS
2:15 P.M. - 3:45 P.M.
SCALe: Professional Development
Target Audience
Anyone interested in research, including all trainees, Committee
administrators seeking to understand their reportees’ challenges,
2:15 P.M. - 3:45 P.M.
and all investigative team members
Target Audience
Objectives Clinicians, clinician-scientists, educators and researchers across
At the conclusion of this session, the participant will be able to: all stages of career development and those navigating potential
• summarize the impact of recent changes to the healthcare career changes
research funding Objectives
• assess the viability of non-governmental organizations as At the conclusion of this session, the participant will be able to:
alternate funders for research • identify common drivers and challenges associated with career
• develop practically grounded plans for funding research in the transitions in pulmonary, critical care, and sleep medicine and
face of NIH cutbacks science, including burnout, evolving professional interests, and
institutional demands
Research is a fundamental part of medicine and the allied health
professions. This has traditionally relied on funding from large, • describe practical strategies and frameworks for navigating
objective, neutral funders supporting investigators in non-profit transitions between clinical, administrative, research, and
contexts. Recent pullbacks from large funders represent the most hybrid roles, with attention to skill development, mentorship,
significant changes in living memory. What should public health and identity shifts
advocates anticipate in terms of impact? How can individual • apply insights from real-world case examples to support
researchers maintain viable programs? What alternatives exist, intentional career planning and foster resilience, fulfillment,
and how can they be accessed? This session grapples with a and leadership growth across diverse career pathways
question existential to a significant fraction of ATS membership
from an informed global perspective. Attendees will leave with a This session explores the diverse career trajectories of clinicians
deeper understanding of the current state and future of health and scientists in pulmonary, critical care, and sleep medicine and
and behavioral science research funding. science. Through personal narratives, practical strategies,
evidence-based and interactive discussion, attendees will gain
2:15 Introduction insights into navigating transitions such as moving from clinical to

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 75

administrative roles, re-engaging in research, or redefining • present real-world data detailing how multidisciplinary cystic
purpose in mid-career. Targeted towards trainees, early career fibrosis (CF) care teams deliver healthcare to LGBTQIA2S+
professionals and those in mid-career considering a new people living with CF, as an example for other patient and
direction, this session will provide tools to support long-term clinician groups
success in aligning career decisions with personal values, Lesbian, gay, bisexual, transgender, queer, intersex, asexual,
maintaining professional satisfaction, and adapting to evolving two spirit (LGBTQIA2S+) patients face well-documented
goals across a range of professional pathways in medicine. healthcare disparities rooted in long-standing stigma,
2:15 Introduction 1 socioeconomic and political inequality, and a lack of culturally
2:18 Introduction 2 competent medical providers. The health and wellbeing of
LGBTQIA2S+ individuals is under increasing threat under
2:20 Revive Your Drive: Strategies for Mitigating Burnout recently expanded anti- LGBTQIA2S+ legislation. This
and Enhancing Career Satisfaction symposium will orient participants on the importance of culturally
2:37 Navigating Your “Second Curve”: Mid-Career competent care for LGBTQIA2S+ individuals. After establishing a
Transitions shared understanding, this symposium will cover more advanced
topics, including techniques for creating a safe and inclusive
2:53 Success Strategies for Shifting Between Research
space for all patients and strategies for advocacy for minoritized
and Clinical Roles
populations in care, education, and research.
3:09 Redefining the Role: Moving to Administrative
2:15 Introduction
Leadership
2:20 From Acronyms to Allyship: How A Deeper
3:25 Panel Discussion: Choosing Academic, Private
Understanding of Sexual and Gender Identity Can
Practice, Community-Focused, or Industry Careers
Improve Care for All
2:40 What to Say When You Don’t Say Gay: How
BEHAVIORAL • CLINICAL anti-LGBTQ2IA+ Laws Impact Patients and
Providers
SCIENTIFIC SYMPOSIUM
3:00 Physician Advocacy in Research and Care:
C89 TAKING PRIDE IN OUR WORK: Lessons Learned from Pride-CF
ADVANCING LGBTQIA2S+ ALLYSHIP 3:20 Why Inclusive Care Matters: Current State and Next
THROUGH EDUCATION AND Steps
ADVOCACY
3:35 Moderator Wrap-Up
Assemblies on Pediatrics, Clinical Problems, Critical Care;
Health Equity and Diversity Committee (HEDC)
CLINICAL
2:15 P.M. - 3:45 P.M.
Target Audience SCIENTIFIC SYMPOSIUM
ATS members with an interest equitable care of diverse patients,
ATS members with an interest in advocacy for minoritized C90 ADVANCING HYPOXEMIA
populations, members with leadership roles, training program ASSESSMENT AND OXYGEN ACCESS:
directors, international medical graduates U.S. AND INTERNATIONAL
Objectives PERSPECTIVES
At the conclusion of this session, the participant will be able to: Assemblies on Clinical Problems, Nursing; International
• provide an overview of nomenclature, concepts, and best Health committee ; International Health committee
practices relevant to the care of the LGBTQIA2S+ population 2:15 P.M. - 3:45 P.M.
and understand why learning to provide culturally competent
Target Audience
care for LGBTQIA2S+ should matter to all ATS members Clinicians of any level supporting patients who potentially need
• describe the current executive and legislative climate supplementary oxygen, either in hospital or at home
impacting LGBTQIA2S+ patients and providers

ATS 2026 Advance Conference Program • Orlando, Florida

76 Click on the session title to view the speakers TUESDAY • MAY 19

Objectives 2:15 P.M. - 3:45 P.M.

At the conclusion of this session, the participant will be able to: Target Audience
• define challenges in the identification of hypoxemia in different An international and interprofessional group of pulmonary-critical
healthcare settings and across ethnicities around the world care and palliative care clinicians (nurses, therapists, physicians,
social workers), scientists, medical educators, and trainees
• define challenges in the diagnosis and access to oxygen in the (fellows, residents, medical students).
United States
Objectives
• define challenges in the diagnosis of hypoxemia and access to At the conclusion of this session, the participant will be able to:
oxygen in low- and middle-income countries
• describe and implement a “PalliPulm” framework for
An overarching principle of the American Thoracic Society is to integrating primary palliative care into PCCM outpatient and
improve global lung health and to serve as a resource for global inpatient practice, based on priority skills identified by expert
members, of whom more than 30% reside outside the United consensus
States across 129 countries. Despite a wide variety of local
contexts, common challenges are faced by members in all • describe evidence-based medical education strategies for
countries. One such common challenge is access to oxygen teaching palliative care skills to PCCM trainees and clinicians
therapy. This symposium invites perspectives from multilateral • identify principles of culturally appropriate and equitable
organizations and in-country experts to address challenges and primary palliative care for diverse patient populations with
opportunities regarding inequities in the assessment of serious respiratory illness
hypoxemia and oxygen access.
This session will disseminate findings from the official ATS
2:15 Opening Remarks: Why Is it Important to Achieve Workshop Report, “A PalliPulm Framework to Improve Palliative
Equity in Oxygen Access? Care Education and Practice in Pulmonary-Critical Care
2:27 Unmasking Racial Bias in Pulse Oximetry: Insights Medicine.” It will summarize the development of the framework
and Imperatives and showcase its application across education, practice, and
policy. Speakers will highlight key results, present prioritized
2:39 Advancing Equity and Access: The Medical Oxygen palliative care skills in outpatient and inpatient settings, and
Imperative describe strategies for clinician training, culturally appropriate
2:49 Bridging the Gap: Enhancing Medical Oxygen care, and systems-level implementation.
Access in Low- and Middle-Income Countries 2:15 Propelling Palliative Care in Pulmonary Critical Care
3:01 Enhancing Pediatric Respiratory Care: Global through PalliPulm
Initiatives in Oxygen Therapy 2:30 Core Primary Palliative Care Skills Across Settings
3:13 Developing Oxygen Equipment for the World: What 2:45 Exemplar Palliative Care Educational Opportunities
is the Business Case for Pulmonary-Critical Care Clinicians and Trainees
3:25 Panel Discussion 3:00 Delivering Equitable and Culturally Appropriate
Primary Palliative Care
BEHAVIORAL • CLINICAL • TRANSLATIONAL 3:15 Implementation and Future Directions

SCIENTIFIC SYMPOSIUM 3:30 Panel Discussion: Question and Answer

C91 PRIMARY PALLIATIVE CARE IN

PULMONARY-CRITICAL CARE
MEDICINE: A ‘PALLIPULM’
FRAMEWORK FOR EDUCATION,
PRACTICE, AND POLICY
Assemblies on Behavioral Science and Health Services
Research, Clinical Problems, Critical Care, Nursing

ATS 2026 Advance Conference Program • Orlando, FL

TUESDAY • MAY 19 Click on the session title to view the speakers 77

CLINICAL
ADULT CLINICAL CORE CURRICULUM
CC5 ADULT PULMONARY CLINICAL CORE
CURRICULUM
SCALe: Core Curriculum Committee
2:15 P.M. - 3:45 P.M.
Target Audience
Advanced Practice Providers,Clinicians,Medical Educators
Objectives
At the conclusion of this session, the participant will be able to:
• integrate guidelines on the identification and management of
pulmonary vascular disease into clinical practice
• counsel patients and families on efficacy of available treatment
options for pulmonary vascular disease
• identify knowledge gaps in the diagnosis and management of
pulmonary vascular disease
The goal of the core is to support clinicians who are engaged in
maintenance of certification activities by providing updates on
subjects included in recertification requirements.
2:15 A Little Change Would Do You Good: Pulmonary
Hypertension Diagnosis and Classification
2:40 Tomorrow Never Knows: Risk Stratification in
Pulmonary Hypertension
3:05 Under Pressure: Chronic Thromboembolic
Pulmonary Disease
3:30 Panel Discussion

ATS 2026 Advance Conference Program • Orlando, Florida

78 Click on the session title to view the speakers WEDNESDAY • MAY 20

CLINICAL • TRANSLATIONAL
CLINICAL TOPICS IN PULMONARY MEDICINE
D2 A TALE OF TWO TRANSPLANTS: THE
CONVERGENT PATHS OF CHRONIC
LUNG ALLOGRAFT DYSFUNCTION AND
PULMONARY GRAFT VERSUS HOST
DISEASE
Assembly on Clinical Problems
8:15 A.M. - 9:45 A.M.
Target Audience
Wednesday Morning, May 20 Providers and researchers for persons who have pulmonary
complications after lung or cell transplant
Objectives
At the conclusion of this session, the participant will be able to:
YEAR IN REVIEW • have an improved understanding of the mechanisms
underlying tissue injury and the cells and signaling pathways
D1 CLINICAL YEAR IN REVIEW responsible for fibrogenesis in transplant related pulmonary
8:15 A.M. - 9:45 A.M. fibrosis

Target Audience • define new strategies for more accurate and earlier
Pulmonary, critical care, and sleep providers identification of BOS after lung and cell transplant
Objectives • improve the health status of persons with TPF by applying
At the conclusion of this session, the participant will be able to: established and emerging therapeutics to reduce morbidity
and improve quality of life. Identify cases in which these
• apply new clinical research knowledge to clinical practice therapies may have the potential to alter progression
• learn new findings about key conditions in pulmonary, critical Bronchiolitis obliterans syndrome is a highly morbid complication
care and sleep after lung transplant (LT) and hematopoietic cell transplant
• have new strategies to manage the care of common conditions (HCT), characterized by progressive airway fibrosis and leading
in pulmonary, critical care, and sleep to respiratory failure. While sharing clinical and histological
This program has been developed to include core topics in similarities, these conditions differ in their triggers, fundamentally
pulmonary, critical care, and sleep medicine. The goal of the caused by immune activation due to self (host versus graft in LT)
session is to discuss critical state-of-the-art topics and evolving and non-self (graft versus host in HCT) discordance between
concepts. The learner will be exposed to a carefully curated donor and recipient. The proposed symposium aims to create
review of the current literature by emerging leaders in the field. cross-pollination between experts in transplant-related pulmonary
After the course, participants will better understand novel fibrosis (TPF) through discussion of pathobiology, strategies for
concepts in each specific domain that we hope will translate to earlier detection and risk stratification, and emerging antifibrotic
improved patient care. therapies.

9:15 COPD 8:15 Introduction on Transplant Related Pulmonary

Fibrosis and Facilitation of Questions After Each
9:37 Interventional Pulmonary Presentation
10:00 Medical Education 8:30 Clinical Similarities and Differences Between BOS
10:23 Lung Cancer After Lung and Cell Transplant
8:45 Predicting Lung Allograft Dysfunction: Integrating
Clinical Risk Factors and Novel BAL Strategies

ATS 2026 Advance Conference Program • Orlando, Florida

WEDNESDAY • MAY 20 Click on the session title to view the speakers 79

9:00 Fibrogenic Transformation of Mesenchymal Cells 8:15 Tobacco Treatment for Adolescents and Young
and Chronic Lung Allograft Dysfunction Adults: A Summary of the ATS Clinical Practice
9:15 Earlier Detection of Transplant Related Pulmonary Guideline
Fibrosis with Quantitative CT 8:30 ‘For the First time in Forever’: Cytisinicline, a New
9:30 Emerging Antifibrotic Therapies for Transplant Medication for Nicotine Dependence
Related Pulmonary Fibrosis 8:45 Co-Use of Cannabis and Nicotine: Implications for
Patients and Clinicians

BEHAVIORAL • CLINICAL 9:00 ‘I Just Can’t Quit’: Approaching Tobacco Treatment

for Challenging Populations
CLINICAL TOPICS IN PULMONARY MEDICINE 9:15 The New Tobacco End Game: Anticipated Policy
Needs and Challenges in an Evolving Landscape
D3 THE CUTTING EDGE OF TREATMENT
FOR NICOTINE ADDICTION: WHAT ALL 9:30 Panel Discussion
CLINICIANS SHOULD KNOW
Tobacco Action Committee CLINICAL
8:15 A.M. - 9:45 A.M. CRITICAL CARE TRACK
Target Audience
Clinicians of all types, including trainees, who care for patients D4 OPTIMIZING CRITICAL CARE THROUGH
who use nicotine products (e.g. vaping, cigarettes), clinicians LEARNING HEALTH SYSTEMS:
and researchers who may participate in advocacy efforts to COMPONENTS AND CONSIDERATIONS
decrease morbidity from tobacco products
Assembly on Critical Care
Objectives
At the conclusion of this session, the participant will be able to: 8:15 A.M. - 9:45 A.M.
Target Audience
• incorporate new guidelines for providing high-quality treatment
Intensive care unit clinicians and researchers
to adolescents and young adults struggling with nicotine
addiction Objectives
At the conclusion of this session, the participant will be able to:
• define new strategies to address potential challenges for
cessation, such as co-use of cannabis and tobacco products, • describe the critical components of a learning health system in
and understand strategies for addressing nicotine and tobacco the ICU (leveraging data sources to support the conduct of
use in populations with barriers to cessation embedded trials, quality improvement and implementation)
• better counsel patients about cytisinicline, a new medication • understand the ethical imperatives that compel systems to
for the treatment of nicotine addiction, focusing on supporting work towards a learning health paradigm
evidence and experience with its use • understand the advances in health informatics for us in active
This symposium will educate clinicians on the rapidly evolving clinical research and quality improvement initiatives
landscape of treatment for nicotine addiction. Experts will In this session we will review the potential of ICU learning health
address key topics including the anticipated approval of systems (LHS) to transform critical care delivery, describe key
cytisinicline, the first new treatment for nicotine addiction in components of an effective ICU LHS, and provide
nearly 20 years. Speakers will summarize two recent ATS recommendations to build LHS infrastructure in attendees’ own
documents (guideline for the treatment of nicotine dependence in systems. An ICU LHS advances the field by 1) leveraging data
adolescents and young adults, research policy statement on generated during routine ICU care to inform knowledge
co-use of inhaled nicotine and cannabis) and discuss strategies generation, 2) creating a culture of continuous process
for addressing nicotine addiction among patients who struggle to improvement and 3) embedding effectiveness and
quit. This session will equip clinicians with the most up to date implementation research in daily practice. Such systems are
information to help their patients in treating nicotine addiction and critical for seeking equity in our healthcare system, and fulfilling
also empower them to advocate for tobacco control efforts. the promise of improved care for all our patients.

ATS 2026 Advance Conference Program • Orlando, Florida

80 Click on the session title to view the speakers WEDNESDAY • MAY 20

8:15 What Is a Learning Health System and How Can it imbalance-between aging processes and regenerative capacity,
Impact ICU Care? we can uncover new therapeutic targets to halt or reverse
8:28 Leveraging Health-Care System Data for Knowledge emphysema progression.
Generation 8:15 AT2 Cells and Emphysema: Heroes of Repair or
8:41 Fulfilling Ethical Duties and Honoring Patient Hidden Villains?
Privacy in a Learning Health System 8:30 Aging Lungs and Broken Barriers: Is the
8:54 Building Quality Improvement Programs in a Endothelium to Blame?
Learning Health Paradigm 8:45 Immune Pathways in Emphysema: Balancing Aging
9:07 Conducting Clinical Trials Within a Learning Health and Repair
System Paradigm: The Pragmatic Critical Care 9:00 AT1 Cells: The Unusual Suspects in Emphysema
Trials Group Experience Pathogenesis
9:20 Implementation Trials as a Means to Support a LHS 9:15 From Code to Collapse: Genes Behind Aging and
9:33 Panel Discussion Emphysema Repair
9:30 Rebuilding the Lung: Toward a Systems Approach
to Emphysema Repair
BASIC • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM BASIC • CLINICAL • TRANSLATIONAL
D5 EMPHYSEMA DECODED: AGING GONE SCIENTIFIC SYMPOSIUM
WRONG OR REPAIR GONE MISSING?
D6 MEET THE BOS: PHENOTYPES AND
Assemblies on Respiratory Cell and Molecular Biology,
PATHWAYS IN BRONCHIOLITIS
Allergy, Immunology and Inflammation, Respiratory Cell and
Molecular Biology OBLITERANS SYNDROME

8:15 A.M. - 9:45 A.M. Assemblies on Pediatrics, Allergy, Immunology and

Inflammation, Clinical Problems, Critical Care, Pediatrics,
Target Audience Pulmonary Infections and Tuberculosis, Respiratory Cell
Basic and translational scientists and clinicians
and Molecular Biology, Thoracic Oncology
Objectives
8:15 A.M. - 9:45 A.M.
At the conclusion of this session, the participant will be able to:
Target Audience
• describe the role of cellular senescence in the pathogenesis of Pulmonary physicians, oncologists, general medicine physicians,
emphysema and how it contributes to impaired lung function critical care physicians, cardio-thoracic surgeons, clinical
• explain the mechanisms of failed alveolar repair and educators, physicians-in-training, basic science researchers in
regeneration in emphysema, including the dysfunction of lung injury and repair
progenitor cell populations Objectives
• evaluate emerging therapeutic strategies targeting At the conclusion of this session, the participant will be able to:
senescence and enhancing lung regeneration as potential • recognize early manifestations of BOS after lung
interventions for emphysema transplantation, hematopoietic cell transplantation, and
This session delves into the cellular and molecular drivers of respiratory viral infections
emphysema, exploring whether the disease is primarily fueled by • understand the differences in epidemiology, clinical
premature cellular senescence or by a failure of lung tissue presentation, and pathobiology of various forms of BOS
regeneration. We will examine emerging evidence from human
• address critical knowledge gaps in the diagnosis and
studies and experimental models that link impaired repair
treatment of BOS subtypes, and highlight emerging molecular
pathways, stem cell exhaustion, and persistent inflammation to
pathways and targets for future interventions
alveolar destruction. By understanding the balance-or

ATS 2026 Advance Conference Program • Orlando, Florida

WEDNESDAY • MAY 20 Click on the session title to view the speakers 81

Bronchiolitis obliterans syndrome (BOS) is a severe and • identify common pathways responsible for endothelial
debilitating obstructive airway disease marked by small airway dysfunction and disrupted cell-cell communication in
inflammation and fibrosis. While fibrosis is a common outcome, developing and mature lungs
there are crucial differences in the many forms of BOS that merit • learn about novel tools and mouse models to study lung
a nuanced exploration. This session will examine the endothelial heterogeneity
epidemiology, pathobiology, histology, clinical and radiological
manifestations, and treatments for different forms of BOS, Exciting advancements are shedding light on endothelial
including chronic lung allograft dysfunction after lung heterogeneity in the lungs, revealing the complex landscape of
transplantation, post-hematopoietic stem cell transplantation distinct lung endothelial cell subpopulations. However, significant
(HSCT), and post-infectious BOS. A concluding summary will knowledge gaps remain, particularly regarding cell-cell
highlight key similarities and differences, offering practical communication and how these interactions shape the lung
insights for diagnosis and management. microenvironment in both developing and mature lungs. In this
symposium, we will discuss novel insights into the dynamic
8:15 Unlocking Bronchiolitis Obliterans Syndrome interplay between the lung endothelium, considered in its cellular
(BOS): Overview of Its Complexities and Clinical diversity, and resident lung cell populations, we will highlight
Impact similarities and differences across the lifespan, and explore
8:20 BOS After Lung Transplantation- Improving potential implications for human health and disease.
Outcomes of a Deadly Disease 8:15 Introduction to Endothelial Heterogeneity in the
8:40 The Importance of Early Diagnosis in Lung Microenvironment: Age and Disease
Post-Hematopoietic Stem Cell Transplantation Perspectives
(HSCT) BOS 8:19 Lung Cell Cross-Talk in Development and Disease
9:00 Post-Infectious BOS: When Infection Leaves a 8:33 Endothelial Transitional States and Cell-Cell
Lasting Mark on the Lungs Dynamics During Neonatal Hyperoxia
9:20 BOS: Clinical Insights, Current Challenges, and 8:47 Endothelial Heterogeneity: A Key Player in Lung
Future Directions Aging and Fibrosis Progression
9:40 Question and Answer 9:01 Contribution of Endothelial Diversity to Lung
Fibrosis and Lung Adenocarcinoma
BASIC • TRANSLATIONAL 9:15 Lung Endothelial Cell Heterogeneity in Health and
Pulmonary Vascular Disease
SCIENTIFIC SYMPOSIUM
9:29 Endothelial Cell Arterialization and Aberrant
D7 ENDOTHELIAL HETEROGENEITY IN Vascular Remodeling in Pulmonary Arterial
THE LUNG MICROENVIRONMENT: AGE Hypertension
AND DISEASE PERSPECTIVES 9:43 Closing Summary
Assemblies on Pulmonary Circulation, Respiratory Cell and
Molecular Biology BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
8:15 A.M. - 9:45 A.M.
SCIENTIFIC SYMPOSIUM
Target Audience
Basic and translational scientists interested in pulmonary D8 THERAPEUTIC ACUTE INTERMITTENT
endothelial biology across life span and disease HYPOXIA: TRANSLATION FROM
Objectives ANIMAL MODELS TO HUMANS WITH
At the conclusion of this session, the participant will be able to: INJURY OR DISEASE
• describe novel findings about the contribute of the lung Assemblies on Sleep and Respiratory Neurobiology,
endothelium, in its cellular diversity, to lung health and disease Pulmonary Rehabilitation
8:15 A.M. - 9:45 A.M.

ATS 2026 Advance Conference Program • Orlando, Florida

82 Click on the session title to view the speakers WEDNESDAY • MAY 20

Target Audience BEHAVIORAL • CLINICAL

Clinicians and scientists in pulmonary, sleep, neuro, rehab, and
critical care. Ideal for those treating or researching SCI, stroke, SCIENTIFIC SYMPOSIUM
ALS, or OSA, and those exploring neuromodulation and motor
plasticity to enhance function D9 THE SCIENCE OF PALLIATIVE CARE IN
Objectives THE ICU: HIGH HOPES, MIXED
At the conclusion of this session, the participant will be able to: RESULTS
• describe new findings on how therapeutic acute intermittent Assemblies on Behavioral Science and Health Services
hypoxia induces respiratory and locomotor neuroplasticity in Research, Critical Care, Nursing
humans 8:15 A.M. - 9:45 A.M.
• apply low-dose AIH protocols to enhance breathing and Target Audience
walking function in patients with ALS, spinal cord injury, and Critical care physicians, palliative care specialists,
stroke implementation scientists, ICU nurses, and healthcare
• integrate mechanistic insights and timing strategies (e.g., administrators interested in improving quality of care and
circadian modulation) to optimize AIH delivery for outcomes for critically ill patients and their families
sleep-disordered breathing and neurorehabilitation Objectives
Therapeutic acute intermittent hypoxia (tAIH) is an emerging At the conclusion of this session, the participant will be able to:
intervention that applies brief, controlled episodes of low oxygen • critically evaluate the strengths and limitations of recent
to stimulate endogenous neuroplasticity. Low-dose tAIH randomized and implementation trials in ICU-based palliative
protocols, initially characterized in animal models, are now care, including which components are most likely to impact
demonstrating promising results in clinical trials. This session will patient and family outcomes
present evidence that tAIH enhances gait recovery in chronic
• identify and apply strategies for improving the delivery of
spinal cord injury and stroke, improves breathing in ALS, and
ICU-based palliative care that are tailored to specific patient
reduces apnea burden in OSA when timed to diurnal rhythm.
populations, care settings, and resource constraints, including
Attendees will learn the mechanisms, protocols, and
models that address equity and continuity
patient-specific considerations that underpin tAIH, offering a
roadmap for clinical translation and research application in • integrate insights from implementation science, health equity,
rehabilitation and respiratory care. and emerging tools like AI into clinical care or program design
to better align ICU-based palliative care with the needs of
8:15 Molecular Mechanisms and Diurnal Modulation of
seriously ill patients and their families
AIH-Induced Neuroplasticity
This symposium will examine the evolving science of ICU-based
8:30 Harnessing AIH to Restore Respiratory Motor
palliative care, where interventions often fall short of
Function in ALS
expectations. Despite strong evidence, improvements in
8:45 Walking Again: AIH-Induced Functional Recovery outcomes, especially psychological distress among families,
After Chronic Spinal Cord Injury remain limited. Drawing on recent trials and implementation
9:00 Integrating AIH and Gait Training to Improve studies, speakers will explore what distinguishes effective
Outcomes in Stroke Rehabilitation strategies, when and how palliative care should be delivered, and
why commonly measured outcomes may miss the mark.
9:15 Circadian Timing of AIH to Reduce Apnea Severity Emerging models that better reflect the needs of critically ill
in Sleep-Disordered Breathing patients and families will be highlighted. The session will close
9:30 Panel Discussion with a look at future research and implementation priorities to
help palliative care fulfill its promise.
8:15 Welcome and Introduction
8:20 Built In, Left Out: What the ICU Team Can (and
Can’t) Do Alone

ATS 2026 Advance Conference Program • Orlando, Florida

WEDNESDAY • MAY 20 Click on the session title to view the speakers 83

8:35 Specialty Palliative Care in the ICU: What the CLINICAL

Evidence Tells Us (and What It Doesn’t)
8:50 Rethinking Goals: If It’s Not About Reducing ADULT CLINICAL CORE CURRICULUM
Distress, What Is It About? CC6 ADULT PULMONARY CLINICAL CORE
9:05 Equity by Design: Rethinking Serious Illness CURRICULUM
Communication for Underserved Patients
Assembly on SCALE
9:20 What’s Next: AI, Hybrids, and Human Connection
SCALe: Core Curriculum Committee
9:35 Closing Remarks and Questions
Target Audience
Advanced Practice Providers,Clinicians,Medical Educators
CLINICAL Objectives
At the conclusion of this session, the participant will be able to:
PEDIATRIC CLINICAL CORE CURRICULUM
• integrate guidelines on the identification and management of
PCC3 PEDIATRIC CLINICAL CORE pulmonary vascular disease into clinical practice
CURRICULUM • counsel patients and families on efficacy of available treatment
SCALe: Core Curriculum Committee options for pulmonary vascular disease
9:30 A.M. - 10:30 A.M. • identify knowledge gaps in the diagnosis and management of
pulmonary vascular disease
Target Audience
Advanced Practice Providers,Clinicians,Medical Educators The goal of the core is to support clinicians who are engaged in
maintenance of certification activities by providing updates on
Objectives
subjects included in recertification requirements.
At the conclusion of this session, the participant will be able to:
11:00 Everything Now: Comprehensive Management Of
• Define new strategies to manage pediatric patients with
Patients with Pulmonary Hypertension
pulmonary disease and critical illness
11:25 Don’t Stop Believin’: Pulmonary Arterial
• Better counsel pediatric patients and families on new
Hypertension Therapies
treatment options for pulmonary disease and critical illness
11:50 Special: Care Of Specific Populations with
• Identify knowledge gaps in the care of pediatric patients with
Pulmonary Hypertension
pulmonary disease including bronchiectasis.
12:15 Panel Discussion
The goal of the core is to support clinicians who are engaged in
maintenance of certification activities by providing updates on
subjects included in recertification requirements.
9:30 Connecting The Dots: Bronchiectasis in Systemic
Conditions
9:55 Innovative Frontiers: Diagnosing and Treating
Bronchiectasis-Associated Microorganisms
10:20 Panel Discussion

ATS 2026 Advance Conference Program • Orlando, Florida

84 Click on the session title to view the speakers WEDNESDAY • MAY 20

and EKG technologies for early detection and precision diagnosis

and monitoring of PH.
12:00 Right Heart Mechanics as a Window into Early
Pulmonary Vascular Disease Advancing Detection,
Screening, and Longitudinal Monitoring
12:15 Beyond the Right Heart Cath: 129Xe MRI for
Noninvasive, Multidimensional Monitoring in PH
12:30 AI-Driven CT Radiomics for Vascular Remodeling
and PH Subtyping: From Early Detection to
Therapeutic Monitoring
12:45 Listening with Intelligence: AI-Enabled
Stethoscopes for Early PH Detection
Wednesday Mid-day, May 20
BASIC • TRANSLATIONAL
BASIC • CLINICAL • TRANSLATIONAL
MID-DAY SYMPOSIUM
MID-DAY SYMPOSIUM
MD26 LUNG MAP PHASE 3- HIGH
MD25 NOVEL TOOLS FOR DIAGNOSIS AND RESOLUTION MOLECULAR
LONGITUDINAL MONITORING OF PROFILING OF LUNG DISEASES
PULMONARY HYPERTENSION Division of Lung Disease, National Heart, Lung, and Blood
Division of Lung Disease, National Heart, Lung, and Blood Institute, National Institutes of Health
Institute, National Institutes of Health 12:00 P.M. - 1:00 P.M.
12:00 P.M. - 1:00 P.M. Target Audience
Target Audience Basic and clinical researchers interested in lung biology,
Health providers, trainees, and researchers developmental biology, lung disease mechanisms, multi-omics,
bioinformatics, and systems biology
Objectives
At the conclusion of this session, the participant will be able to: Objectives
At the conclusion of this session, the participant will be able to:
• learn about the use xenon mri in ph diagnosis and longitudinal
monitoring. • learn the innovative technologies for single-cell multiomics,
spatial multiomics, and data analysis of the lung
• learn about the ai-driven ct radiomics for vascular remodeling
and ph • learn the newest discoveries from lungmap that could inform
lung research
• learn about the ai-enabled stethoscopes and new
echocardiographic advances in early ph diagnosis and • learn how to access and use the lungmap resources
longitudinal monitoring. The overall goal of LungMAP is to build a molecular and cellular
Pulmonary hypertension (PH) has no cure, the average 5-year atlas of the human lung to serve as a reference to better
patient survival rate is 54% with an increased mortality rate by understand both normal biology and disease pathobiology.
1.9% per year. One of the main reasons for this high mortality in LungMAP Phase 3 aims to utilize the power of single-cell omics
PH was due to the difficulty in early diagnosis of PH and and other innovative technologies to identify the pathogenic
accurately monitoring of the therapeutic effects. This session will mechanisms of lung disease at cellular resolution, including cell
introduce four NHLBI-funded studies on novel imaging and other types critical to disease initiation and progression, aberrant
noninvasive tools for early and accurate diagnosis and molecular pathways in abnormal and diseased cell states, and
longitudinal monitoring of PH. Specifically, we focus on utilizing targets for novel lung disease therapies. Speakers will describe
xenon MRI, echocardiogram, CT, AI-assist digital stethoscope progress on profiling pediatric and adult diseases using

ATS 2026 Advance Conference Program • Orlando, Florida

WEDNESDAY • MAY 20 Click on the session title to view the speakers 85

single-cell multiomics, spatial multiomics, and other innovative effectiveness-implementation trials that focus on clinical and
technology platforms as well as advance data analysis tools implementation outcomes in inpatient settings. During this
12:00 Alveolar Niche Evolution in Chronic Lung Disease session, investigators funded by this RFA will present key results
Across the Lifespan of their trials involving acute respiratory diseases and discuss the
challenges associated with implementing evidence-based
12:12 Global Unbiased Spatial Transcriptomic Methods to interventions in everyday clinical practice.
Study Cell-Cell Interactions in ILD
12:00 Hybrid Effectiveness-Implementation Trials: What,
12:24 Mapping Airway Epithelial Cell-Immune Cell Why, and How?
Interactions in Asthma and COPD
12:08 The Maximizing Extubation Outcomes Through
12:36 Cross-Disease Multimodal Profiling of the Lung Educational and Organizational Research
12:48 Multiomics Prediction of Molecular Drivers of (METEOR) Trial
Cellular Alterations in Childhood Interstitial Lung 12:20 Implementation of Coordinated Spontaneous
Diseases Awakening & Breathing Trials Using
Telehealth-Enabled, Real-Time Audit & Feedback
for Clinician AdHerence
BEHAVIORAL • CLINICAL
12:32 TEACH Long Term Outcomes Substudy
MID-DAY SYMPOSIUM
12:40 Eliminating Monitor Overuse (EMO) Hybrid
MD27 KEY RESULTS OF HYBRID Effectiveness-Deimplementation Trial.
EFFECTIVENESS-IMPLEMENTATION 12:52 Q&A
TRIALS INVOLVING ACUTE
RESPIRATORY DISORDERS
BASIC • CLINICAL • TRANSLATIONAL
Division of Lung Disease, National Heart, Lung, and Blood
Institute, National Institutes of Health MID-DAY SYMPOSIUM
12:00 P.M. - 1:00 P.M. MD28 UPDATES FROM THE LUNG HEALTH
Target Audience COHORT (LHC) STUDY
Researchers interested in conducting implementation science
Division of Lung Disease, National Heart, Lung, and Blood
research in inpatient settings and clinicians wanting to increase
adoption of evidence-based care in their practice. Institute, National Institutes of Health

Objectives 12:00 P.M. - 1:00 P.M.

At the conclusion of this session, the participant will be able to: Target Audience
Basic and Clinical researchers interested in understanding the
• learn about advances of hybrid effectiveness-implementation
latest developments for Lung Health Cohort status updates.
trials in acute respiratory disorders.
Objectives
• participate in quality improvement and implementation science
At the conclusion of this session, the participant will be able to:
research in clinical practice.
• describe the purpose and baseline demographics of the lhc
• incorporate cutting-edge approaches from organizational
science, and data science into implementation research. • present associations between lifetime exposure to air pollution
and physical activity to lung function and respiratory
Inpatients with acute respiratory disorders often do not receive
symptoms, respectively
evidence-based interventions that have been shown to improve
survival rates and reduce morbidity. Hybrid • illustrate novel ct features that are associated with impairment
effectiveness-implementation trials, which simultaneously in respiratory health; and also present associations between
examine the effectiveness of an intervention and the process of blood eosinophil counts in health young adults, lung function,
implementation, are crucial for ensuring that evidence-based and risk of medically-attended respiratory illnesses
practices are effectively adopted. To address this need, the The current framework for investigating respiratory diseases is
NHLBI developed RFA-HL-21-001 to support hybrid based on defining lung health as the absence of lung disease. In

ATS 2026 Advance Conference Program • Orlando, Florida

86 Click on the session title to view the speakers WEDNESDAY • MAY 20

order to develop a comprehensive approach to prevent the structure, physiology, and other clinical features. Insight into
development of lung disease, there is a need to evaluate the full COPD heterogeneity requires comprehensive and longitudinal
spectrum of lung health spanning from ideal to impaired lung data to elucidate the genetic, clinical, and radiographic
health. The Lung Health Cohort is a community-based cohort determinants of disease progression. The COPDGene study,
study focused primarily on characterizing lung health in 25-35 with over fifteen years of data, has created the largest
year olds without diagnosed severe respiratory disease initiated longitudinal cohort of well-characterized current and former
in 2021. This session will present baseline data for this novel smokers for respiratory disease [Link] session will
epidemiological study. describe how COPDGene has contributed to a molecular
12:00 Overview of the Lung Health Cohort understanding of COPD progression as well as different
approaches to identifying COPD phenotypes.
12:05 Wildfire Exposure and Respiratory Health in Young
Adults 12:00 Omics of COPD Progression Workshop

12:17 Physical Activity and Respiratory Health in Young 12:12 Mucus Plugs and COPD
Adults 12:24 Proteomics of COPD Progression
12:29 Radiologic Indicators of Impaired Respiratory 12:36 Lithium and COPD
Health in Young Adults 12:48 Precision Nutrition and COPD
12:41 Medically Attended Respiratory Illnesses in Young
Adults
12:53 Discussion

CLINICAL
MID-DAY SYMPOSIUM
MD29 COPD UNDERSTANDING COPD
PROGRESSION AND
HETEROGENEITY
Division of Lung Disease, National Heart, Lung, and Blood
Institute, National Institutes of Health
12:00 P.M. - 1:00 P.M.
Target Audience
Researchers, medical trainees, those interested in origins and
subtypes of COPD
Objectives
At the conclusion of this session, the participant will be able to:
• understand how different omics approaches can aid
understanding of copd progression
• understanding how lung structural features impact copd
phenotypes
• understand how environmental factors impact copd and copd
progression
Chronic obstructive pulmonary disease (COPD), a leading cause
of death in the United States, is a heterologous syndrome with
affected individuals demonstrating marked differences in lung

ATS 2026 Advance Conference Program • Orlando, Florida

WEDNESDAY • MAY 20 Click on the session title to view the speakers 87

evidence-based follow-up, and health policy approaches

including emerging evidence and advocacy for guideline
modification to expand access to LCS for patient groups with
high disease burden.
11:00 Patient-Sourced Solutions to Engage Communities
in Lung Cancer Screening
11:16 Health Policy Considerations for Expanding Access
to Lung Cancer Screening: Perspective from the
American Cancer Society
11:32 Emerging Strategies to Enhance Access to Lung
Cancer Screening Within the Veterans Health
Administration
Wednesday Afternoon, May 20 11:48 Beyond Navigators: Patient Empowerment As a
Means to Improving Lung Cancer Screening
Adherence and Timely Follow-Up
CLINICAL
12:04 Innovative Lung Nodule Management Strategies to
SCIENTIFIC SYMPOSIUM Advance Early Lung Cancer Diagnosis
12:20 Panel Discussion: Implications, Challenges, and
D81 INNOVATIVE APPROACHES TO
Opportunities for Translating Evidence into
IMPROVE LUNG CANCER SCREENING Practice
ACCESS AND ADHERENCE
Assemblies on Thoracic Oncology, Behavioral Science and
Health Services Research; Health Equity and Diversity
BEHAVIORAL • CLINICAL
Committee CRITICAL CARE TRACK
11:00 A.M. - 12:30 P.M.
D82 THE AGE OF INCLUSION: BUILDING
Target Audience BETTER CRITICAL CARE TRIALS FOR
Health professionals providing care for patients with current or
OLDER ADULTS
former tobacco use and at risk for lung cancer
Objectives Assemblies on Critical Care, Behavioral Science and Health
At the conclusion of this session, the participant will be able to: Services Research

• define novel strategies to improve access to lung cancer 11:00 A.M. - 12:30 P.M.
screening for high-risk populations Target Audience
• describe novel approaches to improve patient and clinician Interprofessional clinicians and researchers who care for patients
or conduct research in an ICU setting with adult patients
awareness of lung cancer screening
Objectives
• describe novel approaches that improve adherence to annual
At the conclusion of this session, the participant will be able to:
lung cancer screening and timely evaluation of abnormal
findings • describe the limitations of generalizing existing clinical trial
evidence to the growing population of critically ill older adults
This session will highlight innovative approaches to address
access barriers to lung cancer screening (LCS) and adherence to • define new strategies to improve the representation of older
follow-up testing. The session includes speakers from adults in critical care clinical trials
pulmonology, cancer epidemiology, and primary care. Topics will • incorporate new approaches to trial analysis to understand
include new evidence for novel approaches to engage a high-risk differential impact of interventions on older adults
communities in LCS, the latest studies on innovative strategies at
the health-system level to improve adherence to timely

ATS 2026 Advance Conference Program • Orlando, Florida

88 Click on the session title to view the speakers WEDNESDAY • MAY 20

Up to half of ICU admissions are for older adults (ages 65+), yet • describe new basic and translational research techniques to
critical care trials often exclude older ICU patients. Randomized better understand the pathogenesis and mechanisms behind
data addressing this growing demographic is scarce and typically ambient air pollution and respiratory disease
confined to subgroup analysis. Critical care trials also lack data • improve understanding of the effects of environmental
on frailty or multi-morbidity, key determinants of outcomes in the exposures on respiratory microbiota and host inflammatory
older ICU population. We will discuss interpretation of previously response
completed trials, addressing how data may be applied to older or
more frail adults. We also explore how future trials could better • increase the awareness of how environmental exposures
incorporate age, frailty, and multimorbidity in design. Experts will impacts the health of patients with respiratory disease
discuss how aging and frailty could be incorporated into From birth through adulthood, environmental exposures play a
heterogeneity of treatment effect, and how outcomes for this crucial role in the development of both acute and chronic
population must include not only survival but “what matters most” respiratory diseases. As climate change accelerates and the
to older adults. frequency of manmade and natural disasters increases, the
11:00 When Research Listens: A Caregiver’s Voice in the health impacts of these exposures continue to grow. Despite this,
Future of Critical Care Trial Design the underlying mechanisms and pathophysiology driving the
onset of new respiratory conditions-or the worsening of existing
11:11 Invisible in the ICU: The Silent Exclusion of Older ones-remain poorly understood. The goal of this symposium is to
Adults from Critical Care RCTs spotlight key translational insights from exposure studies,
11:28 Meaning Over Metrics: Designing and Collecting emphasizing both basic science and clinical/translational
Trial Outcomes based on the Values of Older Adults research. Special focus will be given to understanding the health
11:45 Inclusive by Design: Strategies to Improve Clinical effects and disease mechanisms associated with occupational
Trial Relevance for Aging Populations and environmental exposures such as wildfires, military
deployment, and air pollution.
12:02 Aging and Analytics: Unlocking Age and
Frailty-Based Differences in Treatment Response 11:00 Lessons of Epithelial Biology from Human Studies
of Deployed Military Veterans
12:19 Panel Discussion
11:15 Human Studies of Wildfire Smoke Exposure and
Respiratory Microbiome
BASIC • CLINICAL • TRANSLATIONAL 11:30 Human Studies of Air Pollution and Host Immune
Response
SCIENTIFIC SYMPOSIUM
11:45 Heat and Dust: Understanding Air Pollution
D83 EARTH, WIND, AND FIRE: Exposure, Risk, and Epidemiology of Clinical
TRANSLATIONAL LESSONS FROM A Outcomes in Populations in Kuwait and Iraq
CHANGING PULMONARY 12:00 Building a Framework for the Future: Clinical and
(MICRO)ENVIRONMENT Translational Lessons from Military Deployments
Assemblies on Environmental, Occupational and Population and the PDCEN Experience
Health, Allergy, Immunology and Inflammation, Pulmonary 12:15 Question and Answer Session
Infections and Tuberculosis
11:00 A.M. - 12:30 P.M.
BASIC • TRANSLATIONAL
Target Audience
Providers of patients with lung disease; researchers focused on SCIENTIFIC SYMPOSIUM
non-tobacco and environmental exposure, those with clinical,
research, or administrative responsibilities D84 EAT. KILL. SURVIVE. THE
MACROPHAGE-NTM STANDOFF
Objectives
At the conclusion of this session, the participant will be able to: Assemblies on Pulmonary Infections and Tuberculosis
11:00 A.M. - 12:30 P.M.

ATS 2026 Advance Conference Program • Orlando, Florida

WEDNESDAY • MAY 20 Click on the session title to view the speakers 89

Target Audience CLINICAL

Basic and translational researchers with interests in elucidating
the innate immune response to NTM; macrophage biologists; SCIENTIFIC SYMPOSIUM
those with NTM interest
Objectives
D85 AIMING HIGHER: THE JOURNEY
At the conclusion of this session, the participant will be able to: TOWARD ASTHMA REMISSION
• describe mechanisms of resident and recruited macrophage Assemblies on Allergy, Immunology and Inflammation,
interactions with clinically significant nontuberculous Behavioral Science and Health Services Research, Clinical
mycobacterium Problems
• define knowledge gaps regarding macrophage responses to 11:00 A.M. - 12:30 P.M.
NTM to inspire new research initiatives in a collaborative Target Audience
environment Clinicians (physicians, nurses, fellows, residents, pharmacists),
• identify potential targets for enhancing macrophage function to researchers, administrators, regulators and policymakers:
improve NTM clearance via host directed therapies anyone involved in the delivery of care and the science of
patients with asthma
Nontuberculous mycobacteria (NTM) are opportunistic pathogens
Objectives
that cause highly morbid lung disease, particularly in individuals
At the conclusion of this session, the participant will be able to:
with bronchiectasis. Current treatments are prolonged, toxic, and
often fail to eradicate infection. Macrophages are central to NTM • learn existing evidence of research related to asthma
clearance but can also serve as a niche for persistence. While remission and pros and cons of various asthma remission
most prior research has focused on Mycobacterium tuberculosis, definitions
NTM species such as M. avium and M. abscessus exhibit distinct • better understand the role of biologics in achieving asthma
host-pathogen dynamics. This session will highlight emerging remission
insights into macrophage-NTM interactions in the lung and spur
discussion for potential host-directed therapies to augment or • improve understanding of practical challenges in achieving
replace current antimicrobial strategies. asthma remission. Participants will be able to identify
research/clinic gaps in asthma remission as treatment goals
11:00 Introduction: Macrophage Heterogeneity and NTM and begin to develop methods/research questions to address
Infection - Barriers are Falling them
11:05 The Role of GM-CSF in Macrophage Control of The goals of asthma therapy have been to control symptoms and
Mycobacterium Abscessus in Healthy Lungs and in prevent exacerbations. With the recent advances in asthma
Bronchiectasis therapy (i.e. biologics) there has been an ambition to achieve
11:24 Macrophage Responses to Clinically Relevant NTM: greater disease control and the belief that clinical remission can
Patient-Level Insights be a realistic goal in asthma. Achieving that goal requires an
acceptable definition of asthma remission and prospective clinical
11:43 Trans-formative Immunomodulation to Enhance
trials to determine the patient and treatment factors associated
Macrophage Responses in NTM Infection
with arriving at the goal. This session will discuss current
12:02 Leveraging Macrophage Biology for Antimicrobial definitions of asthma remission and available evidence on
Drug Discovery in NTM Lung Disease remission, as well as obstacles and challenges in defining
12:20 Panel Discussion: Methods, Approaches, and asthma remission.
Insights into Macrophage-NTM Interactions 11:00 Introduction and Overview of Clinical Course of
Asthma
11:07 Asthma Treatment Goal Evolution: From Treating
Obstruction to Achieving Remission
11:24 Pros and Cons of Asthma Remission Definitions
11:41 Role of Biologics in Asthma Remission

ATS 2026 Advance Conference Program • Orlando, Florida

90 Click on the session title to view the speakers WEDNESDAY • MAY 20

11:58 Obstacles and Challenges in defining Asthma 11:05 Mechanical Cues in Tissue Remodeling and
Remission: Proposed Goals for Future Studies Regeneration
12:15 What We have Learned about Asthma Remission: 11:25 Environmental Cues in Driving Crosstalk Between
Conclusions and Panel Discussion Immune and Structural Cells
11:45 Extracellular Vesicles Driving Epithelial-Fibroblast
BASIC • CLINICAL • TRANSLATIONAL Crosstalk in the Injured Lung
12:05 Uncovering Blood Signatures of Pulmonary
SCIENTIFIC SYMPOSIUM Pathobiology
D86 LOCATION, LOCATION, LOCATION: 12:25 Conclusion of the Symposium
INTERCELLULAR COMMUNICATION
DRIVING LUNG DISEASE
Assemblies on Respiratory Structure and Function, Allergy,
Immunology and Inflammation, Environmental,
Occupational and Population Health, Pediatrics, Respiratory
Cell and Molecular Biology
11:00 A.M. - 12:30 P.M.
Target Audience
Basic, translational, and clinical scientists who seek to acquire
advanced knowledge of how lung physiology and disease
progression are regulated through intercellular communication
within the lung microenvironment
Objectives
At the conclusion of this session, the participant will be able to:
• describe emerging mechanisms of intercellular communication
in the lung microenvironment
• define novel signaling pathways and biomarkers involved in
chronic lung disease progression
• define translational and clinical strategies targeting intercellular
communication for lung disease intervention
Intercellular communication is fundamental to lung physiology
and pivotal in determining the lung microenvironment. Novel
mechanisms underlying how cells within the lung transmits and
receives information is an emerging area. Both intrinsic and
extrinsic factors such as mechanical forces, environmental
exposures, and extracellular vesicles, are powerful cues that
influence tissue inflammation, repair, and regeneration. In this
session, we intend to discuss novel and emerging concepts in
cellular communication with emphasis on signals that promote
chronic lung disease. We will also discuss new translational and
clinical approaches to leverage mechanisms in cellular
communication to establish novel biomarkers for chronic lung
disease progression.
11:00 Introduction to the Symposium

ATS 2026 Advance Conference Program • Orlando, Florida

 Orlando | May 15-20
[Link]